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Hypertension affects one in ten pregnancies and its sequelae can affect women and their 
offspring in later life.  The placenta has been the focus of much of the research into the 
pathogenesis of hypertension in pregnancy.  A functioning placenta requires a functioning 
cardiovascular system, hence investigating whether concepts from hypertension research 
(echocardiographic structure and function, altered ventricular and arterial elastance and 
monocyte biology) apply to pregnancy hypertension is of great interest.  Evidence for 
cardiovascular changes in hypertensive disorders of pregnancy is mounting, but the 
adaptations in subsequent pregnancy are unclear.  The aim of this study was to compare 
cardiovascular (patho)physiology in pregnant women with and without previous hypertension 
in pregnancy.  Monocyte subset heterogeneity was studied to provide mechanistic insight.  
Prospective changes in study parameters were analysed in each trimester of pregnancy and 
healthy non-pregnant women were studied as a control group at baseline.  I found more 
prehypertension and increased arterial stiffness in pregnant women with prior hypertension 
and a corresponding increase in the CD14++CD16–CCR2+ (Mon1) and 
CD14+CD16++CCR2– (Mon3) monocyte subsets and their aggregates with platelets in these 
women.   Changes in cardiovascular performance and their relationship to monocyte subsets 
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I begin my thesis by introducing the topic cardiac function in pregnancy, the interface of 
cardiovascular and obstetric medicine.  The hypertensive disorders of pregnancy, gestational 
hypertension (GH) and preeclampsia (PET), are introduced in Chapter 1 as my research 
interest.  The pathogenesis and clinical aspects of hypertension in pregnancy are explored.  In 
Chapter 2, I provide a systematic review the literature relating to cardiac structure and 
function in gestational hypertensive disease, with a focus on echocardiography.  To further set 
the scene for my laboratory work I then review the literature pertaining to monocytes and 
their subsets in women’s health.  Chapter 3 outlines the objectives for my experimental work 
and the hypotheses to be tested.  In Chapter 4, I describe the methodology for Evaluating 
Cardiovascular Changes in Hypertension in Obstetrics (ECCHO), my prospective study.  The 
results from ECCHO are found in the following three chapters.  The echocardiographic 
observations are contained in Chapter 5.  Within Chapter 6 are my experimental data 
relating to monocytes and their subsets.  In Chapter 7, I integrate my findings and relate them 









1.1 Pregnancy and the heart 
1.1.1 Physiological adaptations of the cardiovascular system in pregnancy 
The maternal cardiovascular system must adapt to the pregnant state as the gravid uterus, 
placenta and developing fetus place a new demand on the circulation.  Maternal 
haemodynamics adjust as early as the fifth week of pregnancy2 and cardiac structure and 
function must adjust in turn.  The hyperdynamic circulation tests the cardiac functional 
reserve.3   Failure of physiological cardiovascular adaptation to pregnancy is associated with 
adverse pregnancy outcomes.  The study and early recognition of maladaptation could lead to 
the development of novel screening techniques.4  
 
An increase in heart rate by 10-30%5-10 is the one of the first responses to the pregnant state.11  
Blood pressure is a function of the cardiac output (CO) and systemic vascular resistance 
(SVR).  SVR decreases in pregnancy.5-8, 11-13  Cardiac output (CO) is determined by heart rate 
and stroke volume.  CO increases in pregnancy.5-8, 12  This is primarily due to an increase in 
stroke volume rather than in heart rate.14, 15  CO has been shown to rise in the first and second 
trimesters then either plateau8, 16, increase13, 17 or decrease9, 10, 15, 18 towards term.  The 
different findings in the third trimester may be due to variation between individual patients or 
to different timing of the measurements between early third trimester and close to term.  In 
uncomplicated pregnancy there should be no significant change in systolic blood pressure 
(SBP).  The diastolic blood pressure (DBP), and hence the mean arterial pressure (MAP) 
decreases during the first trimester, then plateaus in the second trimester before rising in the 
final weeks of pregnancy.17, 19  Physiological changes in the renal, haematological and 
respiratory systems also affect haemodynamics.20 
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The myocardium hypertrophies during pregnancy in order to compensate for the increased 
load on the left ventricle (LV).21  The increased load has two elements, the preload (the 
physiological blood volume expansion in pregnancy) and afterload (increased peripheral 
resistance).  The intrinsic myocardial contractility may increase.6, 11  Left ventricular mass 
(LVM) increases during pregnancy7, 8, 12, 17 by 10 – 52%.4, 8, 13, 21, 22  This reversible increase in 
LVM is an adaptation to maintain the necessary cardiac output, whilst aiming to reduce wall 
stress and oxygen demand.5  LV hypertrophy means that the cardiac myocytes increase in 
size.  This is usually concentric hypertrophy whereby the LV wall thickness increases without 
an increase in cavity size.17, 19  In parallel with this fibroblasts also hypertrophy so cardiac 
structure changes (remodelling) and the myocardium becomes less compliant.7  The LV 
becomes more globular or spherical in shape as pregnancy progresses,5 as it becomes dilated 
by increased blood volume.15  Some studies report no change in LV dimension during 
pregnancy.7, 12  
 
Loading conditions, contractility and heart rate all contribute to left ventricular function.5   
Some investigators report that ejection fraction stays the same throughout pregnancy5, 7, 14 
whilst others report a decrease in the third trimester.8, 12  A left ventricle subjected to 
increased loading conditions for some time will become stiffer and diastolic function will be 
impaired.  Diastolic dysfunction means there is resistance to filling of the LV.  When diastolic 
function is normal, the LV should fill to its expected volume at the end of diastole without the 
pressure in the chambers becoming abnormally high.19  As the LV becomes less compliant, 
due to realignment of collagen,21 the pressure relative to its volume is increased.  This means 
it takes longer for the to fill with blood and longer to relax.  Myocardial contractility and 
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relaxation (both energy-dependent processes) have been shown to be altered at term in normal 
pregnancy.3 
 
The consequences of a shorter diastole are reduced coronary artery perfusion and less filling 
time.4   Reduced blood supply is damaging to the heart.  Myocardial perfusion in diastole is 
also reduced by the physiological increase in heart rate.  Diastolic dysfunction’s preceding 
systolic dysfunction in cardiac disease is well recognised outside of pregnancy23-27 but only 
more recent studies in pregnancy have shown this.4, 7  
 
Arterial compliance, which refers to how the pulse wave is propagated throughout the arterial 
system, increases by about 30% in pregnant women.19, 22, 28  Arterial compliance is defined as 
volume change per unit change in blood pressure .  This elastic property is necessary to offset 
the effect of increased blood volume (which causes a similar rise in venous return) without a 
rise in mean arterial pressure.  Large arteries with preserved elastic properties are able to 
stretch during systole, thus retaining some of the blood volume to be returned to the 
circulation during diastole.  This reduces cardiac cycle-dependent fluctuations in blood 
pressure, reduces cardiac afterload and improves coronary perfusion pressure during diastole.  
Increased vascular and LV stiffening on the other hand may lead to an alteration in 
ventriculo–arterial coupling, which can be assessed reproducibly by echocardiographic 
measurement of arterial and cardiac elastance.29-32  Despite the growing evidence of abnormal 
arterial stiffness and diastolic dysfunction in pregnancy, the mechanisms of these changes and 
mutual relationship between arterial and cardiac abnormalities are not clear.33  Abnormal 
cardiovascular interactions (coupling) are likely to take place, but more data are required to 
support this hypothesis.  
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1.1.2 Cardiac disease in pregnancy 
Cardiac disease is the leading cause of death in pregnancy and the puerperium in the United 
Kingdom.34-36  This has been case since the turn of the millennium and the rate of deaths due 
to cardiovascular complications continues to rise.34  The overall maternal mortality rate from 
cardiac disease, reported in the Confidential Enquiries into Maternal Deaths for the period 
2012–2014 was 2.18 per 100,000 maternities37 and from 2014–2016 was 2.39 per 100,000 
maternities.38  Hypertension in pregnancy causes one third of severe maternal morbidity.1  Up 
to 15% of maternal deaths in the developing world are due to pregnancy hypertension and a 
similar proportion of direct of obstetric deaths in the UK and USA are attributable to 
complications of hypertension.39  Investigations into maternal and neonatal morbidity and 
mortality due to hypertensive disorders in pregnancy suggest that improvements in the care 
provided is required to achieve better outcomes.40 
 
1.1.3 Echocardiography in pregnancy 
Methodology and technology for measuring cardiac structure and function has improved 
greatly over the last century since cardiac output was first measured in 1915.17  Grollman 
demonstrated increased cardiac output in pregnancy by measuring concentrations of 
exogenous gases in the blood.41  Hamilton later used right heart catheterisation, a technique 
developed by Cournand and colleagues,42 to determine cardiac output based on the Fick 
principle.9, 43  Until about 1970 other invasive methods including indicator dye dilution and 
thermodilution techniques were used.44, 45  Invasive hemodynamic monitoring is the most 
reliable6 but may not reflect the resting state (due to effects of anxiety and autonomic 
stimulation) and outside the context of management of critical illness it is not used as a 
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Figure 1:  Infographic focusing on cardiovascular disease from MBRRACE-UK37 
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research tool as the risks to a pregnant woman are unacceptable in modern practice.  Electrical 
impedance cardiography and M-mode echocardiography emerged in the 1970s as safe and 
acceptable non-invasive techniques which can provide serial measures in pregnancy.8, 11, 16, 46  
Doppler ultrasound imaging technology has been used since 1985 to assess volumetric 
flow.47, 48   Doppler echocardiography is operator-dependent, requiring training in technical 
skills to provide reliable and reproducible measurements.46  Temporal variability of Doppler 
echocardiography is small,49  and it is a validated modality in pregnancy17 making it suitable 
for longitudinal studies.  
 
Tissue Doppler Imaging (TDI) can detect the low velocity, high intensity echoes of 
myocardial deformation so can demonstrate subtle changes in myocardial performance.5  TDI 
is also relatively independent of preload50 making it a better measure of LV diastolic function 
in pregnancy.3, 21  Three dimensional imaging, strain measurements and speckle tracking 
technology provide further information about cardiac geometry.51  
 
Pulsed wave Doppler echocardiography is the most common modality used to assess LV 
diastolic function.21  Blood flow from the left atrium (LA) across the mitral valve to the LV in 
diastole has a measurable E-wave (early filling) and A-wave (late filling), illustrated later in 
Figure 4.  These indicate the pressure gradients between the two left-sided chambers in early 
diastole and after atrial contraction in late diastole.  Increased preload increases the maximum 
velocity of both E- and A-waves.  Increased afterload decreases the maximum velocity of the 
E-waves and increases the maximum velocity of the A-wave.4  Several studies have shown 
that in normal pregnancy the E/A ratio decreases towards term, which corresponds to an 
increase in the A-wave maximum velocity.4, 7, 17, 21, 52  Atrial contraction has been shown to be 
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more important to ventricular filling as pregnancy progresses,21  which is different to the 
situation in healthy, non-pregnant young women where LV filling is almost completed in 
early diastole before the atrial ‘kick’.7  The atrial contribution to LV filling also becomes 
more pronounced with increasing maternal age.10   Enhanced LV end-diastolic function in 
healthy pregnancy is an important adaptation to handle the increased preload.21  
 
The velocity of lengthening of the left ventricular myocardial fibres can be measured in early 
diastole (E’) and after atrial contraction in late diastole (A’) by TDI.  The ratio E’/A’ 
measured at the mitral annulus has been shown to decrease in the third trimester when the 
atrial contraction becomes more important to maintain ventricular filling.10, 21, 53   As a 
measure of diastolic function, E’ has the advantage of being relatively load-independent 
compared with the transmitral E-wave which depends on preload.10   The ratio E/E’ reflects 
left atrial pressure,54  which has shown to remain normal in healthy pregnancy.7, 10 
 
1.2 Hypertensive disorders of pregnancy 
1.2.1 Definition 
Hypertensive disorders of pregnancy are an important cause of morbidity and mortality, 
impacting on both maternal and fetal wellbeing.  There are two hypertensive disorders 
specific to pregnancy, namely gestational hypertension (GH) and preeclampsia (PET).  The 
diagnosis and classification of hypertensive disorders in pregnancy depend on the gestation at 
which elevated blood pressure is identified (both occur in the second half of pregnancy), the 
presence or absence of significant proteinuria (traditionally the hallmark of PET), and 
whether the blood pressure normalises in the postnatal period (if it does not then the diagnosis 
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is chronic hypertension). 
 
The definition of hypertension in pregnancy requires either a systolic blood pressure of at 
least 140mmHg or a diastolic blood pressure of at least 90mmHg, with a second confirmatory 
reading separated in time usually by 4 hours.55  Blood pressure should be measured with a 
device validated in pregnancy.56  Proteinuria has traditionally been the second criterion 
required for the diagnosis of preeclampsia.  Proteinuria is defined as at least 300mg protein in 
a 24 hour urine collection or a urine protein/creatinine ratio of at least 30mg/mmol.1  A urine 
dipstick showing “1+” proteinuria or more can be used as a guide to prompt laboratory 
confirmation.  
 
In the most recent guidelines from the American Congress of Obstetricians and 
Gynecologists, the Society of Obstetric Medicine of Australia and New Zealand and the 
Society of Obstetricians and Gynaecologists of Canada there is not an absolute requirement 
for proteinuria, with various alternative maternal and fetal sequelae of the disease listed in the 
diagnostic criteria for PET.57-60  This wider definition of preeclampsia is in accordance with 
the recommendations of the International Society for the Study of Hypertension in Pregnancy 
(ISSHP)61, 62 and the concept of preeclampsia as a syndrome comprising hypertension and end 
organ dysfunction, with renal, hepatic, haematological, neurological or placental 
manifestations.  The National Institute for Health and Clinical Excellence (NICE) have not 
updated their guideline since 2011, therefore proteinuria is still a mandatory criterion for a 
diagnosis of PET in the UK.1  
 
Women with chronic hypertension may become pregnant and the condition may be 
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discovered for the first time in pregnancy.  Secondary hypertension can present in pregnancy, 
meaning that the raised blood pressure is a consequence of an underlying disease, for example 
endocrine or renal problems.  Although most definitions require the onset of hypertension to 
be in the second half of pregnancy in order for it to be considered pregnancy-induced, severe 
PET has been known to present before 20 weeks of gestation when associated with other 
pregnancy complications such as molar or multiple pregnancy.  PET can affect women with 
no known previous hypertension or can be superimposed on chronic hypertension.  A basic 
algorithm to differentiate between the hypertensive disorders of pregnancy is shown in Figure 
2, which is based mostly on the NICE Clinical Guideline with the concept of ‘superimposed’ 
PET drawn from North American and ISSHP guidance. 1, 57, 59, 61 
Figure 2:  Diagnosis of hypertensive disorders in pregnancy 
 





Hypertension in pregnancy is common, with around 10% of women diagnosed at some point 
in pregnancy.39  The incidence of preeclampsia is 2%.63  In a systematic review of controlled 
studies, the following maternal factors present at the start of pregnancy were associated with 
increased risk of preeclampsia: antiphospholipid antibodies; history of preeclampsia; diabetes; 
multiple pregnancy; family history; nulliparity; increased BMI; maternal age >40; renal 
disease; chronic hypertension; ≥ 10 year birth interval; increased blood pressure.64 
 
There is much interest in finding a genetic basis for preeclampsia, with the plasminogen 
activator inhibitor-1 (PAI-1) gene polymorphism and the soluble fms-like tyrosine kinase-1 
(sFlt-1) gene showing consistent associations.65, 66.  Several genes, such as certain lipoprotein 
lipase alleles and SERPINE1 variants, have been linked to preeclampsia, cardiovascular 
disease and adverse lipid profiles, demonstrating the complex interplay between genes and 
environment contributing to the pathogenesis of hypertension in pregnancy.  A recent ‘review 
of reviews’ highlighted the importance of metabolic syndrome, with obesity and polycystic 
ovarian syndrome conferring increased risk of hypertension in pregnancy, as well as increased 
cardiovascular risk in later life.65  Diabetes mellitus, being overweight before pregnancy and 
gaining excessive weight during pregnancy and high levels of triglycerides are associated 
with development of preeclampsia.66-68 
 
Ethnic variation is reported in various pregnancy-related complications, but it is important to 
bear in mind the difference between ethnicity (which has a cultural basis) and racial groups 
(more related to geography and genetics).69  The relationship between ethnicity and health 
outcomes is complex and caution is required when interpreting any associations.  Although 
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hypertension in pregnancy has been shown to vary depending on ethnicity and geographical 
region, this may reflect other influences such as lifestyle and access to healthcare.70, 71 
Nevertheless it is acknowledged that women from African ancestral groups are at increased 
risk of hypertension in pregnancy, with nulliparous black women in the United States twice as 
likely to develop preeclampsia compared to nulliparous white women.72 
 
1.2.3 Pathophysiology 
The traditional theory to explain the rise in blood pressure in PET is the disordered invasion 
of the placenta and its vasculature into the uterus.73  There is a consequent reduction in blood 
flow to the fetus, which results in compensatory mechanisms to increase the blood flow to 
avoid fetal compromise.  Late onset preeclampsia is thought to be related to endothelial 
dysfunction and an exaggerated systemic inflammatory response.74  More recently the 
placental origin hypothesis has been challenged and contemporary research is focusing on the 
role of the maternal cardiovascular system in relation to placental syndromes.75  If the 
maternal haemodynamic adaptation to pregnancy is impaired or inadequate, subsequent 
placental dysfunction may manifest as PET and/or fetal growth restriction (FGR).76  There 
may be a genetic predisposition to preeclampsia since it is more common in women whose 
mother or sister was affected.39  Maternal medical problems affecting the vasculature or blood 
clotting are associated with increased risk of preeclampsia, with the commonest conditions 
being diabetes, systemic lupus erythematosus and antiphospholipid syndrome.  
 
1.2.4 The immune system and preeclampsia 
The maternal immune system must adapt in pregnancy in order protect the semi-allogenic 
fetus from rejection.77  This immunological tolerance is an essential feature of the 
 8 
immunology of pregnancy.78  Cells of the innate immune system have been implicated in the 
pathophysiology of gestational hypertensive disease.79  Pathological inflammatory processes, 
both systemic and localised to the placenta, occur in PET.80  An imbalance between placental 
factors and the maternal adaptation to them may result in the syndrome of PET.81  Molecules 
involved in cell signaling, regulation and activation at the placental interface continue to 
attract scientific interest in pregnancy hypertension research.   
 
During physiological implantation, the newly formed uterine decidua and underlying 
myometrium are invaded by fetal trophoblastic cells.  The extravillous cytotrophoblast 
invades the maternal vasculature, transforming its endothelium and muscle layer leading to 
decreased resistance and increased placental blood flow.78  The impaired vascular remodeling 
of the uterine spiral arteries in PET, associated with altered trophoblast invasion, leads to 
high-resistance vessels and a reduction in placental perfusion.80, 82  The altered trophoblast 
invasion in PET has been attributed to an abnormal maternal immune response in early 
pregnancy.78, 79  The fetal/paternal alloantigens to which the maternal immune system 
responds generate partner specificity, which explains the increased incidence of preeclampsia 
in first pregnancies, or pregnancies with a new partner, where there is no immune memory 
and the maternal adaptation may be defective.81   
 
Sargent et al suggest two stages in the immunological origin of PET.83  Firstly immune 
regulation by cytokines and angiogenic factors is impaired as HLA-G, a class 1 major 
histocompatibility complex molecule, is underexpressed and therefore decidual NK cells are 
not activated.  Secondly a systemic inflammatory response involves leucocytes and 
endothelial cells.  The immune response is thought to start in the placenta, as cellular debris 
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from syncytiotrophoblast necrosis or apoptosis, due to placental hypoxia and infarction, is 
released as antigen into the maternal circulation. It has been proposed that these placental 
microparticles activate maternal monocytes through their toll-like receptors and lead to 
endothelial activation.80, 84, 85  Histology from placentas of preeclamptic women is consistent 
with these principles, revealing shallow trophoblast invasion, thrombosis and changes 
associated with inflammation and ischaemia/infarction.80 
 
The progesterone and cytokines produced by the placenta alter the usual equilibrium between 
the two subsets of T helper (Th) cells. There should be a shift towards the Th2 immunological 
state in healthy pregnancy, with the diminished Th1 response creating an immune-tolerant 
environment.86  In PET this shift is thought not to occur since preeclamptic women have a 
cytokine profile characteristic of a Th1 response.79  Th1 cells trigger cell-mediated immunity 
and phagocytosis, with elevated levels of pro-inflammatory cytokines such as IL-6 and TNF-
a.78 
 
1.2.5 Clinical symptoms and signs 
Women with mild disease may have no symptoms.  In severe disease there may be clinically 
detectable end organ dysfunction affecting the liver, kidneys, brain and coagulation.  These 
abnormalities lead to symptoms including headache, visual disturbance and epigastric pain.  
The most serious complications are rare, and include eclampsia (seizure), stroke, the 
syndrome of haemolysis, elevated liver enzymes and low platelets (HELLP) or disseminated 
intravascular coagulation (DIC).  Fetal risks are associated with prematurity and growth 
restriction, of which the consequent morbidity may manifest throughout the life of survivors. 
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1.2.6 Clinical management 
The only known cure for PET is to empty the womb of the placenta, thus ending the 
pregnancy.  The timing of this definitive intervention has implications on the short and long 
term outcomes for the neonate.  Management of PET remote from term is more challenging, 
as the risks to the woman must be balanced with the complications of prematurity resulting 
from iatrogenic preterm delivery.  In severe PET presenting extremely preterm when the fetus 
is not viable, termination of pregnancy may be indicated.  If safe, pregnancy can continue to 
term and with the default mode of delivery being vaginal birth unless Caesarean section is 
indicated for another reason.  Preterm delivery is required when the maternal or fetal risks of 
continuing the pregnancy outweigh the benefits of prolonging the gestation for the fetus.  
Delivery should be expedited when there is severe hypertension which is difficult to control, 
worsening biochemical or haematological parameters, worsening symptoms, maternal 
complications such as eclampsia or placental abruption, or evidence of fetal compromise in 
the form of growth restriction or cardiotocograph abnormality.  
 
Hypertension can usually be controlled with antihypertensive medication.  Blood pressure 
control will usually be dependent on antihypertensives until after delivery.  Labetalol and 
nifedipine are the first line oral medications.  Methyldopa is also safe to use.  Severe 
hypertension is an indication for admission to hospital and may require intravenous 
antihypertensives such as hydralazine.  Magnesium sulphate is used for prophylaxis and 
treatment of eclampsia (seizures in the context of hypertension in pregnancy) and also has the 
benefit of neuroprotection for the early preterm fetus.87  Antenatal corticosteroids for fetal 
lung maturity should be given in case of anticipated preterm delivery.88 
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Routine practice in the UK involves the prescription of low dose aspirin (acetylsalicylic acid, 
an antiplatelet and cyclooxygenase inhibiting drug) to women considered at high risk of 
developing PET based on maternal history.1  NICE recommend 75mg aspirin daily from 12 
weeks until delivery for women with one “high risk” factor or more than one “moderate risk” 
factor, as shown in Table 1 below.  
Table 1:  Risk factors for preeclampsia 
High risk Moderate risk 
Hypertensive disease in previous pregnancy First pregnancy 
Chronic kidney disease Age 40 or older 
Lupus erythematosus Pregnancy interval of more than 10 years 
Antiphospholipid syndrome Body mass index of 35kg/m2 or more at first visit 
Pre-existing diabetes (Type 1 or Type 2) Family history of preeclampsia 
Chronic hypertension Multiple pregnancy 
 
From Hypertension in pregnancy: The management of hypertensive disorders during 
pregnancy. NICE Clinical Guideline 107. London: National Institute for Health and Clinical 
Excellence, 2011. Aspirin recommended if >1 factor from first “high risk” column or ≥2 
factors from second “moderate risk” column. 
 
Development of prediction models for preeclampsia is an interest of many research groups 
worldwide.  The Fetal Medicine Foundation has proposed a screening algorithm which 
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combines maternal characteristics with biophysical (uterine artery pulsatility index and mean 
arterial pressure) and biochemical (placental growth factor  and pregnancy-associated plasma 
protein A) measurements at 11-13 weeks gestation.63  This model detects 76% of preterm 
preeclampsia at a screen positive rate of 10%.  When women identified as being at ≥1:100 
risk of developing preterm preeclampsia were randomised to prophylaxis with 150mg aspirin 
or placebo to take from the time of first trimester screening until 36 weeks gestation, the 
incidence of preterm preeclampsia was reduced in the treatment arm of the trial by over 
80%.89  Calcium supplementation for high risk women with low calcium intake has been 
recommended by the World Health Organization (WHO) and the ISSHP.90 
 
1.2.7 Prognosis  
PET will recur in a future pregnancy in one in six women.1  The risk of recurrence increases 
according to the severity of the disease, with those who delivered before 28 weeks having 
more than 50% chance of developing PET again.1  A woman affected by PET is at higher risk 
of future cardiovascular morbidity and mortality,91, 92  This may be due to persistent changes 
in cardiac structure and function, or to irreversible injury to the cardiovascular system.50, 93  
Women with preterm PET are at significantly increased risk of LV dysfunction and essential 
hypertension within two years of delivery.50  Women with PET are more likely to develop 
hypertension, ischaemic heart disease, stroke or venous thromboembolism later in life as these 
conditions share aetiological factors with pregnancy hypertension.92  A recent systematic 
review and meta-analysis reported that PET confers a 4-fold increased chance of heart failure 




1.2.8 Unanswered questions  
Current research in the field of hypertension in pregnancy is focused on prediction and 
prevention of PET, as well as on improving treatment once the disease is clinically apparent.   
More data are required to aid clinicians with the decision regarding timing of delivery.  
Cardiovascular imaging is emerging as an important tool in obstetric medicine and may 
represent a novel strategy to improve the detection of patients at risk of adverse pregnancy 
outcomes and to guide the management of hypertensive pregnancies.95-97  Post-pregnancy 
follow up, where clinicians use learning from a woman’s response to pregnancy in order to 
optimise future health outcomes, is likely to become a key public health strategy.  Many of 
the “gestational” syndromes have a counterpart for which the obstetric complication reveals a 
risk or tendency, for example gestational diabetes and Type 2 diabetes.  Understanding the 
underlying pathophysiology leading to the late effects of hypertension in pregnancy is an 
important area of research in order to discover how to improve women’s cardiovascular 
health. 
 
The interaction between the heart and vasculature is an important aspect of cardiovascular 
performance.  Adaptations in the arterial system are important in healthy pregnancy.  The 
concept of arterial stiffness is introduced in the next section. 
 
1.3 Arterial stiffness 
1.3.1 Introduction to arterial stiffness 
Large arteries should be able to regulate blood flow.  Their elastic property allows for a 
smoother passage of blood through the arterial tree compared to the initial strong pulsation of 
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ejected blood from the heart.98  A healthy vessel is compliant (normal volume change per unit 
change in blood pressure) and distensible (normal compliance relative to initial volume).  A 
vessel should expand and contract to adapt to pressure changes.99  Arterial stiffness is a 
measure of the ability of the vessel to adapt to pressure changes appropriately.  Arterial 
stiffness, or elastance, describes the change in pressure (∆P, stress) relative to a change in 
volume (∆V, strain).100  Elastance is the inverse of compliance, which is ∆V/∆P.  Non-
invasive assessment of arterial stiffness can be performed using Pulse Wave Analysis and/or 
cardiac imaging. 
 
Altered arterial stiffness can be caused by vascular aging, endothelial damage or increased 
mean arterial pressure.  Increased arterial stiffness means there is less capacitance in the 
central arterial reservoir which causes impaired cardiac performance and a reduction in end 
organ perfusion.101  If the aorta and other large arteries lose their elasticity, the pulse wave 
reaches smaller vessels in distal organs and tissues without having been buffered and this can 
be harmful and may induce remodelling.101  Arteries should be more compliant in pregnancy 
in order to accommodate increased intravascular volume and maintain smooth perfusion to 
vital organs.22  A recent systematic review and meta-analysis has demonstrated a significant 
increase in arterial stiffness indices in women with preeclampsia compared women with 
gestational hypertension and normotensive pregnant women.102  Arteries stiffen in 
hypertension due to hyperplasia and hypertrophy of vascular smooth muscle, leading to 
deposition of collagen. 
 
1.3.2 Pulse Wave Analysis 
Pulse wave analysis employs applanation tonometry to assess central haemodynamics and 
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arterial stiffness.  It estimates the augmentation of systolic blood pressure by pulse wave 
reflection from the periphery.  The principle involves studying the shape of the arterial 
waveform, providing more information than the two traditional systolic and diastolic, peak 
and trough, measurements of peripheral blood pressure.103  The pressure waveform obtained 
non-invasively has been shown to be well matched to invasive measures.101  The height of the 
pulse wave is determined by both the advancing wave and the retrograde flow caused by 
reflections from resistance in the arterial tree.103  In a recent consensus statement from the 
International Working Group on Maternal Hemodynamics, the principle of wave reflections 
has been likened to when a stone is dropped in a small pond and the waves hitting the pond 
edge are reflected back and summate with advancing waves.98  Usually the retrograde blood 
flow reaches the aorta only during diastole when the aortic valve is closed, so it boosts the 
central diastolic blood pressure.  This is beneficial for coronary artery perfusion.  Increased 
arterial wall stiffness, or sites where the arterial walls are less elastic, cause the reflected wave 
to return more rapidly.  The returning wave therefore meets the advancing wave earlier in 
systole, thus amplifying the systolic peak rather than the diastolic portion of the waveform.  It 
is this meeting of forward-moving and reflected pressure waves that makes central aortic 
pressure higher when arteries are less compliant, and results in increased cardiac work and 
less coronary perfusion in diastole.  Key findings from previous studies of Pulse Wave 
Analysis in pregnancy are summarised in Table 2.  
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Table 2: Summary of findings of studies using pulse wave analysis in pregnancy 
Findings Reference 
AIx is significantly lower throughout pregnancy compared to 




Aortic stiffness falls significantly in the second trimester and 




There is no difference in arterial stiffness between White 
European and Black African ethnic groups.  
Khalil, 2009103 
Central blood pressures and Aix are higher in hypertensive 







AIx is higher in preeclampsia compared to normal pregnancy 
and gestational hypertension. 
Khalil, 2009110 
Spasojevic, 2005108 
AIx is significantly higher in early onset preeclampsia 
compared to late onset preeclampsia.  
   
Khalil, 2009110 
AIx is raised in preeclampsia and remains elevated 
postpartum even once blood pressure has normalised. 
   
Robb, 2009111 
Increased Aix is associated with severity of preeclampsia, 
reduced time to delivery and need for antihypertensives in 





1.3.3 Aortic augmentation 
There are two inflection points in the aortic pulse waveform, representing the incident 
pressure wave generated by the heart and the reflected wave from when that wave meets 
resistance (see Figure 3).  The aortic pressure is the difference between the first and second 
inflection points.  The augmentation index (AIx) is the augmentation pressure (AP) expressed 
as a percentage of the central pulse pressure, which is then standardised to a heart rate of 75 
beats per minute (AIx75).  
Figure 3:  The arterial waveform 
 
Figure reproduced under license (reference 4555290597134) from the citation Foo FL, 
Mceniery CM, Lees C and Khalil A. Assessment of arterial function in pregnancy: 
recommendations of the International Working Group on Maternal Hemodynamics. 
Ultrasound in Obstetrics and Gynecology 2017; 50; 324 – 331.  
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The augmentation pressure is calculated as the difference in amplitude between the forward 
wave (P1) and the reflected wave (P2).  The augmentation index (Aix) is the ratio of this 
pressure difference in relation to the pulse pressure (PP).  
 
AIx	(%) = P2 − 	P1PP × 	100 
 
The adjustment to standardise to a heart rate of 75 beats per minute is done at an inverse rate 
of 4.8% for each 10 beats per minute increment in heart rate, according to the following 
formula, which is derived from previous published studies113: 
 
AIx75	(%) = Aix + 4.8	 ×	(HR − 75)10  
 
The augmentation index is a marker of the interaction between the arterial tree and the left 
ventricle or so called ventricular-arterial coupling which reflects the interaction between the 
pump (heart) and the load (arterial system).  The augmentation index is a more sensitive early 
marker of arterial stiffness than measurement of pulse wave velocity.98  There is no 
significant association between AIx-75 and maternal ethnicity, parity, smoking status or body 
mass index.33 
 
1.3.4 Aortic blood pressure  
Pulse wave analysis also estimates the central systolic and pulse pressures.  Central blood 
pressure may be more important than peripheral blood pressure as this is the pressure to 
which the left ventricle is exposed, for which brachial measures are only a surrogate.101, 103  
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The mathematical transfer function used to derive the aortic waveform from the radial artery 
waveform is not validated in pregnancy.  It has been validated in a wide variety of other 
physiological and pathological conditions.  The properties of the arterial tree between the 
heart and the radial artery should not change in women of childbearing age.  With this in mind 
the transfer function can be applied in pregnancy.  
 
1.4 Chapter 1 Summary 
This opening chapter has introduced maternal cardiac function and the hypertensive disorders 
of pregnancy as my research themes.  At the heart of this thesis is a study of the underlying 
pathophysiology of hypertension in pregnancy and associated cardiovascular dysfunction.  I 
have explored the physiological adaptation of the heart to the pregnant state, concepts which 
are important to appreciate in order to understand what happens when this goes wrong.  
Echocardiography has been introduced as the key modality of interest in my investigations, 
with further detail to follow in the form of a systematic review in the next section.  The 
concept of ventricular-arterial interaction has been described, and an overview of the Pulse 
Wave Analysis technique was given.  The interface of immunology and cardiology was 
covered, and this will be explored in more detail in Chapter 2 when monocytes, their subsets, 






2.1 Echocardiographic structure and function in hypertensive 
disorders of pregnancy: A systematic review 
2.1.1 Introduction 
Cardiac disease is the leading non-obstetric cause of death in pregnancy and the puerperium.35  
In uncomplicated pregnancy there is no significant change in systolic blood pressure.17, 19 
Diastolic blood pressure and mean arterial pressure decrease during the first trimester, then 
plateau in the second trimester before rising in the final weeks of pregnancy.17, 19 
Hypertension is seen in 6-8% of pregnancies1 and the incidence is increasing as the obstetric 
population becomes older and more obese.114  Hypertension causes one third of severe 
maternal morbidity1 and is the second most common direct cause of maternal mortality 
worldwide, accounting for approximately 14% of maternal deaths.115  The hypertensive 
disorders specific to pregnancy are gestational hypertension (GH) and preeclampsia (PET), as 
defined previously.  Adverse fetal outcomes include preterm birth, growth restriction and 
stillbirth.1  
 
Understanding the structure and function of the heart in pregnancy is vital if we are to 
recognise abnormalities at an early stage and plan appropriate interventions to avoid adverse 
outcomes.  Echocardiography is a safe, non-invasive technique to assess cardiac structure and 
function in pregnancy.8, 11, 16, 46  Although operator-dependent and requiring training to 
provide reproducible measurements46, the temporal variability of echocardiography is small.49  
Modern ultrasound technologies can demonstrate subtle changes in cardiac geometry and 
performance3, 5, 21, 51, and echocardiography has important potential for longitudinal 
assessment in view of its non-invasive nature.  However, evidence for the role of 
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echocardiography for serial measurements in pregnancy is lacking, and despite common use 
in clinical practice, the application of echocardiography to study hypertensive disorders of 
pregnancy is inconsistent.  
 
My aim was to systematically review the current literature to assess changes in 
echocardiographic structure and function in women developing GH and PET.  I hypothesise 
that echocardiography would be a useful screening tool to identify: (1) high-risk women in 
whom cardiovascular changes occur before manifesting clinically as a hypertensive disorder; 
and (2) women at increased risk following a diagnosis of GH or PET.   
 
Wolters Kluwer, publishers of Circulation: Cardiovascular Imaging, have granted permission 
to reproduce content from my published systematic review116 within this thesis. 
 
2.1.2 Methods 
Information sources and search strategy 
Studies using echocardiography in pregnancies complicated by GH or PET were eligible for 
inclusion in the systematic review.  The definitions of GH and PET used by each individual 
study were accepted.  Figure 2 shows a typical algorithm for the classification of 
hypertensive disorders of pregnancy.  My search included MEDLINE, EMBASE, CINAHL 
and the Cochrane Library from inception to March 2015, as well as relevant reference lists.  
The MEDLINE search strategy is shown in Table 3, which was adapted for the requirements 
of the other databases.  There was no restriction on the type of study design or publication 
language.  Full text articles were obtained after screening the title and/or abstract of eligible 
studies by two authors (JSC and FT).  The review process was conducted according to the 
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Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist 
117, and prospectively registered with the PROSPERO database (CRD42015015700); 
(http://www.crd.york.ac.uk/PROSPERO/DisplayPDF.php?ID=CRD42015015700). 
Table 3:  Search strategy 
1. PREGNANCY/ (MeSH) 
2. gestation* .mp 
3. pregnan* .mp 
4. HYPERTENSION, PREGNANCY-INDUCED/ (MeSH) 
5. PRE-ECLAMPSIA/ (MeSH) 
6. HYPERTENSION/ (MeSH) 
7. BLOOD PRESSURE/ (MeSH) 
8. HEART/ (MeSH) 
9. cardi* .mp 
10. “cardiac function” .mp 
11. “cardiac structure” .mp 
12. “cardiac geometry” .mp 
13. diastolic OR systolic .mp 
14. function OR dysfunction .mp 
15. 13 AND 14 
16. ECHOCARDIOGRAPHY/ (MeSH) 
17. CARDIAC IMAGING TECHNIQUES/ (MeSH) 
18. DIAGNOSTIC IMAGING/ (MeSH) 
19. ELASTICITY IMAGING TECHNIQUES/ (MeSH) 
20. IMAGING, THREE-DIMENSIONAL/ (MeSH) 
21. 1 OR 2 OR 3 
22. 4 OR 5 OR 6 OR 7 
23. 8 OR 9 OR 10 OR 11 OR 12 OR 15 
24. 16 OR 17 OR 18 OR 19 OR 20 
25. 21 AND 22 AND 23 AND 24 
Key to syntax used: 
* after a word is used as a truncation (“wildcard”) to retrieve plurals or different endings, e.g. 
gestation* would retrieve ‘gestational’ and ‘gestation’ 
MeSH Medical Subject Heading 
/   at the end of a phrase, searches the phrase as a subject heading 
.mp mapping alias (searches title, abstract, heading words, table of contents and key phrase 
identifiers) 
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Eligibility criteria and study selection 
The population of interest was pregnant women with GH or PET.  My inclusion criteria 
required an echocardiogram during pregnancy (before and/or after the diagnosis of GH/PET).  
Pregnant women with normal blood pressure were included as a comparison group.  The 
exclusion criteria were: (1) studies published only in abstract form; (2) duplicate publications 
or publications using the same dataset (in the latter case only the largest study including the 
same patients would be included, unless different data were presented in each paper); (3) case 
reports, editorials, opinion articles, commentaries and letters; (4) animal studies; (5) studies 
including only multiple pregnancies; (6) studies assessing therapeutic effects; and (7) studies 
of pregnant women with chronic hypertension, unless a group with GH or PET were also 
included. 
 
Data collection, outcomes and quality assessment 
A standardised data extraction form was used.  Outcome measures included any 
echocardiographic assessment of left-ventricular (LV) structure or function (see Table 4 and 
Figure 4).  The Risk of Bias Assessment Tool for Non-Randomised Studies (RoBANS)118 
was used to critique methodological and reporting quality of the included manuscripts, 
addressing key criteria such as selection bias, exposure measurement, blinding, the 
completeness of outcome data and selectivity of reporting.  Two authors (JSC and FT) 
completed the data quality assessment independently, and any disagreements were resolved 
by consensus.   
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Table 4:  Outcome measures using echocardiography 
Parameter Measurement 
Stroke volume 
(SV, ml) – see Figure 2 
π x (Left ventricular outflow tract diameter / 2)2 x velocity time integral; 
measurements in cm 
Cardiac output 
(CO, L/min) 








(End diastolic volume – end systolic volume) / end diastolic volume x 
100; measurements in mL 
E/A ratio 
see Figure 2 
Mitral valve E wave [early filling] peak velocity / mitral valve A wave 
[late filling during atrial contraction] peak velocity 
E/e’ – see Figure 2 
Mitral valve E wave peak velocity / e’ wave [early diastolic mitral 
annular] velocity on tissue Doppler imaging; measurements in m/s (can be 
derived from the septal or lateral mitral valve annulus) 
LV geometry 
Left ventricular wall thickness, including hypertrophy that is eccentric 
(wall thickness increased in proportion to the increase in chamber size) 
and concentric (increased wall thickness without dilatation). 
Left ventricular mass 
(LVM, g) 
0.8 x [1.04((left ventricular end diastolic dimension + posterior wall 
thickness + interventricular septum thickness)3 – left ventricular end 
diastolic diameter3)] + 0.6; measurements in mm, at end diastole 
 
*Mean arterial pressure (mmHg) is calculated as [Systolic Blood Pressure + (2 x Diastolic 
Blood Pressure)]/3.  Values for stroke volume, cardiac output and left ventricular mass are 
often indexed to body surface area (m2) using the Du Bois formula 119:  0.20247 x 










Assessment of cardiac output (Panels A and B) and left-ventricular diastolic function (Panels 
C and D) using transthoracic echocardiography.  LVOT, left-ventricular outflow tract.  See 






Statistical pooling of data from separate studies was not possible because of marked variation 
in study design and reported outcome measures, thus precluding meta-analysis.  Data were 
therefore synthesised qualitatively. 
 
2.1.3 Results 
Study selection and study characteristics 
The search strategy identified 36 studies, including 745 women with GH, 815 women with 
PET and 7189 normotensive pregnant controls (see Figure 5).   
 





The characteristics of included studies are shown in Table 4.  All studies had an observational 
design, with 25 case-control studies,120-144 8 cross-sectional studies 145-152 and 3 longitudinal 
cohort studies.153-155  The majority of studies (n=20) were of women with PET.120, 125, 127, 128, 
130, 131, 137-140, 142-145, 147-149, 152, 154  There were nine studies assessing GH only 122, 124, 126, 129, 135, 
136, 141, 151, 155 and seven studies evaluating both GH and PET.121, 123, 129, 132, 146, 150, 153  All 
investigators recruited women during antenatal visits to hospital.  In three of the studies where 
women were scanned prior to the onset of hypertension, the women had already been 
identified as a high risk group due to fetal growth restriction,145 raised uterine artery Doppler 
133 or PET in a previous pregnancy.154  
 
The majority of studies investigated patients with a single echocardiogram during the third 
trimester (n=29).  Of the three longitudinal studies, one included echocardiography in each 
trimester153 and the other two covered two trimesters.154, 155  Considerable heterogeneity was 
seen between and within the study populations (see Table 6), such that meta-analysis was not 
deemed appropriate.  In six studies, a proportion of the patients were on antihypertensive 
therapy.131, 137, 141, 146, 154, 155  In two studies, the PET group included a small number of women 
with chronic hypertension and superimposed PET.146, 154  
 
Other obstetric outcomes, for example birthweight and gestation at delivery, were recorded in 
15 of the studies.127, 130, 132, 137, 138, 143-145, 147, 149-154  Only three authors analyzed the 
relationship between these pregnancy outcomes and echocardiographic measurements130, 132, 
151 (see Table 7).  
 
The risk of bias assessment identified variable study quality (see Table 8).  Due to the nature 
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of the studies, the risk of specific biases (particularly blinding) was uncertain due to limited 










Author, year Population (Country) 
Inclusion 
criteria  Exclusion criteria Controls/comparison 
Timing of 
echocardiography 
(gestational age in 
weeks) 
Longitudinal cohort studies 
1 
-3 
Bosio, 1999 153 Antenatal patients 
attending hospital 
(Ireland) 
GH or PET Parity >0; cardiac disease; essential hypertension; chronic illness; 
long term medication; multiple pregnancy; significant obstetric or 
medical complication 
Nil 5 appointments: 10-











Multiple pregnancy; renal disease; missed > 2 appointments Nil Prior to pregnancy 









GH Essential hypertension; diabetes; structural heart disease Normotensive pregnant 24±3 and 36±1 
Cross sectional studies 






Multiple pregnancy; missing outcome data; miscarriage; termination 
of pregnancy; major anomalies at birth 
Normotensive pregnant 
women split into two groups: 
SGA (n=532) and 
uncomplicated (n=3591) 
11+0 to 13+6  
Khaw, 2008 147 Antenatal patients 
attending hospital 
(UK) 















Parity >0; essential hypertension; proteinuria prior to 20 weeks 
gestation; comorbidities; smoking; medication; fetal anomalies; 
persistent hypertension after 12 weeks post-partum 
Women with normal uterine 
artery pulsatility index and 
women with raised pulsatility 
index (term delivery) 
20-23 













Multiple pregnancy; undetermined gestational age; smoking; multiple 
pregnancy; cardiac disease; pre-existing medical problem; fetal 
anomalies; persistent hypertension at 1 year follow up 







Author, year Population (Country) 
Inclusion 
criteria  Exclusion criteria Controls/comparison 
Timing of 
echocardiography 
(gestational age in 
weeks) 
3 Bamfo, 2008 145 Pregnant women 






GH; multiple pregnancy; co-morbidities; medication; fetal anomalies; 
chromosomal abnormalities; genetic syndromes; infections 
Normotensive with fetal 
growth restriction 
28 (24-35) 
Estensen, 2013 148 Antenatal patients 
attending hospital 
(Norway) 
PET Essential hypertension; diabetes; renal impairment; hyperlipidemia; 
uncontrolled endocrine or rheumatological disease; cardiovascular 
disease 
Non-pregnant with previous 
PET 
36 
Shahul, 2012 150 Antenatal patients 
attending hospital 
(USA) 
GH or PET Multiple pregnancy; age < 18 years; gestation < 24 weeks pre-
existing cardiovascular disease; pulmonary disease; diabetes; poor 
image quality; preterm prelabor rupture of membranes 











Mild GH Systolic blood pressure >150; diastolic blood pressure >100; 
proteinuria; essential hypertension; hemolysis, elevated liver 
enzymes and low platelets (‘HELLP’); antihypertensive therapy; 
small for gestational age fetus; abnormal fetal Doppler; abnormal 
liquor volume; undetermined gestational age; smoking; multiple 
pregnancy; maternal heart disease; maternal chronic medical 
problems; fetal anomaly 
Normotensive pregnant 28-31 
Case control studies 
3 Borghi, 2000 120 Antenatal patients 
attending hospital 
(Italy) 
PET Essential hypertension; secondary hypertension; obesity; diabetes; 
cardiomyopathy; valvular heart disease; major electrocardiogram 
abnormality 




Borghi, 2011 121 Antenatal patients 
attending hospital  
(Italy) 





Cho, 2011122 Antenatal patients 
attending hospital 
(South Korea) 
GH Diabetes; essential hypertension; cardiac disease Normotensive pregnant NTP 35.1±3.4; 
GH 33.3±3.6 
Degani, 1989 123 Antenatal patients 
attending hospital 
(Israel) 
GH or PET Multiple pregnancy; previous hypertension; previous heart disease; 
antihypertensive therapy 







Author, year Population (Country) 
Inclusion 
criteria  Exclusion criteria Controls/comparison 
Timing of 
echocardiography 
(gestational age in 
weeks) 
Demir, 2003 124 Antenatal patients 
attending hospital 
(Turkey) 
GH Essential hypertension Normotensive pregnant 38 
 Dennis, 2012 125 Antenatal patients 
attending hospital 
(Australia) 
PET In labour; smoking; vasoactive medication; critically ill requiring 
urgent antihypertensive or magnesium sulfate 








GH Parity >0; age under 16; history of heart disease; multiple pregnancy Non-pregnant 26-42 
Hamad, 2009 127 Antenatal patients 
attending hospital 
(Sweden) 
PET Parity >0; smoking; assisted conception; multiple pregnancy; 
clinically unstable; antihypertensive therapy; chronic disease; 
extreme obesity 
Normotensive pregnant NTP 33±4; 
PET 35±4 
Ingec, 2005 128 Antenatal patients 
attending hospital 
(Turkey) 
PET Not stated Normotensive pregnant NTP 38±1; 
PET 37±3 
Kuzniar, 1982 130 Antenatal patients 
attending hospital 
(Poland) 
PET Multiple pregnancy; uncomplicated pregnancy; cardiorespiratory 
disease 
Normotensive pregnant and 
pregnant with essential 
hypertension 
30-40 
Kuzniar, 1992 129 Antenatal patients 
attending hospital 
(Poland) 
Mild GH Previous hypertension; renal disease; persistent hypertension 3 
months post-partum; hypertension prior to 3rd trimester; SBP > 160; 
DBP >110   
Normotensive pregnant 32-41 
Lang, 1991 131 Antenatal patients 
attending hospital 
(USA) 








GH or PET Multiple pregnancy; co-morbidities; smoking; antihypertensive 
therapy 






PET Multiple pregnancy; comorbidity; smoking; medication;  Normotensive pregnant (50 
term; 54 preterm) 
preterm NTP 32 
(28.6 – 35.7); 
preterm PET 35.5 
(28.1-35.8) 
Novelli, 2003 134 Antenatal patients 
attending hospital 
(Italy) 
GH Multiple pregnancy; medications other than vitamins/iron; 
indeterminate gestational age; smoking; cardiac disease; 
antihypertensive therapy; pre-existing medical problem 
Normotensive pregnant and 









Author, year Population (Country) 
Inclusion 
criteria  Exclusion criteria Controls/comparison 
Timing of 
echocardiography 
(gestational age in 
weeks) 
 
Oren, 1996 135 Antenatal patients 
attending hospital 
(Israel) 
GH Essential hypertension; diabetes; renal disease; molar pregnancy; 
hydrops 
Normotensive pregnant and 




Sanchez, 1986 136 Antenatal patients 
attending hospital 
(Argentina) 
GH Complicated pregnancy; cardiorespiratory disease Normotensive pregnant; non-








PET Medical co-morbidities; essential hypertension; diabetes; multiple 
pregnancy; vasoactive medication 
Normotensive pregnant and 
non-pregnant 
NTP 12±2, 22±1, 
35±5; 
PET 35±4 
Solanki, 2011 138 Antenatal patients 
attending hospital 
(India) 
PET Multiple pregnancy; unsure of dates; essential hypertension; cardiac 
disease; moderate or severe anemia; multiple pregnancy; alcohol use; 
smoking 






PET Essential hypertension; medication Normotensive pregnant 32-38 
Tyldum, 2010 140 Antenatal patients 
attending hospital 
(Norway) 
PET Diabetes; essential hypertension; cardiac disease; multiple pregnancy Normotensive pregnant 27-40 (mean 35) 
Veille, 1984 141 Antenatal patients 
attending hospital 
(USA) 
GH Essential hypertension; antihypertensive therapy other than 
magnesium sulfate or diuretics; multiple pregnancy 
Normotensive pregnant 38±2 
Yuan, 2006 142 Antenatal patients 
attending hospital 
(China) 
PET Essential hypertension; renal disease; cardiac disease; diabetes Normotensive pregnant mean 39 
Yuan, 2014 143 Antenatal patients 
attending hospital 
(China) 
PET Parity >0; multiple pregnancy; GH; essential hypertension; risk 
factors for arterial stiffening (smoking; obstructive sleep apnea; in 
vitro fertilization; diabetes; hypercholesterolemia) 






PET Age under 18; post-partum PET Normotensive pregnant NTP 37 (36-39); 
PET 34 (31-35) 
Data are presented as means ± standard deviation or medians (interquartile range).   
GH, gestational hypertension; NTP, normotensive pregnant control; PET, preeclampsia
34 





Number of cases Age Parity 
NTP GH PET NTP GH PET NTP GH PET 
Bamfo, 2008 
145










 85 35 0 40 31±3 n/a 31±5 2±7 n/a 2±1 
Borghi, 2011 
121
 112 39 24 33 31±4 29±5 32±5 2±1 2±1 2±1 
Bosio, 1999 
153

















 199 93 106 0 30±4 32±4 n/a not reported 
De Paco, 2008 
146
 





















 92 56 36 0 26±6 29±9 n/a not reported 
Dennis, 2012 
125
 100 40 0 40  
(6 early; 
34 late) 


















145 65 0 40 32±5 n/a 32±6 58% P0 n/a 67% P0 
Hamad, 2009 
127
 65 30 0 35 
(8 early;  
27 late)  






 37 17 0 20 29±6 n/a 32±7 not reported 
Khaw, 2008 
147




(22 -33);  
with 
SGA 31 




























































Number of cases Age Parity 




214 168 0 46 
(18 
preterm; 


















 114 38 36 0 32±6 31±6 n/a not reported 
Oren, 1996  
135
 30 10 10 0 23±2 23±3 n/a not reported 
Sanchez, 1986 
136






































71 44 0 15 29±5 n/a 32±6 not reported 
Solanki, 2011 
138
 40 20 0 20 
(12 mild; 
8 severe) 




35 11 0 10 24 (range 
19-29) 
































1226 1119 0 107 
(75 early; 
32 late) 














47 12 35 0 30±4 30±6 n/a not reported 
Yuan, 2006 
142
 56 24 0 32 27±3.1 n/a 27±3 not reported 
Yuan, 2014 
143












35% P0 n/a 45% P0 
Data are presented as means ± standard deviation or medians (interquartile range). 
 * Definition of GH could include patients with PET; † GH group includes patients with essential 
hypertension.  
Comp., complicated; uncomp., uncomplicated; GH, gestational hypertension; n/a, not applicable; NTP, 
normotensive pregnant control; P1, parity 1 etc.; PET, preeclampsia; SGA, small for gestational age fetus. 
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Table 7:  Obstetric outcomes 
Author, year Obstetric outcomes 
Bamfo, 2008
145
 Earlier delivery and lower birthweight in PET. 
Bosio, 1999
153
 Perinatal mortality in GH = 2/24 (8.3%). 
Perinatal mortality in PET = 6/20 (30%) 
Earlier delivery and lower birthweight in PET. 
Hamad, 2009
127
 Earlier delivery and lower birthweight in PET. 
Kuzniar, 1982
130
* Positive correlation between cardiac index and fetal birthweight.  
Inverse relationship between infant birthweight and TVR. 
Khaw, 2008 
147
 Lower birthweight in PET. 
Melchiorre, 2011
132
* In the PET group there were the following outcomes: 
Hemolysis, elevated liver enzymes and low platelets (HELLP syndrome) 
= 3/50 (6%) 
Acute kidney injury = 1/50 (2%) 
Pulmonary edema = 1/50 (2%) 
Fetal growth restriction = 11/50 (22%) 
Melchiorre, 2013
149




 Earlier delivery and lower birthweight in PET. 
Shahul, 2012
150
 Earlier delivery in PET.  
No significant difference in birthweight in PET. 
More women with PET had a history of GH in a previous pregnancy. 
Simmons, 2002
137
 Earlier delivery and lower birthweight in PET. 
Solanki, 2011
138
 Earlier delivery and lower birthweight in PET. 
Valensise, 2006
151
* In the GH group there were the following outcomes: 
Perinatal death = 2/268 (0.7%) 
PET = 17/268 (6.3%) 
Placental abruption = 3/268 (1.1%) 
Hemolysis, elevated liver enzymes and low platelets (HELLP syndrome) 
= 6/268 (2.2%) 
Fetal growth restriction = 19/268 (7.1%) 
Neonatal unit admission = 5/268 (1.9%) 
Valensise, 2008
152
 Lower birthweight in early PET (<34 weeks).  
Earlier delivery in early and late PET. 
Yuan, 2014
143
 Lower birthweight in PET. 
Zieleskiewicz, 2014
144
 In the PET group there were the following outcomes: 
Perinatal mortality = 3/20 (15%) 
Hemorrhage = 2/20 (10%) 
Eclampsia = 2/20 (10%) 
Pulmonary edema = 4/20 (20%) 
Placental abruption = 2/20 (10%) 
Fetal growth restriction = 5/20 (25%) 
Preterm delivery before 34 weeks = 6/20 (30%) 
 
* analysis includes obstetric outcomes in relation to cardiovascular parameters. 
GH, gestational hypertension; PET, preeclampsia; TVR, total vascular resistance. 
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Table 8:  Risk of bias assessment 
















 Low risk Low risk Low risk High risk Low risk Unclear risk 
Borghi, 2000
120
 Low risk High risk Low risk Low risk High risk Unclear risk 
Borghi, 2011
121
 Low risk High risk Low risk Low risk Low risk Unclear risk 
Bosio, 1999
153
 Low risk High risk Low risk Unclear risk High risk Unclear risk 
Cho, 2011
122
 High risk High risk Low risk Low risk Low risk Unclear risk 
De Paco, 2008
146
 Low risk Low risk Low risk Unclear risk High risk Unclear risk 
Degani, 1989
123
 Low risk High risk Low risk Unclear risk Low risk Unclear risk 
Demir, 2003
124
 Unclear risk High risk Low risk Unclear risk Low risk Unclear risk 
Dennis, 2012
125
 Low risk Low risk Low risk Unclear risk Low risk Unclear risk 
Escudero, 1988
126
 Unclear risk High risk Low risk Unclear risk Low risk Unclear risk 
Estensen, 2013
148
 High risk High risk Low risk Unclear risk High risk Unclear risk 
Hamad, 2009
127
 Low risk High risk Low risk Unclear risk Low risk Unclear risk 
Ingec, 2005
128
 Unclear risk High risk Low risk Low risk Low risk Unclear risk 
Khaw, 2008
147
 Low risk Low risk Low risk Unclear risk High risk Unclear risk 
Kuzniar, 1982
130
 High risk High risk Unclear risk Unclear risk High risk Unclear risk 
Kuzniar, 1992
129
 Low risk High risk Low risk Low risk Low risk Unclear risk 
Lang, 1991
131
 Low risk High risk Low risk Unclear risk Low risk Unclear risk 
Melchiorre, 2011
132
 Low risk Low risk Low risk High risk Low risk Unclear risk 
Melchiorre, 2012133 Low risk Low risk Low risk High risk Low risk Unclear risk 
Melchiorre, 2013
149
 Low risk Low risk Low risk Unclear risk Low risk Unclear risk 
Novelli, 2003
134
 Low risk High risk Low risk Unclear risk Low risk Unclear risk 
Oren, 1996
135
 Unclear risk High risk Low risk Unclear risk Low risk Unclear risk 
Sanchez, 1986
136
 Unclear risk High risk Low risk Unclear risk Low risk Unclear risk 
Sep, 2011
154
 Low risk High risk Unclear risk Low risk High risk Unclear risk 
Shahul, 2012
150
 Low risk Low risk Low risk Low risk Low risk Unclear risk 
Simmons, 2002
137
 Low risk High risk Low risk Unclear risk Low risk Unclear risk 
Solanki, 2011
138
 Unclear risk High risk Low risk Unclear risk Low risk Unclear risk 
Thompson, 1986
139
 Unclear risk High risk Low risk Low risk Low risk Unclear risk 
Tyldum, 2010
140
 Low risk High risk Low risk Unclear risk Low risk Unclear risk 
Valensise, 2006
151
 Low risk High risk Low risk Unclear risk Low risk Unclear risk 
Valensise, 2008
152
 Low risk High risk Low risk Low risk Low risk Unclear risk 
Veille, 1984
141
 Unclear risk High risk Low risk Unclear risk High risk Unclear risk 
Vlahovic-Stipac, 2010
155
 Low risk High risk Low risk Low risk Low risk Unclear risk 
Yuan, 2006
142
 Unclear risk High risk Low risk Unclear risk Low risk Unclear risk 
Yuan, 2014
143
 Low risk Low risk Low risk Unclear risk Low risk Unclear risk 
Zieleskiewicz, 2014
144
 Low risk High risk Low risk High risk Low risk Unclear risk 
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Synthesis of results 
Results are summarised below according to hemodynamic parameters and systolic function, 
diastolic function, and cardiac structure.   The details of extracted parameters from all studies, 
including the earlier screening studies, are presented in Table 9.  Table 10a presents an 
overview of findings for the main echocardiographic variables investigated in the third 
trimester studies.  Figure 6 highlights the major echocardiographic changes that may be seen 
in hypertensive disorders as compared to normal pregnancy.  Figure 7 provides representative 
images from echocardiograms of women with and without gestational hypertensive disease. 
 
Haemodynamics and systolic function 
Total vascular resistance was significantly higher in GH compared with normotensive 
pregnant controls 123, 134, 135, 141, 153 but lower than in PET.129, 153  In GH, there were conflicting 
reports for cardiac output, including an increase121, 146, 153, 155 or no change compared to 
normal pregnancy.123, 134, 135  Myocardial performance index and LV function were unchanged 
in a longitudinal study of GH with second and third trimester measurements.155  In GH studies 
with a third trimester echocardiogram, only one showed a significant reduction in LV ejection 
fraction 135, whilst three others showed no difference.122, 135, 155   
 
In PET, studies covering early trimesters demonstrated that the preclinical phase is 
characterised by a hyperdynamic circulation with high cardiac output and low peripheral 
resistance.146, 147, 149, 153  In the second trimester, women who go on to develop PET have 
increased total vascular resistance at mid-gestation, with lower cardiac output.149, 152  Once 
PET manifests clinically, there is reduced cardiac output and increased resistance,148, 153 
described as a “hemodynamic crossover” in the clinical phase of PET.153  The increased total 
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vascular resistance seen in PET121, 125, 129, 138, 145, 148 is an independent predictor of adverse 
maternal and fetal outcomes.151  In the clinical phase, early onset PET (<34 weeks gestation) 
is characterised by significantly lower cardiac output and higher total vascular resistance 
compared with late onset PET.149, 152  Pregnant women who develop recurrent PET have also 
been shown to have lower cardiac output and higher peripheral resistance than women 
without recurrent disease.154 
 
Stroke volume is lower in PET than in normal pregnancy 129, 130 and in the first trimester this 
is an independent predictor of subsequent development of PET.147  Due to the factors 
discussed, cardiac output in PET has been shown to be both lower 121, 125, 130, 137, 145, 148 and 
higher 125, 129, 138, 146, 147 compared to normotensive pregnancies.  The variation in cardiac 
output is shown in Table 9, which also indicates its derivation, since the use of different 
calculations (based either on Doppler or volume calculation) is likely to contribute to the 
disparity for this parameter.  There was similar variability with regard to LV ejection fraction, 
with the majority of studies showing no significant difference compared with normotensive 
pregnant women125, 139, 143, 144, 148 and only one showing a decrease.120  Myocardial 
performance index was reduced in a study of women with PET and fetal growth restriction in 
the third trimester.145  Systolic dysfunction, with marked LV hypertrophy, is significantly 
more common in preterm PET compared to term PET 133, even before the condition manifests 
clinically.149 
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Author, year Results: systolic function Results: diastolic function Results: Cardiac structure 
Longitudinal cohort studies 
1 
-3 
Bosio, 1999 153 F Presented as Box and Whisker plot and then numerically as 









At baseline (24±3 weeks): 
CO V: NTP 3.5 (0.8); GH 4.6 (1.3) 
TVR: NTP 2046 (464); GH 1933 (537) 
LVEF: NTP 64 (5); GH 61 (7) 
At follow up (36±1 weeks): 
CO: NTP 3.7 (0.7); GH 4.6 (1.1) 
TVR: NTP 1998 (486); GH 1821 (454) 
LVEF: NTP 60 (8); GH 58 (6) 
At baseline (24±3 weeks): 
E/A: NTP 1.9 (0.9); GH 1.3 (0.5)* 
E/e’: NTP 6.2 (1.1); GH 7.6 (1.9)* 
At baseline (24±3 weeks):  
LVMI: NTP 110 (23) GH 127 
(33) 
  
Cross sectional studies 
1 De Paco, 2008 146 Mean log MoM CO F: NTP 0.000 (95% CI -0.0025 to 0.0025); 
PET 0.0261 (95% CI 0.0065 to 0.0457)*; GH 0.0257 (95% CI 
0.0079 to 0.0435)* 
  
Khaw, 2008 147 CO F: NTP 4.9 (4.3-5.5); PET not SGA 6.2 (5.4-7.1)*; PET with 
SGA 4.9 (4.1-5.6)* 
CI: NTP 2.9 (2.6-3.3): PET not SGA 3.3 (3.0-4.0)*; PET with SGA 
2.8 (2.4-3.0)* 
TVR: NTP 1260 (1110-1460); PET not SGA 1105 (920-1280); PET 
with SGA 1410 (1300-1530) 
SV: NTP 67 (11.7); PET not SGA 87.9 (15.2); PET with SGA 66.3 
(10.9) 
  
2 Melchiorre, 2013 149 CI V: term PET 3.2 (2.8-3.5); preterm PET 2.6 (2.3-2.8) 
TVRI: term PET 2138 (1995-2469); preterm PET (3090 (2351-
3376) 
LVEF: term PET 60 (51-69); preterm PET 64 (48-67);  
E/A ratio: term PET 1.6 (1.3-2.2); 
preterm PET 1.4 (0.9-1.6) 
Average E/e’: term 6.2 (5.3-6.7); preterm 
6.5 (5.3-7) 
LVMI: term PET 65 (57-71); 
preterm PET 62 (57-71) 
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2 Valensise, 2008 152 CO F: NTP 6.61 (1.1); early PET 4.49 (1.09)*; late PET 8.96 
(1.83)* 
TVR: NTP 990 (179); early PET 1605 (248)*; late PET 739 (244)* 
SV: NTP 83 (11): early PET 61 (13)*; late PET 102 (19)* 
Significant difference between early and late PET groups and 
controls, and between early and late PET. 
E/A: NTP 1.17 (0.23); early PET 1.68 
(0.5)*; late PET 1.09 (0.15)* 
LVMI: NTP 33 (6); early PET 
35 (7)*; late PET 43 (12)* 
Significant difference between 
early and late PET groups and 
controls, and between early and 
late PET. 
3 Bamfo, 2008 145 CO F: NTP 4.79 (0.52); PET 5.52 (1.21)* 
CI: NTP 2.94 (0.30); PET 3.12 (0.71) 
TVR: NTP 1434.05 (255.93); PET 1573.51 (268.87) 
SV : NTP 61.06 (8.80); PET 75.10 (15.88)* 
E/A ratio: NTP 1.39 (0.23); PET 1.33 
(0.42) 
E/e’ septal: NTP 6.13 (1.04); PET 8.70 
(2.31)* 
E/e’ lateral: NTP 4.61 (1.12); PET 6.27 
(2.15)* 
 
Estensen, 2013 148 CO F: NTP 5.8 (1.1); PET 6.3 (1.2)* 
SV: NTP 75 (13); PET 76 (16)* 
LVEF: NTP 54 (7); PET 56 (6) 
  LVMI: NTP 80 (17); PET 92 
(25)* 
Shahul, 2012 150 LVEF F: NTP median 65.0 (64.6-66.5); GH 66.7 (65.4-67.5); PET 
67.5 (64.2-70.0) 
   
Valensise, 2006 151 CO F: NTP 6.75 (0.96); complicated PET 5 (1); uncomplicated PET 
7.4 (1.2)* 
TVR: NTP 949 (150); complicated PET 1754 (425); uncomplicated 
PET 1138 (183)* 
SV: NTP 77 (10); complicated PET 62 (11); uncomplicated PET 82 
(11)* 
  LVM: NTP 148 (20); 
complicated PET 169 (32); 
uncomplicated PET 176 (25)* 
LVMI: NTP 40 (6); 
complicated PET 45 (9); 
uncomplicated PET 47 (8)* 
Case control studies 
3 Borghi, 2000 120 CO F: NTP 7.9 (1.0); PET 6.5 (1.0)* 
TVR: NTP 779 (203); PET 1320 (278) 
LVEF: NTP 67.7 (5.0); PET 65.9 (6.0). 
E/A ratio: NTP 1.59 (0.3); PET 1.29 
(0.3)*  
LVMI: NTP 101.1 (16.0); PET 
110.3 (19.0)* 
Borghi, 2011 121 CO F: NTP 6.6 (2); GH 8.1 (2); PET 5.6 (2) 
TVR: NTP 939 (192); GH 1006 (253); PET 1517 (295) 
 LVMI: NTP 101.1 (16); GH 
109.5(21); PET 111.9 (18) 
Cho, 2011 122 LVEF: NTP 60.7 (7.8) GH 62.3 (9) E/A: NTP 1.27 (0.22); GH 1.00 (0.29)*  LVMI: NTP 86.1 (14.5); GH 
95.6 (17.3)* 
Degani, 1989 123 CO: NTP 5.4 (1.1); GH 5.6 (2.3) 
CI: NTP 3.52 (0.7); GH 3.55 (0.7) 
TVR: NTP 1340.1 (211.0); GH 1636.6 (521.3)* 
SV: NTP 68.4 (13); GH 70.5 (22.2) 
LVEF: NTP 72.0 (0.2); GH 75.0 (7.0) 
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Demir, 2003 124 LVEF: NTP 37 (6); GH 72 (3)   LVMI: NTP 117 (15); GH 138 
(13.8)* 
61% of GH patients had 
abnormal LV geometry 
compared with 21% NTP* 
 Dennis, 2012 125 CO F: NTP 4.109 (0.595); PET 4.789 (1.419)* 
TVR: NTP 1613 (315); PET 2016 (625)* 
E/A: NTP 1.45 (0.24); PET 1.29 (0.34) 
E/e’: NTP 6.7 (1.3); PET 10.4 (2.4)*  
LVM: NTP 131 (21); PET 189 
(40)* 
Escudero, 1988 126     LVM: non-pregnant 161 (29.6); 
GH 185 (53.1)*  
Hamad, 2009 127   E/A: NTP 1.54 (0.07); PET 1.29 (0.07)* 
E/e’ septal; NTP 7.49 (0.40); PET 10.92 
(0.38)* 
E/e’ lateral: NTP 5.72 (0.20); PET 8.23 
(0.43)* 
LVM: NTP 180 (8); PET 239 
(8)* 
Ingec, 2005 128     LVMI: NTP 82.8 (26); PET 
127.6 (42)* 
Kuzniar, 1982 130 CO V: NTP 7.5 (1.3); PET 5.9 (1.0)* 
CI: NTP 4.3 (0.7); PET 3.3 (0.5)* 
TVR: NTP 877 (197); PET 1727 (408)* 
SV: NTP 101.3 (14); PET 89 (15.9)* 
    
Kuzniar, 1992 129 CI V: NTP 4.23 (0.65); GH 4.72 (0.67); PET 3.62 (0.62)* 
TVRI: NTP 1670 (312); GH 1881 (396); PET 2555 (365)* 
SVI: NTP 57.1 (6.4); GH 58.9 (6.3); PET 51.2 (5.6)*  
    
Lang, 1991 131 CO F: NTP 6.18 (1.91); PET 5.52 (1.55) 
TVR: NTP 1203 (466); PET 1786 (496) 
SV: NTP 72 (17); PET 65 (10)  
  LVMI: NTP 105 (13); PET 108 
(19) 
Melchiorre, 2011 132 CI V: NTP 3.2 (2.2-3.9); GH 2.8 (2.4-3.2); PET 2.9 (2.1-3.8) 
TVRI: NTP 645 (570-840); GH 951 (756-1086); PET 716 (574-
1036) 
E/A: NTP 1.14 (0.88-1.43); PET normal 
diastolic function (n=30) 1.34 (1.27- 1.55); 
PET diastolic dysfunction (n=20) 0.81 
(0.73-0.95) 
Average E/e’: NTP 6.1 (5.2-6.5); PET 
normal diastolic function 6.5 (6.3-6.9); 
PET diastolic dysfunction 7.9 (6-8.3) 
  
Melchiorre, 2012 133 CI V: NTP 3.2 (2.7-3.7); preterm PET 2.6 (2.1-3.1)* E/A: NTP 1.5 (1.4-1.8); preterm PET (1.2 
(0.7-1.5)* 




Novelli, 2003 134 CO V: NTP 4.9 (0.9); GH 5.3 (1.1) 
TVR: NTP 1422 (221); GH 1621 (358)* 
SV: NTP 68 (10); GH 68 (12) 
E/A: NTP 1.61 (0.31); GH 1.31 (0.28)* LVMI: NTP 33 (7); GH 50 (8)* 
 Oren, 1996 135 CI V: NTP 3.64 (0.64); GH 3.55 (0.89) 
TVR: NTP 14 (2); GH 16.7 (4.0)* 
LVEF: NTP 68.5 (5.6); GH 63 (7.3)* 
E/A: NTP 1.6 (0.5); GH 1.2 (0.3)* LVMI: NTP 86 (21); GH 99.4 
(28)* 
Sanchez, 1986 136     LVM: NTP 154.65 (31); GH 
170.36 (47) 
Simmons, 2002 137 CI F: NTP 4.2 (0.9); PET 4.1 (1.1)* 
TVR: NTP 852 (190); PET 1129 (319)* 
 LVMI: NTP 76 (16); PET 90 
(18)* 
Solanki, 2011 138 TVR F: NTP 1204.5 (71.18); PET 1396.85 (156.2)* 
SV: NTP 70.8 (3.22); PET 73.3 (14.19)  
E/A: NTP 1.35 (0.224); PET 1.497 (0.492)   
Thompson, 1986 139 LVEF F: NTP 71.6 (7.1); PET 70.8 (6.0)     
Tyldum, 2010 140 CO V: NTP 5.4 (1.4); PET 5.8 (1.2) 
SV: NTP 68 (23); PET 76 (11) 
E/A: NTP 1.50 (0.37); PET 1.41 (0.36) 
E/e’: NTP 5.7 (1.0); PET 8.6 (1.5)* 
LVM: NTP 127 (30); PET 161 
(28)* 
Veille, 1984 141 CO V: NTP 5.5 (1.8); GH 5.8 (1.4)   LVM: NTP 105 (14): GH 117 
(20)* 
Yuan, 2006 142 CI F: NTP 4.0 (0.6); PET 3.9 (0.9) 
SV: NTP 71.0 (17.7); PET 79.6 (23.4) 
LVEF: NTP 0.66 (0.08); PET 0.72 (0.07)* 
E/A: NTP 1.4 (0.2); PET 1.2 (0.2)*   
Yuan, 2014 143 CI F: 2.99 (0.56); PET 3.07 (0.72) 
LVEF: NTP 0.66 (0.05); PET 0.68 (0.10). 
E/A: NTP 1.41 (0.31); PET 1.24 (0.36) 
 
LVMI: NTP 96.3 (17.8);  PET 
110.9 (29)* 
Zieleskiewicz, 2014 144 TVRI*: NTP 723 (123); PET 894 (304) E/A: NTP 1.4 (1.2-1.6); PET 1.1 (1.0-1.5) 
E/e’: NTP 6.6 (5.8-7.0); PET 7.9 (5.9-
8.9)* 
  
Data are presented as means (standard deviation) or medians (interquartile range). 
* statistically significant difference with p-value <0.05; F Flow-based hemodynamic calculation (SV calculated from the velocity time integral of the pulsed 
Doppler waveform multiplied by the left ventricular outflow tract cross sectional area); V Volume-based hemodynamic calculation (SV calculated by 
subtracting the left ventricular end systolic volume from the left ventricular end diastolic volume). 
 
A, late diastole transmitral wave peak velocity (cm/s); CO, cardiac output (L/min); CI, cardiac index (L/min/m2); E, early diastole transmitral (filling) peak 
velocity (cm/s); e’, peak early diastolic velocity at mitral valve annulus (cm/s); GH, gestational hypertension; LVEF, left ventricular ejection fraction (%); 
LVM, left ventricular mass (g); LVMI (g/m2), left ventricular mass index; NTP, normotensive pregnant controls; PET, preeclampsia; SGA, small for 
gestational age fetus; SV, stroke volume (ml); SVI, stroke volume index (ml/m2); TVR, total vascular resistance (dynes/ s1/cm5); TVRI, total vascular 
resistance index (dynes s-1 cm-5/m2).  
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* third trimester results from longitudinal study; † all cases early preeclampsia (before 34 weeks gestation); ‡ studies with postnatal follow up. 
á, significant increase; â, significant decrease; =, no significant difference compared to controls; CO, cardiac output; G, gestational hypertension; LVEF, 
left ventricular ejection fraction; LVM, left ventricular mass; P, preeclampsia; TVR, total vascular resistance.
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Summary of major findings comparing normotensive pregnancy with gestational 
hypertension/preeclampsia and association with adverse outcomes.  * A progressive and slight 
increase in left ventricular wall thickness and mass is seen during normal pregnancy that regresses 
post-partum.7, 156
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Figure 7:  Representative echocardiographic images 
 
E, early diastole transmitral (filling) peak velocity (cm/s); e’, peak early diastolic velocity at mitral valve 
annulus (cm/s); LVEF, left ventricular ejection fraction (%) 
 
Both echocardiograms were performed at 30 weeks gestation and both patients had normal blood 
pressure and were not on any medications.  Patient 1 is a 23 year-old with one previous 
uncomplicated pregnancy. Her blood pressure remained normal throughout the current uneventful 
pregnancy, and she delivered at 40 weeks.  Patient 2 is a 25 year-old with one previous pregnancy 
affected by early onset preeclampsia.  The current pregnancy was complicated by gestational 




Several studies have shown that in normal pregnancy the E/A ratio decreases towards term.4, 7, 
17, 21, 52  A greater reduction in E/A has been shown in GH compared to pregnancy unaffected 
by hypertension.122, 134, 135, 142, 155  
 
Diastolic function is also impaired in PET,127, 133, 140 where the usual reduction in E/A is 
exaggerated.120, 127, 133, 142  The ratio of early diastolic mitral inflow velocity to early diastolic 
mitral annular velocity (E/e’), was significantly higher in women with PET in five studies, 
suggesting higher LV filling pressures.125, 127, 140, 144, 149  Interestingly E/e’ was shown to be 
significantly higher in an early-onset PET subgroup compared with a late-onset subgroup.127 
One study used a composite of diastolic indices to diagnose diastolic dysfunction and 
demonstrated diastolic dysfunction in 40% of pregnancies complicated by PET at term, 
compared with 14% of controls.132   In another study, diastolic dysfunction was already 
present at 20-23 weeks in women who developed preterm PET, but not PET at term.149  
Diastolic dysfunction in PET is more marked in cases associated with fetal growth 
restriction145, despite evidence that left atrial mechanical function is similar in PET and 
normotensive pregnant controls.128 
 
Cardiac structure and remodeling 
In most studies, LV mass was significantly increased in GH compared to normotensive 
pregnant controls in the second 135 and third trimester 122, 124, 126, 134, 135, 141, and increased in the 
second half of pregnancy when measured serially.155  One study identified ventricular 
remodeling or hypertrophy in 91% of patients with GH .134  The concentric hypertrophy seen 
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in GH122, 124 is an independent predictor of adverse pregnancy outcomes.151  Other 
investigators found no change in LV mass in GH, showing this instead to be a feature of 
chronic hypertension.136, 139  LV/left atrial diameters were increased in GH compared to 
normotensive controls.125, 142 
 
LV remodeling is more common in PET compared to normotensive pregnant women in the 
third trimester,143 with numerous studies confirming increased LV mass in PET.120, 122, 125, 127, 
128, 132, 137  Hypertrophy in PET tends to be of the concentric type137, and has been shown in 
preterm120, 127, 133 and term PET.128, 132, 133, 142  In one study, concentric LV remodeling was 
demonstrated at 20-23 weeks gestation in 33% of women who subsequently developed 
PET.149  In women who progressed to PET from GH, 27% had abnormal LV structure and 
function at the time of echocardiography.122 
 
2.1.4 Discussion 
I performed a systematic review of all literature pertaining to the use of echocardiography in 
pregnant women with a hypertensive disorder.  My major findings were increased peripheral 
resistance in GH and PET, diastolic dysfunction in PET and conflicting evidence regarding 
changes in cardiac output.  The echocardiographic changes in cardiac structure and function 
can be detected before the condition is clinically apparent.  Current evidence suggests that 
alterations in PET are not due to hypertension alone, but rather reflect PET as a multisystem 
disorder.  PET has a greater impact on the heart than GH, and changes are most pronounced 
in early onset, severe disease.  
 
Currently, echocardiography is not widely used in the clinical management of hypertensive 
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disorders in pregnancy, or as a screening tool for PET.  The application of echocardiography 
in pregnancy has traditionally been in patients with adult congenital cardiac disease, in acute 
illness or for research purposes.  The management of hypertensive disorders in pregnancy is 
based on maternal clinical assessment (symptoms, blood pressure and laboratory parameters) 
and fetal wellbeing.  A decision to deliver the baby can be for maternal or fetal reasons. 
Whereas other reviews have focused on congenital heart disease157 or described 
echocardiographic changes in the context of a broad overview of the management of PET158, 
ours is the first systematic review of cardiac structure and function in gestational hypertensive 
disease. 
 
Clinicians now recognise that PET should no longer be considered as a single disease process.  
There is evidence to suggest that preterm hypertension and proteinuria associated with fetal 
growth restriction is different to hypertension and proteinuria at term when birthweights tend 
to be normal or increased.159  The possible difference in the mechanism of disease and how it 
manifests clinically74 may be responsible for the conflicting results between studies when 
early- and late-onset PET are considered as one entity.  The contradictory hemodynamic 
models described can be explained by noting the distinction between early PET 149, 152 and 
late-onset disease.151, 153 
 
Although based on observational data, my review suggests that echocardiography has the 
potential to improve the management of patients with hypertension during pregnancy and 
categorise patients with GH or PET into high and low risk groups.  Patients with increased 
vascular resistance and LV mass are more likely to have complications.151  As a predictor of 
long term cardiovascular morbidity, diastolic dysfunction in pregnancy is important to 
50 
identify,132 and reduced e’ (and therefore elevated E/e’) may be a useful and early predictor of 
PET.145  Echocardiography can also help to identify the small numbers of women with LV 
systolic impairment who are more likely to deteriorate during pregnancy or post-partum.  
With the currently available data, I suggest the most efficient use of echocardiography is after 
the diagnosis of hypertension, to direct resources to the most vulnerable patients in order to 
improve maternal (and fetal) outcomes (see Figure 8).  The optimal timing of 
echocardiography needs further study.  Whereas an early echocardiogram in the first and 
second trimesters may be helpful for risk stratification, the available data on clinical impact is 
currently limited.  It has also been suggested that echocardiography can stratify hypertensive 
pregnant women into hemodynamic subgroups, thereby enabling clinicians to tailor their 
choice of antihypertensive therapy.147  Hypertension characterised by vasoconstriction 
responds better to beta-blockade whereas in hypertension with reduced plasma volume, 
calcium channel blockers are preferable, as they reduce afterload and improve cardiac 
function.160  Echocardiography can also have an important role in guiding fluid balance, one 
of the most challenging aspects in the management of PET.  Overzealous fluid administration 
can lead to pulmonary edema, and conversely if a patient is under-filled, end-organ 
dysfunction may worsen.  In selected centers and patients, myocardial strain imaging has been 
shown to be more sensitive than LV ejection fraction in detecting differences in LV systolic 
function in women with and without PET.134   Strain measurements can potentially provide 
more information about cardiac function but due to limited data131, 132, 137, 150, further 
investigation is required. 
 
In summary, echocardiography can reveal cardiac impairment in GH and PET, which changes 
antenatal management (medication, frequency of monitoring, timing of delivery) and can 
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indicate when postnatal follow-up is warranted.  More longitudinal studies are required to 
evaluate the cardiovascular changes in hypertensive disorders throughout pregnancy and to 
further define the role of echocardiography in the antenatal assessment of women with GH 
and PET, and in subsequent pregnancies.  It would be useful in clinical and research practice 
to define an ideal dataset for echocardiographic assessment in pregnancy, and agreed outcome 
measures for studies of cardiac structure and function, so that results are comparable and 
pooled data can be analyzed quantitatively.  Clinicians should follow the American and 
European consensus guidelines161 with specific focus on the variables listed in Figure 8.   
 
Diastolic dysfunction can be further graded into impaired myocardial relaxation (E/A <0.73, 
deceleration time [DT] >194ms, isovolumetric relaxation time [IVRT] >83ms), pseudonormal 
filling (E/A 0.73-2.33, DT 138-194ms, IVRT 51-83ms) and restrictive filling (E/A >2.33, DT 
<138ms, IVRT <51ms).  Left atrial dilatation is also a useful echocardiographic marker.  For 
further details, see Melchiorre et al., 2011 132, adapted from recommendations by Nagueh et 
al.162  The criteria listed in the “echo-assisted care” pathway in Figure 8 have not yet been 
subjected to statistical assessment or validation, but rather represent my proposed indices and 
thresholds for triage into low- and high-risk categories based on the findings of my systematic 
review.  Developing collaboration between Cardiologists and Obstetricians has the potential 




Figure 8:  Potential value of echocardiography in hypertensive disorders of pregnancy 




The main limitation of my assessment was the wide variation in patient groups (age, ethnicity, 
body habitus, parity, timing of assessment, disease severity) and reported outcome measures.  
In several studies the participants were grouped based on outcomes other than hypertensive 
disorder diagnosis.  This heterogeneity restricts quantitative synthesis of results and meta-
analysis.  Many of the included studies involve small numbers of patients, with varying levels 
of risk for important bias and likely different levels of echocardiographer experience.  A 
substantial amount of data is derived from load-dependent indices, which may be inferior to 
measurements that take into account the different loading conditions seen in pregnancy.  The 
cross sectional studies capture women at different stages of the disease and offer only a 
snapshot at a single point in time.  At present, there is a paucity of longitudinal data in 
pregnancy.  Only one of the longitudinal studies considered the reproducibility of the 
echocardiographic measurements, and whilst these results were encouraging (intraobserver 
variability 2.4% for cardiac output and 2.0 % for total vascular resistance153), further data in 
pregnant patients are clearly needed. 
 
2.1.5 Implications for current research 
This systematic review demonstrates that cardiac structure and function using 
echocardiography are altered in the preclinical and clinical phases of gestational hypertension 
and preeclampsia.  For women with preeclampsia, diastolic dysfunction and increased 
peripheral vascular resistance correlate with disease severity.  Recognition of impairment in 
cardiac function is important in the contemporary management of gestational hypertension 
and preeclampsia, in order to improve pregnancy outcomes and long-term cardiovascular 
health. 
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2.1.6 Update to systematic review 
Some six eligible studies have been published between March 2015 and March 2019.163-168  
Table 10b presents an overview of the main findings from these studies, which all included a 
third trimester echocardiogram for women with preeclampsia and a normotensive pregnant 
comparison group.  Inconsistent findings relating to cardiac output in preeclampsia are again 
evident. 
Table 10b: Update to Table 10a including more recent studies 
  
















































TVR  á á    
CO  = = â  â 
LVEF   = â  â 
E/A â = â  â  
E/e’  á = á á  
LVM á á á á á  
 
á, significant increase; â, significant decrease; =, no significant difference compared to 
controls; CO, cardiac output; LVEF, left ventricular ejection fraction; LVM, left 
ventricular mass; TVR, total vascular resistance
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2.2 Monocyte subsets in pregnancy: A narrative review 
2.2.1 Introduction 
Cardiac disease is the leading indirect cause of death in pregnancy and the puerperium.35 
Hypertension is seen in 6-8% of pregnancies and causes one third of severe maternal 
morbidity.1  Elevated blood pressure in pregnancy, which includes chronic hypertension, 
gestational (pregnancy-induced) hypertension and preeclampsia, accounts for approximately 
14% of maternal deaths115 and is a risk factor for future cardiovascular disease.92  Gestational 
hypertensive disease is also an important cause of fetal morbidity and mortality, mostly due to 
growth restriction and preterm birth.1 
 
The prediction and early detection of preeclampsia require improvement and new strategies 
for prevention and management are needed.  A greater understanding of the underlying 
mechanisms of disease is required in order to improve outcomes.  Hypertension in pregnancy 
and disorders of the cardiovascular system share many of the same risk factors and underlying 
pathophysiology.  For example, endothelial dysfunction, vascular inflammation and 
remodelling are involved in preeclampsia and in atherosclerosis.169, 170  Monocyte subsets are 
implicated in the pathophysiology of cardiovascular disease and in pregnancy complications.  
Monocytes may play a role in the pathogenesis of pregnancy hypertension. 
 
In this review I provide an overview of the biology of monocytes and their subsets and then 
discuss separately their roles in cardiovascular disease and in maternal health.  Gestational 
hypertensive disease is then proposed as an important area for monocyte research in order to 
investigate the link between pregnancy outcomes and long-term cardiovascular risk. 
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2.2.2 Search strategy 
Any published work on monocyte biology or the roles of monocyte subsets in cardiovascular 
or women’s health was eligible for inclusion in this review.  My search included MEDLINE, 
EMBASE, CINAHL and the Cochrane Library from inception to December 2018, as well as 
relevant reference lists.  The search strategy included the keywords “monocytes”, “subsets”, 
“women”, “cardiac”, “hypertension” and their synonyms.  There was no restriction on the 
type of study design or publication language.  Full text articles were obtained after screening 
the title and/or abstract of relevant studies.   
 
2.2.3 Monocytes 
About 3-8% of peripheral blood leucocytes are monocytes.171  Their phagocytic function 
gives them a principal role in innate immunity.172  They are also involved in procoagulant 
states by their interaction with platelets and play a part in regeneration after tissue injury.173  
Monocytes are the largest pool of progenitor cells, able to differentiate into many phagocytic 
cells types.174, 175  They demonstrate the plasticity to differentiate into a wide range of cells 
including macrophages, dendritic cells, osteoclasts, microglia and Kupffer cells. 
Differentiation of monocytes in various cellular milieu allows them to perform tissue-specific 
roles in different parts of the body, for example they may also act as endothelial progenitor 
cells.176 
 
Monocyte trafficking allows them to migrate out of the circulation, where their half-life is 
around three days177, into areas of injury where they are involved in resolving inflammation 
and restoring the tissue, for example in healing after myocardial infarction.172, 178  Cytokines 
whose expression is induced by monocytes include TNF-α, the interleukins IL-1 and IL-6, 
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transforming growth factors, macrophage colony stimulating factor and insulin-like growth 
factor.172  Monocyte subsets express receptors involved in angiogenesis, tissue repair and 
remodelling, which may point to the nuclear factor kB (NFkB) pathway in effecting the 
reparative role of monocytes.179 
 
Monocytes in the peripheral blood can be divided into three types (Mon1, Mon2 and Mon3), 
based on their expression of cell surface receptors (see Figure 9).175  These receptors are the 
lipopolysaccharide CD14 and the Fcγ-III receptor, CD16.  Updated evidence-based guidance 
was recently released and endorsed by the European Society of Cardiology.171  
 
Figure 9: Nomenclature for human monocyte subsets 
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The cluster of differentiation molecules or markers (CD) 14 and 16 are the standard cell 
surface markers used to define monocyte subsets.  A ‘+’ designates where the CD expression 
level is more than 10-fold above the isotype control and ‘++’ where CD expression is 
increased more than 100-fold.175  When Mon2 and Mon3 are not separately defined (in older 
studies) they have been collectively referred to as CD16+ monocytes.175  Unfortunately these 
studies cannot provide reliable information on phenotype and roles of either of these very 
different subsets.  Both the phenotypic definition and the terminology for the monocyte 
subsets should be understood when interpreting the literature, since the variation in 
nomenclature over the years may cause confusion when older studies are compared with 
contemporary work. 
 
In terms of their developmental origin, previous work has shown that the three monocytes 
subsets are already in the bone marrow, although at this stage the Mon2 subset is 
proportionally greater compared to in the blood.174  Monocyte levels in the blood may not 
reflect levels in the bone marrow, marginal pool and other tissues.  Monocytes within a subset 
do not have the same role in every disease process, for example Mon2 is associated with 
improved outcomes in stroke but adverse outcomes in renal failure.180-182  Further work is 
required to understand how these cells contribute to pathophysiology within different disease 
milieu.  The three monocyte subsets are described in more detail below and their functional 
roles are summarised in Table 11. 
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Table 11: Functional roles of the monocyte subsets 
Mon1 Mon2 Mon3 
Phagocytosis 
Cytokine production 
Clearance of cellular debris 
Release of matrix 
metalloproteinases 








Immune surveillance by 
patrolling endothelium 
 
Flow cytometry can differentiate between monocyte subsets based on their light scatter 
properties and cell surface markers and has superseded morphological and cytochemical 
analysis.175  Flow cytometry is relatively observer-independent and allows data to be collected 
rapidly from a large number of cells.171  Cells must firstly be clearly defined as monocytes by 
using antibodies for specific epitopes, their light scatter properties and careful gating 
strategies to exclude other types of leucocytes.  An example of the gating system used in flow 
cytometry is shown in Figure 10.  The left panel shows selection of monocytes based on 
forwards scatter and side scatter.  The central panel shows selection of monocytes based 
CD14 expression and side scatter.  In the right panel cells that belong to both left and central 




Figure 10: Example of the gating strategy used in flow cytometry software to distinguish 




These are large cells, which are highly phagocytic.  A feature of innate immunity is its not 
being antigen-specific, therefore monocytes must possess pattern recognition molecules such 
as Toll-like receptor 4 (TLR4) and CD14.  CCR2 is the receptor for monocyte chemo 
attractant protein-1 (MCP1), which enables Mon1 to be actively recruited to sites of 
inflammation.183  Mon1 phagocytose low-density lipoprotein and generate reactive oxygen 
species.184  They express CD62L and CD64 and produce increased levels of IL1b, IL6, 
MCP1, and IKKb compared to Mon2.172, 174  This subset expresses genes involved in 
angiogenesis, wound healing and coagulation.185 
 
2.2.5 Mon2 
Mon2 expresses genes associated with inflammation and angiogenesis, which the other 
subsets do not.186  They also have cell surface receptors linked with angiogenesis and tissue 
repair.174, 187  These features, as well as maximal production of the anti-inflammatory IL-10, 
suggest that this subset of monocytes is important in tissue remodelling.187, 188  Genetic 
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sequencing has shown Mon2 to express genes equipping them for antigen processing and 
presentation, a role that has been demonstrated by functional studies.186, 189  They show an 
intermediate phenotype for the cell surface receptors CCR2 and CX3CR1181, 190 and CCR5 
surface-expression is specific to this subset.181, 190  They have increased expression of the 
angiogenic receptors CXCR4 and vascular endothelial growth factor (VEGF).  They express 
CD163 (a tissue repair marker), CD115, receptors to intercellular adhesion molecule-1 
(ICAM-1), and have the highest surface levels of apolipoprotein B and ferritin.174, 187  The 
angiopoietin receptor Tie-2 and major histocompatibility complex class II molecules are also 
expressed on Mon2.172  Like Mon1, Mon2 have been shown to produce reactive oxygen 
species.186 
 
2.2.6 Mon3  
Mon3 may have a protective function in tissues with a patrolling and reparative role in case of 
injury.  They are smaller and less granular than Mon2 and have a much lower phagocytic 
activity than Mon1 and Mon2.171, 174  If there is endothelial dysfunction Mon3 can migrate out 
of the circulation.187  CCR2 distinguishes the two distinct populations of CD16+ monocytes, 
with very few if any of these receptors found on the Mon3 subset, which expresses lower 
levels of CD14 and high levels of CD16.174  Mon3 express CX3CR1, cytoskeletal 
rearrangement genes and CD294172 and have the highest expression of VCAM-1 receptors 
and CD204174 and does not express CD62L.172  Fractalkine is an adhesion molecule found on 
activated endothelial cells and is responsible for the recruitment of Mon3.172 
 
2.2.7 Monocyte-platelet aggregates 
Monocytes combine with platelets to form monocyte-platelet aggregates (MPAs).  Platelets 
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have a role in regulation of circulating cell types and their physical interaction with 
monocytes is an example of such an interaction that may influence their function.188, 191  The 
notion that platelets regulate monocyte activity is supported by the correlation between IkB 
kinase b levels (a marker of activation of the NFkB pathway) in Mon2 and CD42 expression 
on MPA2.179  Formation of MPAs is associated with increased cytokine production by 
monocytes, with CD16+ monocytes being upregulated192, 193 and may be associated with 
induction of monocyte gene activation.171  Another explanation for monocytes forming 
aggregates with platelets is as part of phagocytosis of activated platelets.  MPAs serve as a 
marker of monocyte and platelet activation.188, 194  Platelets are activated when there is 
denudation of the endothelium, and if they undergo degranulation and adhere to circulating 
monocytes, then MPAs are formed via an interaction between P-selectin on activated platelets 
and P-selectin glycoprotein ligand-1 on leucocytes.171  Monocytes bound to platelets express 
macrophage adhesion ligand(Mac)-1, activate NFκB and produce IL-1β, IL-6, IL-8 and tissue 
factor.173  It is proposed that the cross-talk between monocytes and platelets is the link 
between thrombosis and inflammation.193  Aggregation is not permanent as the complexes 
have been shown to dissociate as they migrate across an endothelial surface.195  
 
2.2.8 Monocyte subsets and cardiovascular health 
The interface between cardiology and immunology has emerged as an exciting field of 
research.  Leucocytosis is known to be a predictor of cardiovascular events.196  Evidence has 
accumulated over the last several years for the distinct subpopulations of monocytes with 
distinct roles in the pathogenesis of cardiovascular diseases, which are often characterised by 
tissue injury and inflammatory processes (Table 12).  
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Whilst the primary role of monocytes is protective (neutralisation and elimination of 
pathogens via cytokine production and phagocytosis) they also have a detrimental role 
causing injury.  When monocytes are high in number or activity, tissue damage may result in  
adverse outcomes.171  An example of such host cell destruction is the vascular wall due to its 
proximity to the circulating monocytes.197  Hypertension may result in endothelial injury due 
to shear stress and adherence and infiltration of monocytes in this circumstance contributes to 
atherosclerosis.  
 
Old platelets are cleared by monocytes by thrombophagocytosis.  Monocyte-platelet 
aggregates might be a precursor to this process leading to foam cell formation which 
contributes to the formation of atheroma.194  Monocytes produce tissue factor via the 
angiotensin II type I receptor.  Angiotensin converting enzyme inhibitors therefore reduce 
plasma tissue factor activity in hypertension.198  Hypertension is an independent predictor of a 
low Mon3 count.199  Monocyte-platelet aggregates in peripheral blood have been shown to 
correlate directly with blood pressure and are particularly closely related to systolic blood 
pressure.200  Elevated blood pressure does not affect monocyte subset mobilisation during an 
exercise challenge.201 
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Table 12. Subsets of monocytes and their platelet aggregates in cardiovascular disease 
 
BMI, body mass index; LVEF, left ventricular ejection fraction; MI, myocardial infarction; STEMI, ST 
elevation myocardial infarction
Condition Comparison Reference 
Acute heart failure 
Mon1, Mon3 and MPA1 increased compared to stable heart 
failure, coronary artery disease and healthy controls Wrigley, 2013188 
Mon3 increased compared to healthy controls 
Atherosclerosis Mon2 associated with increased risk of cardiovascular events Rogacev, 2012202 
Chronic kidney 





Mon1 increased and Mon2 decreased in highest risk patients Czepluch, 2014
203 
Hristov, 2010199 
CD16+ monocytes associated with increased severity 
(multiple vessel disease) Ozaki, 2012
184 
MPA3 increased compared to healthy controls Shantsila, 2014179 
Diminished CD16+ monocytes on initial presentation with 
MI, followed by increase. 
Mon1 peak negative predictor of myocardial salvage. 
Tsujioka, 2009204 
Exercise 
CD16+ monocytes decreased in elderly after exercise 
programme compared to physically inactive 
Timmerman, 
2008205 





Mon1 increased after STEMI and correlates with peak 
troponin level and LVEF at 6 weeks Tapp, 2012
207 
Mon1 negatively correlate with LV function after MI Tsujioka, 009 




Mon3 count significantly associated with increased BMI Rogacev, 2009208 








Stable heart failure MPA1 increased compared to healthy controls Wrigley, 2013188 




Stroke Mon2 increased after stroke and higher levels associated with improved outcome Urra, 2009
180 
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Monocytes are reported to have a role in adverse left ventricular remodelling and in the 
generation of reactive oxygen species in heart failure.176, 215  Patients with oedema due to 
heart failure have higher levels of CD14, monocyte-derived TNF and endotoxin than patients 
with more mild heart failure, and the levels reduce after clinical improvement.  Mon1 and 
Mon2 remained activated for over three months after an episode of acute heart failure in one 
study, even if clinically the patient was better.188  It has been postulated that endotoxins reach 
the circulation due to increased pressure in the bowel mesentery and increased bacterial 
translocation.216  Venous congestion and increased bowel permeability allow the 
lipopolysaccharide (LPS) in the cell wall of Gram negative bacteria to enter the bloodstream. 
LPS is a ligand for CD14 and stimulates its cytokine production.  Another possible 
mechanism is increased sympathetic activity reducing blood flow in the splanchnic 
circulation.  The resulting intestinal ischaemia makes the mucosa more permeable.  TLR4 is 
found in organs including the heart, but mostly in peripheral monocytes.  TLR4 has been 
shown to be an important component in the innate immune system and it is required in the 
monocyte response to LPS, being a co receptor for CD14.217  The expression of TLR4 on 
monocytes is increased in heart failure and correlates with disease severity.218  Monocytes are 
recruited into areas of remodelling in the myocardium.217  Increased TLR4 has been shown in 
association with ventricular remodelling in cardiac failure, demonstrating that monocytes are 
involved in the adaptive response of the myocardium to heart failure.219  
 
2.2.9 Monocyte subsets in Women’s Health 
Women have a significantly lower total monocyte count in peripheral blood compared to 
men.214  The monocyte count is increased after the menopause and decreased with oestrogen 
replacement therapy.220  There is emerging evidence that monocytes are activated in obese 
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women, who have significantly increased Mon2 counts compared to lean controls but overall 
no significant difference in overall monocyte count.209  A high fat diet creates a cellular 
environment akin to inflammation and leads to monocyte emigration from the bone 
marrow.221  Chemokine receptor expression on monocytes, in particular CCR2, is increased in 
obesity and the monocytes therefore show an increased migratory response towards 
inflammatory stimuli in overweight women.209  
 
2.2.10 Monocyte subsets and hypertension in pregnancy 
In pregnancy, blood monocytes are increased as part of the innate immune system’s 
adaptation.222  Mon1 has been shown to comprise a lower percentage of total monocytes in 
pregnant women, with a greater reduction in women with preeclampsia, attributed to an 
increase in Mon2.222  Moreover the Mon2 count has been shown to correlate with the severity 
of preeclampsia223 and has been proposed as an inflammatory mediator and predictor of 
preeclampsia.  TLR4 up regulation has been demonstrated in Mon3 and neutrophils in women 
with preeclampsia.224 
 
Preeclampsia has classically been considered a disease of placental aetiology and 
macrophages play an important role at the fetomaternal interface.225  Macrophages are 
involved in immune tolerance and defence, in placentation and in parturition.225  Melgert and 
colleagues describe the infiltration of the uterine decidua by monocytes, which become 
macrophages and dendritic cells involved in spiral artery remodelling and immune tolerance 
of the “semi-allogenic” fetus.222  Placental microparticles, which are known to activate 
monocytes, are increased in preeclampsia.222  Platelets are activated in preeclampsia and 
activated platelets lead to an increase in Mon2.  These are possible mechanisms for the 
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increased proportion of CD16+ monocytes have been shown to be increased in 
preeclampsia222, and specifically the increased proportion of Mon2.223  Mon3 has also been 
shown to be elevated in preeclamptic women.224  
 
Monocytes, and their platelet aggregates, are a source of soluble fms-like tyrosine kinase 
(sFlt-1), which is implicated in endothelial dysfunction.226, 227  Increased CD14+ macrophages 
have been shown in the decidua basilis of placentas from preeclamptic women compared to 
gestational age matched controls, and these cells also stained positive for sFlt-1 suggesting a 
possible link.226  Differential cytokine expression has been demonstrated between 
normotensive and preeclamptic pregnant women, with decreased IL12 and TNFa production 
in hypertensive pregnancy.228, 229  Monocytes from preeclamptic women have been shown to 
be associated with increased production of IL-1b, IL-6, IL-8 and reactive oxygen species.229-
231  Faas et al showed that there are factors in the plasma of preeclamptic women, which 
activate endothelial cells only when cultured with monocytes.  These factors may be placental 
in origin.232  Work is ongoing to determine the nature of these factors involved in monocyte 
activation and several candidates have been proposed including microparticles (from the 
placenta or other cells), fetal DNA and ATP.  
 
CD11b, which binds to intracellular adhesion molecule-1 and causes firm adhesion of 
leucocytes to endothelium, is upregulated on monocytes in preeclampsia and this is associated 
with increased metabolic activity in the monocytes as demonstrated by production of reactive 
oxygen species.233  CD11b, as well as CD11a, CD11c and CD15 have been shown to be 
expressed more highly on monocytes in blood drawn from the uterine vein of preeclamptic 
women at Caesarean section when compared to the monocytes in their peripheral venous 
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blood.234  This is consistent with the proposal that monocytes are most likely to be activated 
by microparticles in the uteroplacental circulation as this is where they have close 
interaction.235  The phagocytic function of monocytes has been shown to be reduced in 
pregnancy, and this function declines further in preeclampsia, which may contribute to 
reduced elimination of factors causing inflammation and endothelial dysfunction.236 
 
Although leucocyte activation is not specific to preeclampsia, there are qualitative differences 
in the phenotype of monocytes in preeclampsia when compared to pregnancy complications 
such as preterm labour.233  A study comparing pregnant women in preterm labour with term 
pregnancy and non-pregnant controls found increased Mon2 and decreased Mon1 in 
pregnancy.237  Mon2 was significantly increased in the preterm labour group leading the 
authors to suggest that Mon2 is involved in the immunological activation of preterm labour.237 
 
2.2.11 Therapeutic intervention 
Immunomodulation of the monocyte subsets has generated much interest as a new therapeutic 
target.202, 238  Monoclonal antibodies against P-selectin glycoprotein ligand 1 have been shown 
to reduce MPAs.239  Modulation of Mon2 function (for example interrupting the platelet 
chemokine CCR5) has been proposed as a possible mechanism of drug action to prevent 
cardiovascular events.181  Current knowledge regarding the effect of cardiovascular 
therapeutics on monocyte subsets is limited.  A difference in Mon2 levels has been shown in 
heart failure patients on beta blockers.240  Antiplatelet therapy has been shown to reduce 
MPAs whereas anticoagulation has little effect.241, 242  As evidence mounts for the role of 
monocyte subsets in a variety of diseases, research into agents that alter their biological 
activity may lead to development of novel therapies.  Further research is required to 
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incorporate new knowledge of monocyte biology, their genomics and proteomics, into drug 
development. 
  
2.2.12 Implications for current research 
Pregnancy is increasingly being recognised both as a stress test for future cardiovascular 
health and as an important window of opportunity to implement primary and secondary 
prevention strategies to improve long term outcomes for women.243  Recent research has 
encouraged a shift of focus away from the placenta and towards the cardiovascular system as 
central to the pathogenesis and clinical manifestation of preeclampsia. Maternal cardiac 
function and acute atherosis are of particular interest.244, 245  It is time to draw upon 
knowledge of monocyte biology in relation to cardiovascular disease and bring pregnancy and 
specifically gestational hypertensive disorders into the equation since monocytes may be key 
players in women’s cardiovascular health in pregnancy and beyond.  Further research is also 
required to relate the altered haemodynamics in healthy and hypertensive pregnancy to the 
monocyte subsets and to discover whether they are an appropriate biomarker to incorporate 










The aim of this work was to investigate how maternal cardiac structure and function is 
affected by a previous hypertensive pregnancy.  Cardiovascular interactions in pregnant 
women with former GH or PET were compared with those in pregnant and non-pregnant 
women with no history of hypertension.  Techniques including echocardiography, pulse wave 
analysis and flow cytometry were used to study the properties of the heart and blood vessels, 
with a focus on their reciprocal performance in pregnancy. 
 
The antenatal booking appointment is a crucial time to assess risk and to plan safe care for an 
expectant mother and her fetus.  Ultrasound imaging is currently used to perform a first 
trimester risk assessment for the fetus but its role in maternal cardiovascular risk assessment 
is not yet defined and this work may provide evidence to support increased use of 
echocardiography in obstetric medicine.  
 
There is clinical value in establishing the echocardiographic changes throughout pregnancy in 
women with a previous hypertensive disorder, especially if changes manifest while a 
recurrent hypertensive disorder is at an asymptomatic early stage, as it could lead to 
development of a screening tool and affect management decisions.  Echocardiography could 
be used in risk stratification for targeted secondary prevention.   
 
It is also novel to correlate echocardiographic changes in pregnancy with changes in 
monocyte subset heterogeneity.   Peripheral blood monocytes have not been related to 
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vascular changes in pregnancy and this aspect of the study will provide mechanistic insight. 
 
3.2 Hypotheses 
I hypothesised that a history of gestational hypertensive disease  would be associated with 
abnormal ventricular-arterial interaction in a subsequent pregnancy, with reduced arterial 
elastance and altered ventricular function reflecting maladaptation to the pregnant state.  
 
I also hypothesised that there would be altered monocyte subset heterogeneity in pregnant 
women with previous gestational hypertensive disease, and that levels of proinflammatory 
monocytes would be inversely proportional to cardiovascular performance. 
 











4.1 Introduction to chapter 
In this chapter I describe the materials and methods for my prospective study, Evaluating 
Cardiovascular Changes in Hypertension in Obstetrics (ECCHO).  I describe how identified 
and recruited women to participate in my research.  The various modalities used to acquire 
data are explained.  To close the chapter, I show my validation and reproducibility data to 
confirm that I was competent in the experimental procedures and able to record accurate data. 
 
4.2 Study design 
4.2.1 Introduction to prospective study 
“Evaluating Cardiovascular Changes in Hypertension in Obstetrics” (ECCHO) was a 
prospective observational study in which women were recruited at the beginning of pregnancy 
and studied throughout their gestation.  Cross-sectional comparison in the first trimester of 
pregnancy tested the hypothesis that prior hypertension in pregnancy is associated with 
altered arterial and ventricular function.  Pregnant women with prior GH/PET were compared 
to pregnant women without prior hypertension and to healthy non-pregnant controls.  
Secondly all measures performed at baseline for the cross-sectional study, were repeated for 
the pregnant women at around 20 and 32 weeks of gestation (once in each trimester).  The 
longitudinal study of pregnant women tested the hypothesis that women with prior 
hypertension in pregnancy have altered cardiovascular adaptation to pregnancy, which may be 






4.2.2 Study groups 
There are were three study groups.  Group 1 comprised pregnant women with previous GH or 
PET.  Group 2 comprised pregnant women with no history of hypertension.  Group 3 included 
healthy non-pregnant women as controls.  The diagnoses of GH and PET were in accordance 
with the current definitions according to NICE1 (see Figure 2).  The pregnant women were 
followed throughout pregnancy and the pregnancy outcome recorded.  For patients who were 
hypertensive during the studied pregnancy, post natal follow up was organised in order to 
ascribe the appropriate diagnosis.  Women with persistent hypertension or use of 
antihypertensives at 3 months post partum would receive a retrospective diagnosis of chronic 
hypertension whilst those demonstrating normalisation of blood pressure would have a 
confirmed diagnosis of gestational hypertensive disease. 
 
4.2.3 Medical and obstetric history 
A comprehensive medical history was taken from each patient, to assess them against the 
inclusion and exclusion criteria and to provide the necessary data for the study.  Hospital case 
notes were also interrogated to confirm aspects of the history in order to reduce recall error 
and bias. 
 
4.2.4 Inclusion criteria 
Inclusion criteria are listed in Table 13. 
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2. GH or PET in a 
previous pregnancy  
 
1. Pregnant 
2. No previous 
hypertensive disorder 
(May be parous or 
nulliparous) 
1. Not pregnant 
2. Not within 1 year post-
partum 
3. Pre-menopausal 
(May be parous or 
nulliparous) 
 
4.2.5 Exclusion criteria 
Exclusion criteria are listed in Table 14. 
 
4.2.6 Recruitment 
Recruitment ran from February 2014 to September 2015.  Patients were recruited from 
women attending the Department of Maternity and Perinatal Medicine at Sandwell and West 
Birmingham Hospitals NHS Trust (SWBH).  The University of Birmingham Institute of 
Cardiovascular Sciences (ICVS) is on the same campus as the Maternity Unit at Birmingham 
City Hospital.  It has its own dedicated clinical suite for cardiovascular physiology.  Professor 
Lip’s group has published all methods and robust Standard Operating Procedures (SOPs) are 
established (included as Appendices).  The hospital serves an ethnically diverse population in 
one of the most deprived inner-city areas of the country.   
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Table 14: Exclusion criteria 
1. Patient refusal 
2. Pre-existing cardiac disease (ischaemic heart disease, valvular heart disease, 
congenital heart defect) 
3. Chronic hypertension 
4. Significant illness 
5. Vasoactive medication 
6. Multiple pregnancy 
7. Inability to consent (language barrier with no translator available, lacks capacity) 
8. Obstetric emergency (haemorrhage, severe symptomatic (pre)eclampsia) 
9. In labour 
10. Age under 16 years 
 
There are approximately 5800 deliveries in the Maternity Unit each year.  Eligible women 
were identified from referrals for antenatal care and approached during their first hospital 
visit.  Non-pregnant controls were recruited from hospital and university staff.   
 
4.2.7 Timing of investigations 
Gestational age was determined by fetal biometry in the first trimester.  Pregnant women were 
studied at baseline (around 12 weeks gestation) and asked to attend two follow up 
appointments, once in each trimester at 20+ and 30+ weeks (Figure 11).  Non-pregnant 
controls were studied only once, following the protocol for the baseline visit for the pregnant 
women.
 78 


















TIME ROUTINE CARE STUDY PROTOCOL
Consent to participate


















• Pulse Wave Analysis
• Venepuncture
Outcomes recorded
Check up with 
General Practitioner
Telephone follow up
Growth scan for 
some women
Data collected





4.2.8 Patient management 
This was a prospective observational study. As such there were no changes in the routine 
antenatal care of patients.  Clinical management of pregnancy was in accordance with 
established local protocols, based on national guidelines.   
 
4.3 Echocardiography 
4.3.1 Equipment and software 
Echocardiography at the baseline visit was performed with a Philips iE33 ultrasound machine 
(Bothell, WA, USA).  A portable echocardiography machine was used for the follow up 
appointments, namely the Philips CX50 (Bothell, WA, USA).  Both machines employed a 
phased array transducer.  The images were converted to Digital Images and Communications 
in Medicine (DICOM) format.  Xcelera software (Philips Medical Systems, Netherlands) was 
used to analyse the stored images.   
 
4.3.2 Procedure for echocardiogram 
After a period of at least 5 minutes rest, the women were examined in a comfortable left 
lateral position on the couch.  Although there was no risk of aortocaval compression in the 
baseline visit and non-pregnant women, the left lateral tilt was employed throughout the 
longitudinal study for standardisation.  The clinic room was temperature controlled and kept 
quiet and undisturbed.  The women were asked to abstain from caffeine, alcohol and smoking, 




Two investigators performed the echocardiograms throughout the study.  Dr Alena Shantsila 
(AS) performed most of the studies.  Dr Richard Brown (RB) deputised during her absence in 
order to maximise the number of possible appointments.  Both of these collaborators are 
experienced in cardiac imaging and are fully accredited with the British Society of 
Echocardiography.  As post graduate researchers at the ICVS they were also trained in good 
clinical practice.  The images were digitally stored and given unique identification numbers.  
All echocardiograms were transthoracic (TTE).  The examination protocol was in accordance 
with the latest published guidelines from the international societies.162, 246, 247 
 
A three-lead electrocardiogram (ECG) was recorded throughout the cardiac ultrasound 
examination.  The left ventricular outflow tract (LVOT) was visualised in the left parasternal 
long axis view (PLAX).  Since the mitral valve opens in early diastole, end systole is in the 
frame before this event.  End systole is also recognised on the ECG as the onset of the Q 
wave.  The left atrial diameter was also measured in the PLAX view.  The LA diameter was 
measured at the end of the T wave on the ECG.  The LVOT velocity time intregral (VTI) was 
measured in the apical 5 chamber view using pulse wave Doppler to acquire the trace.  The 
mitral valve E and A waves were recorded in the apical 4 chamber view using pulse wave 
Doppler.  Tissue Doppler was used to record the motion of the left ventricular walls at the 
level of the mitral valve annulus during diastole, in the apical four chamber view to measure 
the e’ and a’ waveforms.  Isovolumetric relaxation time (IVRT) is recorded from the end of 
the s’ wave until the start of the e’ wave.  The direct measurements the parameters derived 
from echocardiography are shown in Table 15 and Table 16 respectively. 
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Table 15: Echocardiography views and direct measurements 
Image / View Measurement 
Parasternal long axis  
Left ventricular outflow tract diameter (cm) 
Left atrial dimension (cm) 
Interventricular septal dimension (cm)* 
Left ventricular internal diameter (cm)* 
Left ventricular posterior wall dimension (cm)* 
*measured at the end of systole and at the end of diastole 
Apical 2 chamber 
Left ventricular end diastolic area (cm2) 
Left ventricular end systolic area (cm2) 
Left atrium end systolic area (cm2) 
Left atrial major axis (cm) 
Apical 4 chamber 
Left ventricular end diastolic area (cm2) 
Left ventricular end systolic area (cm2) 
Left atrium end systolic area (cm2) 
Left atrial major axis (cm) 
Apical 5 chamber – left 
ventricular outflow tract 
Continuous wave Doppler 
Left ventricular pre-ejection time (cm/s) 
Left ventricular ejection time (cm/s) 
Isovolumetric relaxation time (s) 
Left ventricular outflow tract velocity time integral 
Mitral inflow 




Mitral valve annulus 











Reciprocal of the mean of several consecutive R-R intervals on the 
ECG, multiplied by 60 
Velocity time 
integral 
Mean average of tracings of 4 pulse wave Doppler waveforms for the 
flow across the aortic valve. 
Stroke volume* 
(SV, ml)  
π x (Left ventricular outflow tract diameter / 2)2 x velocity time 
integral; measurements in cm 
Cardiac output* 
(CO, L/min) 




80 x (Mean arterial pressure / cardiac output) 
E/A ratio 
 
Mitral valve E wave [early filling] peak velocity / mitral valve A wave 
[late filling during atrial contraction] peak velocity 
E/e’  
 
Mitral valve E wave peak velocity / e’ wave [early diastolic mitral 
annular] velocity on tissue Doppler imaging (TDI); measurements in 
m/s 
(The value for e’ used is the mean of the septal and lateral e’ from TDI) 
Left ventricular 
volume (ml) 
Single plane, 4-chamber, method of discs 




0.8 x [1.04((left ventricular end diastolic dimension + posterior wall 
thickness + interventricular septum thickness)3 – left ventricular end 
diastolic diameter3)] + 0.6; measurements in mm, at end diastole 
This is the Devereux formula.248 
Relative wall 
thickness 
2 x posterior wall thickness at end diastole / LV end diastolic 





(End diastolic volume – end systolic volume) / end diastolic volume x 





100 x (LVIDd-LVIDs) / LVIDd 
Where LVIDd is the left ventricle internal dimension in diastole and 




ESP = systolic blood pressure x 0.9 




EDP = 1.24 x (E/e') + 1.9 
e' is the average of the septal and lateral e' values.  
Arterial elastance* 
(Ea) End systolic pressure








0.35695 – 7.2266 × tNd + 74.249 × tNd2 – 307.39 × tNd3 + 684.54 × 
tNd4 – 856.92 × tNd5 + 571.95 × tNd6 – 159.1 × tNd7 
 
This polynomial function is used according to Chen et al30, where tNd is 
the ratio of LV pre-ejection time to total systolic period (pre-ejection 





elastance at onset 
of ejection 
(ENd(est)) 
0.0275 – 0.165 × LVEF + 0.3656 × (DBP/ESP) + 0.515 × ENd(avg) 
This is derived from Chen’s single beat method to calculate end 




Ees = (DBP – (ENd(est) × ESP) / (SV × ENd(est)) 
Defined as End systolic pressure / End systolic volume 









Ea / Ees 
 




The echocardiograms were stored digitally for offline analysis.  Measurements were 
performed by a single observer (JSC).  All measurements were performed after completion of 
the study in a random order, with the investigator blinded to the identity of the patient, their 
clinical characteristics, including blood pressure, and their pregnancy outcome.  
Measurements from 2D structural images were recorded once.  Measurements based on 
flow/waveforms were performed on four beats and the mean average was taken.   
 
The LV stroke volume was calculated from the difference between the left ventricular 
volumes in systole and diastole.  The single plane Simpson method was used.  The 
endocardial border of the LV was traced in systole and in diastole.  The Xcelera software 
(Philips Medical Systems, Netherlands) divides the ventricle along its long axis into a series 
of stacked discs of equal height.  The volume is calculated as the sum of these discs.   
 
For quality control ten sets of images from each study group were randomly selected for the 
assessment of interobserver reliability (see Table 18).  The images were presented to the 
second observer (AS) who was blinded to the patient characteristics (including study group) 
and to the measurements of JSC.  Measurements of the parameters of arterial-vascular 
interactions have been previously validated in the ICVS and were done in accordance with 
established SOPs.18  
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Figure 12:  Photograph of subject having an echocardiogram 
 
 
4.3.4 Reproducibility data 
The reproducibility data in Table 17 show the results of repeated measures of the same 
echocardiographic parameters analysed by the same investigator on different days.  The co-
efficient of variation (CV) measures the dispersion of data points around an expected value 
(mean) according to the following formula:  









 IVSd Day 1 IVSd Day 2 mean SD CV 
Controls 0.51 0.58 0.55 0.05 9.08 
  0.86 0.61 0.74 0.18 24.05 
  0.54 0.43 0.49 0.08 16.04 
  0.44 0.49 0.47 0.04 7.60 
  0.63 0.68 0.66 0.04 5.40 
  0.84 0.81 0.83 0.02 2.57 
  0.56 0.76 0.66 0.14 21.43 
  0.64 0.97 0.81 0.23 28.99 
  0.61 0.56 0.59 0.04 6.04 
  0.47 0.52 0.50 0.04 7.14 
        Group: 12.83 
Healthy 0.56 0.84 0.70 0.20 28.28 
pregnant 0.66 0.62 0.64 0.03 4.42 
  0.59 0.52 0.56 0.05 8.92 
  0.54 0.57 0.56 0.02 3.82 
  0.85 1.20 1.03 0.25 24.15 
  1.00 0.94 0.97 0.04 4.37 
  0.56 0.47 0.52 0.06 12.36 
  0.47 0.51 0.49 0.03 5.77 
  0.94 0.84 0.89 0.07 7.95 
  0.91 0.86 0.89 0.04 3.99 
        Group: 10.40 
Previous 0.59 0.44 0.52 0.11 20.60 
hypertension 1.10 0.91 1.01 0.13 13.37 
  0.91 1.20 1.06 0.21 19.44 
  0.74 0.74 0.74 0.00 0.00 
  1.10 0.67 0.89 0.30 34.36 
  0.65 0.62 0.64 0.02 3.34 
  0.69 0.59 0.64 0.07 11.05 
  0.91 0.90 0.91 0.01 0.78 
  0.69 0.69 0.69 0.00 0.00 
  0.50 0.43 0.47 0.05 10.64 
        Group: 11.36 
Combined       Overall: 11.53 
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 LVIDd Day 1 LVIDd Day 2 mean SD CV 
Controls 4.9 4.6 4.75 0.21 4.47 
  4.4 5.4 4.90 0.71 14.43 
  4.9 5.0 4.95 0.07 1.43 
  4.3 3.9 4.10 0.28 6.90 
  4.1 4.6 4.35 0.35 8.13 
  4.9 4.1 4.50 0.57 12.57 
  4.4 4.6 4.50 0.14 3.14 
  4.1 3.7 3.90 0.28 7.25 
  4.4 4.7 4.55 0.21 4.66 
  5.0 5.2 5.10 0.14 2.77 
        Group: 6.58 
Healthy 4.9 4.7 4.80 0.14 2.95 
pregnant 4.6 2.9 3.75 1.20 32.06 
  5.2 5.2 5.20 0.00 0.00 
  5.3 4.3 4.80 0.71 14.73 
  4.7 3.8 4.25 0.64 14.97 
  5.2 5.2 5.20 0.00 0.00 
  4.8 4.9 4.85 0.07 1.46 
  3.9 3.9 3.90 0.00 0.00 
  4.1 2.7 3.40 0.99 29.12 
  4.2 3.1 3.65 0.78 21.31 
        Group: 11.66 
Previous 4.4 4.8 4.60 0.28 6.15 
hypertension 3.3 3.8 3.55 0.35 9.96 
  4.5 4.5 4.50 0.00 0.00 
  5.5 5.8 5.65 0.21 3.75 
  3.6 3.8 3.70 0.14 3.82 
  4.5 5.3 4.90 0.57 11.54 
  4.9 5.3 5.10 0.28 5.55 
  5.1 5.4 5.25 0.21 4.04 
  4.5 4.7 4.60 0.14 3.07 
  4.3 4.2 4.25 0.07 1.66 
        Group: 4.96 
Combined       Overall: 7.73 
 88 
  
 E Day 1 E  Day 2 mean SD CV 
Controls 104.7 115.6 110.12 7.71 7.00 
  72.6 77.5 75.02 3.46 4.62 
  69.8 73.8 71.80 2.88 4.00 
  69.1 71.4 70.27 1.65 2.35 
  89.0 94.8 91.90 4.10 4.46 
  70.1 75.0 72.58 3.46 4.77 
  79.3 88.1 83.70 6.18 7.38 
  80.5 86.0 83.27 3.91 4.70 
  82.8 89.4 86.08 4.64 5.39 
  82.1 89.2 85.65 5.07 5.92 
        Group: 5.06 
Healthy 65.2 66.2 65.70 0.71 1.08 
pregnant 96.7 106.5 101.62 6.91 6.80 
  84.2 89.0 86.60 3.39 3.92 
  70.6 73.3 71.92 1.91 2.65 
  73.6 72.8 73.20 0.57 0.77 
  120.2 125.5 122.83 3.72 3.03 
  60.2 66.0 63.08 4.08 6.46 
  95.3 97.3 96.27 1.41 1.47 
  89.4 86.6 88.00 1.93 2.20 
  77.3 79.2 78.25 1.30 1.66 
        Group: 3.00 
Previous 84.9 87.2 86.07 1.65 1.92 
hypertension 81.8 87.3 84.57 3.91 4.63 
  101.2 110.2 105.72 6.39 6.04 
  88.2 92.6 90.42 3.13 3.47 
  53.4 56.8 55.08 2.38 4.32 
  95.1 103.8 99.43 6.18 6.21 
  110.0 112.5 111.27 1.74 1.57 
  76.2 77.6 76.90 1.04 1.35 
  68.8 78.6 73.70 6.98 9.47 
  81.5 88.4 84.95 4.83 5.69 
        Group: 4.47 
Combined       Overall: 4.18 
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 e' Day 1 e' Day 2 mean SD CV 
Controls 11.4 12.1 11.75 0.49 4.21 
  10.2 10.4 10.32 0.16 1.60 
  10.6 11.0 10.80 0.33 3.06 
  10.8 11.4 11.12 0.45 4.03 
  9.0 9.4 9.17 0.28 3.09 
  13.0 14.3 13.62 0.92 6.75 
  12.8 13.2 12.98 0.26 2.00 
  12.4 12.8 12.62 0.31 2.43 
  13.8 13.8 13.78 0.02 0.17 
  13.4 14.4 13.88 0.68 4.92 
        Group: 3.23 
Healthy 6.4 6.7 6.52 0.21 3.26 
pregnant 14.4 14.3 14.38 0.07 0.49 
  13.0 13.3 13.15 0.26 1.97 
  11.8 12.0 11.90 0.19 1.58 
  5.3 5.5 5.42 0.16 3.05 
  12.0 8.9 10.47 2.17 20.72 
  8.7 8.7 8.70 0.05 0.54 
  12.4 12.6 12.52 0.16 1.32 
  14.3 15.0 14.62 0.49 3.39 
  9.4 9.5 9.45 0.07 0.75 
        Group: 3.71 
Previous 15.3 16.4 15.88 0.78 4.90 
hypertension 11.5 11.6 11.58 0.07 0.61 
  9.8 11.0 10.38 0.82 7.95 
  10.1 9.9 9.98 0.12 1.18 
  11.0 11.1 11.05 0.12 1.07 
  7.9 8.3 8.10 0.24 2.91 
  12.1 12.6 12.37 0.33 2.67 
  8.2 8.1 8.12 0.07 0.87 
  9.8 10.2 9.98 0.31 3.07 
  10.5 11.5 10.98 0.68 6.22 
        Group: 3.14 




 E/e' Day 1 E/e' Day 2 mean SD CV 
Controls 9.2 9.6 9.37 0.26 2.79 
  7.1 7.4 7.27 0.22 3.02 
  6.6 6.7 6.65 0.06 0.95 
  6.4 6.2 6.32 0.11 1.68 
  9.9 10.1 10.02 0.14 1.38 
  5.4 5.3 5.33 0.11 1.98 
  6.2 6.7 6.44 0.35 5.39 
  6.5 6.7 6.60 0.15 2.27 
  6.0 6.5 6.25 0.33 5.22 
  6.1 6.2 6.17 0.06 0.99 
        Group: 2.57 
Healthy 10.2 9.9 10.09 0.22 2.18 
pregnant 6.7 7.4 7.07 0.51 7.29 
  6.5 6.7 6.58 0.13 1.95 
  6.0 6.1 6.04 0.06 1.07 
  13.9 13.2 13.52 0.52 3.82 
  10.0 14.0 12.03 2.85 23.68 
  6.9 7.6 7.25 0.51 7.00 
  7.7 7.7 7.69 0.01 0.15 
  6.3 5.8 6.03 0.34 5.58 
  8.2 8.3 8.28 0.08 0.91 
        Group: 5.36 
Previous 5.5 5.3 5.42 0.16 2.98 
hypertension 7.1 7.5 7.30 0.29 4.02 
  10.3 10.1 10.19 0.19 1.91 
  8.8 9.4 9.06 0.42 4.65 
  4.9 5.1 4.98 0.16 3.26 
  12.0 12.6 12.27 0.41 3.30 
  9.1 8.9 9.00 0.10 1.10 
  9.3 9.6 9.48 0.21 2.22 
  7.0 7.7 7.38 0.47 6.41 
  7.8 7.7 7.74 0.04 0.54 
        Group: 3.04 
Combined       Overall: 3.66 
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Table 18: Interobserver variability for echocardiographic measurements  
These reproducibility data show the results of repeated measures of the same sample analysed 
by two researchers (JSC and AS).  All CVs are expressed as a percentage. 
 
 IVSd AS IVSd JC mean SD CV 
Controls 0.60 0.58 0.59 0.01 2.40 
  0.94 0.61 0.78 0.23 30.11 
  0.64 0.43 0.54 0.15 27.76 
  0.58 0.49 0.54 0.06 11.90 
  0.64 0.68 0.66 0.03 4.29 
  0.70 0.81 0.76 0.08 10.30 
  0.91 0.76 0.84 0.11 12.70 
  0.75 0.97 0.86 0.16 18.09 
  0.78 0.56 0.67 0.16 23.22 
  0.78 0.52 0.65 0.18 28.28 
        Group: 16.90 
Healthy 0.85 0.84 0.85 0.01 0.84 
pregnant 0.67 0.62 0.65 0.04 5.48 
  0.58 0.52 0.55 0.04 7.71 
  0.64 0.57 0.61 0.05 8.18 
  0.78 1.20 0.99 0.30 30.00 
  0.82 0.94 0.88 0.08 9.64 
  0.78 0.47 0.63 0.22 35.07 
  0.63 0.51 0.57 0.08 14.89 
  0.70 0.84 0.77 0.10 12.86 
  0.97 0.86 0.92 0.08 8.50 
        Group: 13.32 
Previous 0.86 0.44 0.65 0.30 45.69 
hypertension 1.10 0.91 1.01 0.13 13.37 
  1.10 1.20 1.15 0.07 6.15 
  1.00 0.74 0.87 0.18 21.13 
  1.00 0.67 0.84 0.23 27.95 
  0.73 0.62 0.68 0.08 11.52 
  0.74 0.59 0.67 0.11 15.95 
  0.98 0.90 0.94 0.06 6.02 
  0.91 0.69 0.80 0.16 19.45 
  0.60 0.43 0.52 0.12 23.34 
        Group: 19.06 




 LVIDd AS LVIDd JC mean SD CV 
Controls 4.8 4.6 4.70 0.14 3.01 
  5.0 5.4 5.20 0.28 5.44 
  4.9 5.0 4.95 0.07 1.43 
  4.3 3.9 4.10 0.28 6.90 
  4.1 4.6 4.35 0.35 8.13 
  4.9 4.1 4.50 0.57 12.57 
  4.4 4.6 4.50 0.14 3.14 
  4.2 3.7 3.95 0.35 8.95 
  4.4 4.7 4.55 0.21 4.66 
  5.0 5.2 5.10 0.14 2.77 
        Group: 5.70 
Healthy 4.9 4.7 4.80 0.14 2.95 
pregnant 4.6 2.9 3.75 1.20 32.06 
  5.2 5.2 5.20 0.00 0.00 
  5.3 4.3 4.80 0.71 14.73 
  4.7 3.8 4.25 0.64 14.97 
  5.2 5.2 5.20 0.00 0.00 
  4.8 4.9 4.85 0.07 1.46 
  3.9 3.9 3.90 0.00 0.00 
  4.1 2.7 3.40 0.99 29.12 
  4.2 3.1 3.65 0.78 21.31 
        Group: 11.66 
Previous 4.4 4.8 4.60 0.28 6.15 
hypertension 3.3 3.8 3.55 0.35 9.96 
  4.5 4.5 4.50 0.00 0.00 
  5.5 5.8 5.65 0.21 3.75 
  3.6 3.8 3.70 0.14 3.82 
  4.5 5.3 4.90 0.57 11.54 
  4.9 5.3 5.10 0.28 5.55 
  5.1 5.4 5.25 0.21 4.04 
  4.5 4.7 4.60 0.14 3.07 
  4.3 4.2 4.25 0.07 1.66 
        Group: 4.96 




 E AS E  JC mean SD CV 
Controls 104.9 115.6 110.23 7.54 6.84 
  78.8 77.5 78.13 0.94 1.21 
  72.6 73.8 73.20 0.90 1.22 
  73.6 71.4 72.50 1.51 2.08 
  97.1 94.8 95.93 1.60 1.67 
  74.9 75.0 74.97 0.09 0.13 
  87.2 88.1 87.62 0.64 0.73 
  85.2 86.0 85.60 0.61 0.72 
  88.7 89.4 89.02 0.49 0.56 
  88.3 89.2 88.78 0.64 0.72 
        Group: 1.59 
Healthy 71.6 66.2 68.90 3.82 5.54 
pregnant 107.6 106.5 107.05 0.78 0.73 
  91.4 89.0 90.20 1.70 1.88 
  73.4 73.3 73.35 0.12 0.16 
  83.6 72.8 78.20 7.64 9.77 
  127.5 125.5 126.50 1.46 1.16 
  62.5 66.0 64.25 2.43 3.78 
  97.6 97.3 97.45 0.26 0.27 
  90.1 86.6 88.37 2.45 2.77 
  79.9 79.2 79.52 0.49 0.62 
        Group: 2.67 
Previous 85.6 87.2 86.40 1.18 1.36 
hypertension 84.1 87.3 85.72 2.29 2.67 
  110.0 110.2 110.13 0.14 0.13 
  84.9 92.6 88.77 5.47 6.16 
  52.3 56.8 54.52 3.18 5.84 
  104.2 103.8 104.00 0.28 0.27 
  115.4 112.5 113.93 2.03 1.78 
  77.6 77.6 77.63 0.00 0.00 
  75.9 78.6 77.25 1.96 2.53 
  80.3 88.4 84.32 5.73 6.79 
        Group: 2.75 





 e' AS e' JC mean SD CV 
Controls 10.8 12.1 11.47 0.90 7.81 
  10.1 10.4 10.27 0.24 2.30 
  10.7 11.0 10.85 0.26 2.39 
  11.5 11.4 11.47 0.05 0.41 
  9.5 9.4 9.43 0.09 1.00 
  14.1 14.3 14.17 0.14 1.00 
  13.0 13.2 13.08 0.12 0.90 
  12.7 12.8 12.77 0.09 0.74 
  14.0 13.8 13.90 0.14 1.02 
  13.9 14.4 14.15 0.31 2.17 
        Group: 1.97 
Healthy 6.3 6.7 6.48 0.26 4.00 
pregnant 14.5 14.3 14.43 0.14 0.98 
  13.1 13.3 13.22 0.16 1.25 
  12.0 12.0 12.00 0.05 0.39 
  5.2 5.5 5.35 0.26 4.85 
  9.0 8.9 8.97 0.05 0.53 
  8.9 8.7 8.80 0.19 2.14 
  12.6 12.6 12.63 0.00 0.00 
  14.8 15.0 14.87 0.14 0.95 
  9.2 9.5 9.35 0.21 2.27 
        Group: 1.74 
Previous 16.1 16.4 16.25 0.26 1.60 
hypertension 11.1 11.6 11.37 0.38 3.32 
  9.8 11.0 10.40 0.80 7.71 
  10.2 9.9 10.07 0.24 2.34 
  11.0 11.1 11.08 0.07 0.64 
  8.1 8.3 8.20 0.09 1.15 
  12.1 12.6 12.33 0.38 3.06 
  8.0 8.1 8.05 0.02 0.29 
  9.8 10.2 10.00 0.28 2.83 
  12.2 11.5 11.82 0.49 4.19 
        Group: 2.71 





 E/e' AS E/e' JC mean SD CV 
Controls 9.7 9.6 9.62 0.09 0.97 
  7.8 7.4 7.61 0.27 3.50 
  6.8 6.7 6.75 0.08 1.17 
  6.4 6.2 6.32 0.11 1.67 
  10.2 10.1 10.17 0.07 0.67 
  5.3 5.3 5.29 0.05 0.87 
  6.7 6.7 6.70 0.01 0.17 
  6.7 6.7 6.70 0.00 0.02 
  6.3 6.5 6.40 0.10 1.57 
  6.3 6.2 6.28 0.09 1.45 
        Group: 1.21 
Healthy 11.4 9.9 10.65 1.01 9.53 
pregnant 7.4 7.4 7.42 0.02 0.25 
  7.0 6.7 6.83 0.21 3.13 
  6.1 6.1 6.11 0.03 0.55 
  16.2 13.2 14.67 2.14 14.58 
  14.2 14.0 14.11 0.09 0.63 
  7.0 7.6 7.31 0.43 5.92 
  7.7 7.7 7.71 0.02 0.27 
  6.1 5.8 5.94 0.22 3.72 
  8.7 8.3 8.51 0.25 2.89 
        Group: 4.15 
Previous 5.3 5.3 5.32 0.01 0.23 
hypertension 7.6 7.5 7.54 0.05 0.65 
  11.2 10.1 10.62 0.80 7.58 
  8.3 9.4 8.83 0.75 8.50 
  4.7 5.1 4.92 0.26 5.20 
  12.8 12.6 12.68 0.18 1.42 
  9.6 8.9 9.24 0.45 4.84 
  9.7 9.6 9.64 0.03 0.29 
  7.7 7.7 7.73 0.02 0.30 
  6.6 7.7 7.15 0.78 10.97 
        Group: 4.00 
Combined       Overall: 3.12 
 
The low CVs suggest that any differences observed in echocardiographic parameters in my 
study are due to real changes.  It is recognised that echocardiography can have around 10% 
intra- and inter-observer variability for volumes.  
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4.4 Blood pressure measurement 
4.4.1 Method for blood pressure measurement 
Blood pressure was measured with a digital blood pressure monitor (Omron Corporation, 
Tokyo, Japan).  This automated, electronic, oscillometric device is validated for use in 
pregnancy56 and was calibrated throughout the study.  The brachial artery of the non-
dominant arm was used for the blood pressure recording.  Care was taken to ensure that the 
arm was free of clothing and that appropriate cuff size was used depending on mid-arm 
circumference.  Blood pressure was recorded whilst the patient was seated comfortably and 
silently, with the arm supported at the level of the heart.  The woman was asked to sit upright 
and still, with her back well supported, legs uncrossed and feet flat on the floor. This 
procedure followed the echocardiogram, therefore the patient was rested and the same 
precautions regarding variables such as caffeine applied.  Three readings were taken one 
minute apart and the mean average was calculated.  
 
4.5 Pulse Wave Analysis 
The concept of arterial stiffness was described in the introductory chapter (section 1.1.3) 
along with a description of the Pulse Wave Analysis technique and the augmentation index 
which it measures. 
 
4.5.1 Equipment and software 
Arterial stiffness was measured using the digital volume pulse analysis (DVP) technique.  The 
DVP analysis method is a non-invasive technique of measuring pulse wave reflections to 
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determine arterial stiffness peripherally.  The SphygmoCor device (Atcor Medical, West 
Ryde, Australia) equipped with a hand-held tonometer like a pencil (Millar Instruments, 
Houston, Texas, USA) was used to perform pulse wave analysis (see Figure 13).  There is a 
micromanometer within the tip of the tonometer to record the pressure within the radial 
artery. 
Figure 13:  Photograph of pulse wave analysis 
 
 
4.5.2 Data acquisition  
Pulse wave analysis followed the procedures for echocardiography and blood pressure 
measurements.  The women were rested and had not been exposed to caffeine, cigarettes etc 
on the day of the study.  Subjects were asked not to move or speak during the measurements, 
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which were performed in a semi-recumbent position with a left lateral tilt to ensure 
consistency with the echocardiogram methodology.  If a cardiac arrhythmia was present on 
the ECG this was noted.  The radial artery was palpated and the point of maximal pulsation 
identified.  The tonometer tip was placed at this point.  The radial artery waveforms were 
recorded over 10 seconds.  The aortic pressure waveform is derived from the radial artery 
waveform by a mathematical transfer function in the Sphygmocor software (Sphygmocor 
Cardiovascular Management Suite Version 9).  Similarly the software was used to derive the 
aortic pressure and augmentation index.  
 
4.5.3 Reproducibility data 
My reproducibility data for Pulse Wave Analysis are shown in Table 19 and Table 20.  Good 
reliability was achieved after a period of supervised training, prior to acquiring measurements 
for the study.  Measurements were obtained from three healthy volunteers on three 
consecutive days to calculate interassay CVs.  For intra-assay CVs, three consecutive 
measurements were taken on the same day.  
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Table 19: Inter-assay Coefficient of Variation for pulse wave analysis 

























































































































































Aix, aortic augmentation index (%); AoD, aortic diastolic pressure (central, mmHg); AoS, 
aortic systolic pressure (central, mmHg); CV, coefficient of variation (%); HR, heart rate 
(beats per minute); MAP, mean arterial pressure (central, mmHg); OI, operator index 




Table 20: Intra-assay coefficient of variation for pulse wave analysis 
 
Measurement 




















































































































































Aix, aortic augmentation index (%); AoD, aortic diastolic pressure (central, mmHg); AoS, 
aortic systolic pressure (central, mmHg); CV, coefficient of variation (%); HR, heart rate 
(beats per minute); MAP, mean arterial pressure (central, mmHg); OI, operator index 
(arbitrary); SD, standard deviation 
 
The Sphygmacor device has good repeatability and reproducibility.249-251.  Healthy young 
women would be expected to have more compliant vessels, which can result in a negative 
value for augmentation index and a corresponding increased variability. 
 
 
4.6 Blood sampling 
4.6.1 Procedure for venepuncture 
The SWBH SOP for venepuncture is included in the Appendix.  Essentially blood was taken 
from the antecubital vein in the same standardised environment as the rest of the study 
protocol.  Venepuncture was performed last to facilitate prompt processing of the samples.   
Consent for venepuncture was a separate item on the informed consent form.  If a woman was 
willing to participate in the study but not willing to give blood for research purposes she was 
not excluded from the study. 
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4.6.2 Laboratory measurements 
The full blood count was performed by the Haematology laboratory at SWBH according to 
their established SOPs.  Similarly the Clinical Biochemistry department at SWBH conducted 
tests of urea, creatinine and urine PCR. 
 
4.7 Flow cytometry 
4.7.1 Equipment and software 
I used a FACSCalibur flow cytometer (Becton Dickinson [BD], Oxford, UK).  VenturiOne, 
Verson 3.1 software (Applied Cytometry, Sheffield, UK) was used to process the data. 
 
4.7.2 Procedure for flow cytometry 
The methodology has been published by my supervisors previously174 and the SOPs are well 
established in our laboratory.  Previous researchers in our group have shown that the methods 
are robust and reliable.  The contemporary definitions of the monocyte subsets, recently 
described in a consensus statement171, are outlined in Chapter 2.  A ‘Mastermix’ of four 
mouse anti-human monoclonal fluorochrome conjugated antibodies was made in small 
batches.  The antibodies used were anti-CD16-Alexa Fluor 488 (clone DJ130c, Bio-Rad 
Laboratories, Oxford, UK), anti-CD14-PE (clone MфP9, BD), anti-CD42a-PerCP (clone 
Beb1, BD) and anti-CCR2-APC (clone 48607, R&D Systems, Abingdon, UK). 
 
A 12.5µL volume of Mastermix (including anti-CD14-PE 2.5μL; anti-CD16 2.5μL; anti-
CD42a-PerCP 5μL and anti-CCR2-APC 2.5μL) was added to a TruCount™ tube (BD, 
Oxford, UK) containing a precise number of fluorescent count beads.  To this tube, 50µL of 
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EDTA-anticoagulated whole blood was added.  The TruCount™ tube was then incubated for 
15 minutes.  Lysis of the red blood cells was achieved using 450µL FACS Lysing solution 
(BD) and a further 15 minutes incubation.  The sample was diluted with 1500µL of phosphate 
buffered saline prior to immediate flow cytometric analysis.  Appropriate isotype controls 
were used to define CD14, CD16 and CCR2 and monocyte subsets were defined as 
CD14++CD16-CCR2+ (Mon1), CD14++CD16+CCR2+ (Mon2) and CD14+CD16++CCR2- 
(Mon3).171  Time delay between sample collection and processing was always less than one 
hour, as delays in processing can compromise results.252 
 
The gating system used in flow cytometry is shown in Figure 14.  The left panel shows 
selection of monocytes based on forwards scatter and side scatter.  The central panel shows 
selection of monocytes (and exclusion of granulocytes) based CD14 expression and side 
scatter.  In the right panel cells that belong to both left and central panels are selected here to 
separate monocyte subsets based on their CD14 and CD16 expression.  CD16+ cells must 
then be separated into Mon2 and Mon3 based on CCR2 expression. This gating technique is  
 
The absolute monocyte count (cells/µL) was calculated from the total number of monocytes 
proportional to the number of TruCount™ beads.  Each subset could be counted individually 
according to the gating strategy. 
 
Detection of monocyte-platelet aggregates (MPAs) was achieved by their CD42a positivity.  
CD42a (glycoprotein IX) is a platelet marker and MPA events were positive for monocyte 
and platelet markers.  The MPAs associated with each monocyte subset, and the total number 
of MPAs, were expressed as a proportion of the number of TruCount™ beads as described 
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above.  Thus, MPAs associated with Mon1 (MPA1) are CD14++CD16-CCR2+CD42a+, 
MPAs associated with Mon2 (MPA2) are CD14++CD16+CCR2+CD42a+ and those MPAs 
associated with Mon3 (MPA3) are CD14+CD16++CCR2-CD42a++. 
Figure 14:  Gating strategy to identify monocyte subsets 
 
Monocytes are identified by their forward and side scatter (a, top left). Granulocytes 
(neutrophils) are distinguished firstly by their higher degree of side scatter secondly by lack of 
CD14 expression, and are excluded (b). Panel (c) separates natural killer cells (CD14-) and 
monocytes (CD14+).  Panels (d) (e) and (f) identify the Mon1 subset (in green boxes) as 
CD14++CD16- cells.  CCR2 expression (g) is then used to separate the CD16+ subsets, Mon2 
and Mon3.  Mon2 are CD14+CD16++CCR2- (in red boxes) and Mon3 are 
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CD14+CD16++CCR2- (yellow boxes).  (Reproduced with permission and thanks to Eduard 
Shantsila253). 
 
4.7.3 Reproducibility data 
My reproducibility data for flow cytometry are shown in the following tables. The 
reproducibility of the method for repeated measures of the same sample (test-retest 
repeatability) was tested by taking a blood sample from three healthy volunteers. Using the 
original sample, three further samples were prepared and analysed consecutively to calculate 
the intra-assay CVs (Table 21). Similarly, results of repeated measures of the same sample 
analysed by two researchers (JSC and RB) were used to calculate the inter-observer CVs 
(Table 22).  All CVs are expressed as a percentage. 
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Table 21: Intra-assay variability for flow cytometry 
 
Measurement 
Subject Parameter 1 2 3 Mean SD CV (%) 
1 
Mon 1 420 390 391 400 17 4.3 
Mon 2 17 18 13 19 3 12.8 
Mon 3 14 13 12 13 1 9.5 
Overall Mon 451 421 424 432 17 3.8 
MPA 1 46 40 44 44 3 6.9 
MPA 2 2 3 4 3 1 30.9 
MPA 3 2 2 1 2 0 18.6 
Overall MPA 51 45 49 48 3 5.8 
2 
Mon 1 437 447 427 437 10 2.3 
Mon 2 13 17 52 27 21 77.2 
Mon 3 36 35 34 35 1 2.4 
Overall Mon 486 499 513 500 13 2.7 
MPA 1 37 42 37 39 3 8.3 
MPA 2 3 3 7 4 2 58.2 
MPA 3 4 5 4 4 0 4.4 
Overall MPA 44 50 48 47 3 6.5 
3 
Mon 1 399 401 397 399 2 0.6 
Mon 2 40 43 38 4 3 6.5 
Mon 3 58 58 56 57 1 1.6 
Overall Mon 497 502 491 497 6 1.1 
MPA 1 31 27 25 28 3 10.1 
MPA 2 3 4 3 3 1 25.7 
MPA 3 5 5 7 6 1 25.1 
Overall MPA 38 37 35 37 2 4.2 
CV, coefficient of variation (%); SD, standard deviation 
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Average intra-assay coefficient for variation for flow cytometry 
 
Measure CV (%) 
Mon 1 2.4 
Mon 2 32.2 
Mon 3 4.5 
Total Mon 2.5 
MPA 1 8.4 
MPA 2 38.3 
MPA 3 16.0 
Total MPA 5.5 
 
The average intra-assay CV is 2.5% for total monocytes and 5.5% for total MPAs.  
 109 
Table 22: Inter-observer variability for flow cytometry 
Subject Mon 1 Mon 2 Mon 3 Mon MPA 1 MPA 2 MPA 3 MPA 
1       JC  
         RB 
     Mean 
         SD 
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Average inter-observer coefficient of variation 
Measure CV (%) 
Mon 1 6.7 
Mon 2 29.9 
Mon 3 11.0 
Total Mon 4.1 
MPA 1 12.2 
MPA 2 54.6 
MPA 3 28.9 
Total MPA 15.8 
 
The average inter-observer CV is 4.1% for total monocytes and 15.8% for total MPAs.  The 
CVs were consistent with previous work from our group.  Diurnal variation and exercise 
status were not controlled for and as such represent limitations.  The Institute for 
Cardiovascular Sciences have robust SOPs and adherence to principles of good laboratory 
practice is expected of all researchers.  I was assessed as being competent to perform all the 
necessary assays prior to recruiting women for my research.  
 
4.8 Power calculation 
For cross-sectional comparison the power calculation was based on the key elastance 
parameter, arterial elastance index (EaI).  It was hypothesised that Group 1 would have higher 
EaI compared to Group 2.  In previous published work patients with high risk hypertension 
(which is likely to show similar values to pregnancy hypertension) had EaI of 1.32±0.47 mm 
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Hg/ml/m2.32  It was hypothesised that this parameter will be lower by half of a standard 
deviation in Group 2 (i.e. 1.09 mm Hg/ml/m2).  Thus, in order to achieve this difference in 
variance at 1–b = 0.8 and P<0.05 (ANOVA F statistic approximately 10), 45 subjects per 
group were required.  However, to provide additional confidence, the recruitment target was 
50.  This number of participants would also suffice for assessment of longitudinal changes in 
study parameters.  After performing the systematic review in Chapter 2, it became clear that 
there are other outcomes of interest and that a descriptive analysis would provide valuable 
insight. 
 
The National Institute for Health and Clinical Excellence (NICE) guideline on Hypertension 
in Pregnancy1 states that about 10% of pregnancies are complicated by a hypertensive 
disorder and that this rate is increasing.  About 2–3-fold higher rates of hypertensive disorders 
are expected in patients with hypertension during a previous pregnancy. 
 
4.9 Statistical Analysis 
Baseline characteristics were statistically tested for normality of distribution using the 
Shapiro-Wilk test.  Normally distributed data are expressed as mean and standard deviation 
(SD).  Continuous data which are not normally distributed are expressed as median and 
interquartile range (IQR, described as the 25th and 75th centiles).  Categorical data, such as 
smoking status, are expressed as number and percentage.  
 
Cross-sectional data were subjected to one way analysis of variance (ANOVA) for normally 
distributed data and Kruskal-Wallis test for non-normally distributed data.  Appropriate post 
hoc testing was performed to account for comparisons between the three groups, using 
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Tukey’s test of pairwise comparisons for normally distributed and the Dunn-Bonferroni 
method for non-normally distributed data respectively.  Categorical data are compared using 
Fisher’s exact test for two groups and the chi-squared test with appropriate degrees of 
freedom for three groups.   
 
The data acquired in the prospective study was analysed using non-parametric statistical tests 
for consistency of presentation style.  The Kruskal-Wallis test was used to analyse differences 
between groups and the Mann-Whitney test was applied to comparisons between the two 
groups of pregnant women.   
 
Longitudinal data were analysed using repeated measures ANOVA, with pairwise comparison 
of each time point to the baseline time point.  Subsequently the Wilcoxon matched-pairs 
signed rank is applied to within-group comparisons of data from different time points. This 
analysis required restructuring of the data into a long format with repeated measures from all 
appointments recorded in a single column.  Each appointment represented a time point.  These 
time points were considered as ordinal variables with fixed gaps.  The first appointment 
(baseline) was the reference time point.  Before employing the repeated measures ANOVA, 
data were explored to verify that the test’s assumptions were met.  Accordingly, the test was 
only applied to continuous data.  The time point of the study appointment was the 
independent variable (“within subjects factor”), with the same subjects present in each related 
group with measurements of the same dependent variable (the experimental measurement).  If 
the dependent variable was not normally distributed (Shapiro Wilk P≥0.05), then the data 
were log transformed.  Box plots were created to ensure that there were no significant outliers 
which would reduce accuracy.  Since the final assumption of sphericity (equality of the 
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variances of the differences between all levels of time points) is so often not valid, 
Greenhouse-Geisser procedure is used throughout.  The Greenhouse-Geisser correction elicits 
are more accurate significance value as it takes account of repeated measures ANOVA’s 
being too liberal when sphericity is violated. 
 
Correlations between continuous variables are performed using Pearson correlation analysis.  
Predictive associations are assessed using regression models.  Logistic regression is used for 
categorical variables and linear regression for continuous data.  Prior to correlation and 
regression analysis, the assumptions that underpin these statistical methods were tested and 
checked.  Non-normally distributed data were log transformed.  Pairwise deletion for missing 
data was done where applicable.   
 
A 2-tailed p-value of <0.05 is considered statistically significant, after appropriate post hoc 
testing where appropriate.  This adjustment reduces the chance of finding an association by 
chance (type 1 error).   
 
The data were entered into a spreadsheet (Excel, Microsoft) and checked for accuracy.  The 
statistical analysis was performed using Stata® (StataCorp. 2015. Stata Statistical Software: 
Release 14. College Station, TX: StataCorp LP).  
 
4.10 Ethical considerations 
This research was approved by the Research and Development Department of Sandwell and 
West Birmingham Hospitals NHS Trust (Reference 13CARD65, 27/11/13), following review 
by the institution’s Ethics Committee.  Prospective approval for the study was also obtained 
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from the Local Research Ethics Committee for West Midlands (Reference 13/WM/0472, 
07/01/14).  All participants gave written informed consent and confirmed ongoing consent at 
each follow up appointment.  The study was conducted in accordance with the Declaration of 
Helsinki.   
 
4.11 Methods Summary 
 
In this chapter I have provided a comprehensive overview of my study design, experimental 
methods and analysis plan.  I have shown the reproducibility data, which were completed 
prior to recruitment in order to confirm that my techniques were valid.  My coefficients of 
variation were in line with expectations based on existing literature and previous work within 
the ICVS.  
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 CHAPTER 5: 
MATERNAL CARDIAC FUNCTION 





5.1 Introduction to chapter 
This is the first of three chapters containing experimental data.  The prospective study at the 
heart of this thesis, Evaluating Cardiovascular Changes in Hypertension in Obstetrics 
(ECCHO), was designed to assess the differences in cardiac structure and function in women 
with a history of gestational hypertensive disease compared to pregnant women without prior 
hypertension. The demographic and clinical data for all women recruited into the study are 
outlined at the beginning of this chapter.  Thereafter the data from the echocardiographic and 
vascular studies are presented and discussed, starting with the cross-sectional comparisons at 
baseline, before continuing to analyse the longitudinal data. 
 
5.2 Aims and hypothesis 
The aims and hypotheses of this work are stated in Chapter 3.  To briefly recap, the 
hypotheses to be tested are: 
1) abnormal ventricular-arterial interaction will be found in women with a history of 
hypertension in pregnancy. 
2) changes in cardiac structure and function over time may be predictive of recurrent 
gestational hypertensive disease. 
 
5.3 Methods and materials 
5.3.1 Study groups 
A total of 115 women were enrolled in the study.  Group 1 comprised 25 pregnant women 
with previous hypertension in pregnancy and Group 2 comprised 50 pregnant women without 
history of hypertension. For cross sectional comparison at baseline there were 40 non-
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pregnant controls in Group 3. 
 
5.3.2 Statistical analysis 
The statistical analysis plan is described in detail in section 4.9.  For cross sectional 
comparison of normally distributed data across the three groups, one-way ANOVA was used, 
with the post hoc Tukey test applied for pairwise comparisons if a significant difference was 
detected.  For consistency, the Kruskal-Wallis non-parametric test was used to compare the 
experimental results. Where appropriate, post hoc testing with the Dunn Bonferroni test was 
applied and differences were considered significant if P<0.01 to account for multiple testing.  
For longitudinal analysis, repeated measures ANOVA was used.  
 
5.4 Results 
5.4.1 Patient characteristics 
The study groups were well matched for age (P=0.74) and ethnicity (P=0.33) with a slight 
majority (50.4%) coming from non-white racial groups (Table 23).  There was no difference 
in maternal medical history apart from gestational hypertensive disease, which by design is 
unique to Group 1.  Where asthma is noted, the cases were mild in severity, with inhaler use 
required only occasionally and not on the day of the study.  The difference in parity between 
the groups is also a feature of the study design, since women in Group 1 are required to have 
a previous pregnancy.  The number of women taking aspirin was significantly higher in 
Group 1, since this daily medication is recommended to women previously affected by 
hypertension in pregnancy for secondary prevention.  This is discussed later as a limitation. 
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Age, years 30 (27–33) 29 (25–33) 28 (25–34) 0.74 


























































































































































Continuous data are expressed as median (interquartile range). Categorical data are expressed 
as n (%). Post hoc testing: * P <0.01 Group 1 vs Group 2; †P<0.01 Group 1 vs Group 3; 
‡P<0.01 Group 2 vs Group 3.
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There was no difference in family history of hypertension.  There was no significant 
difference in current smoking status, however previous smoking habits varied, with the 
pregnant women previously affected by hypertension more likely to have smoked in the past 
(P=0.03 for Group 1 vs Group 3).  Group 1 comprised 9 women with previous gestational 
hypertension, 9 with previous early onset preeclampsia and 7 with previous late onset 
preeclampsia.  All had normal blood pressure and were free of antihypertensive medication at 
enrollment, in accordance with the study protocol. 
 
5.4.2 Baseline measurements 
The pregnant participants were studied at 13±1 completed weeks of gestation (P=0.42).  The 
non-pregnant women were included for cross sectional comparison at baseline.  There was no 
significant difference in weight (P=0.55) or height (P=0.054), although the non-pregnant 
women tended to be taller.  The groups were matched for BMI (P=0.12) and BSA (P=0.74) 
(Table 24). 
 
The protocol mandated that blood pressure be normal for all women at the start of the study.  
Accordingly, systolic blood pressure (SBP) was less than 140mmHg and diastolic blood 
pressure (DBP) was less than 90mmHg at baseline for all.  Women in Group 1 had 
significantly higher peripheral SBP at baseline compared to Groups 2 and 3 (P<0.01 for 
both).  Peripheral and central DBP and mean arterial pressure (MAP) and central SBP were 
significantly higher in Group 1 compared to Group 2.  Group 2 demonstrated a non-
significant reduction in blood pressure compared to Group 3.  Heart rate was increased in 
pregnant women compared to non-pregnant controls (P<0.001). 
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Gestation (weeks) 13±1 13±1 n/a 0.42 
Height (m) 1.61±0.08 1.64±0.07 1.66±0.08 0.054 
Weight (kg) 73 (58–85) 72 (59–81) 67 (58–83) 0.55 
BMI (kg/m2) 27.7 (23.2–31.2) 26.5 (22.3–31.6) 23.8 (21.0–28.8) 0.12 
BSA (m2) 1.78±0.29 1.80±0.22 1.76±0.21 0.74 
SBP (mmHg) 115 (113–121) *† 108 (100–114) 112 (101–119) 0.001 
DBP (mmHg) 71 (65–75) * 64 (50–69) 66 (60–72) 0.003 
MAP (mmHg) 87 (81–91) * 77 (72–82) 81 (74–86) <0.001 
cSBP (mmHg) 102 (95–106) * 91 (85–96)  97 (86–102) 0.001 
cDBP (mmHg) 72 (68–77) * 65 (59–70) 67 (61–73) 0.004 
cMAP (mmHg) 85 (80–90) * 77 (72–82)  81 (74–86) 0.003 
Heart rate (bpm) 79±10 † 74±9 ‡ 65±10 <0.001 
Hb (g/L) 120±11† 122±11 ‡ 132±11 <0.001 
WCC (x109/L) 9.4 (7.2–10.9) † 8.3 (7.0–9.4) ‡ 6.3 (5.3–6.9) <0.001 
Platelets (x109/L) 253 (210–291) 247 (202–292) 270 (249–303) 0.20 
Creatinine (µmol/L) 51 (49–54) † 53 (50–56) ‡ 66 (62–71) <0.001 
BMI, body mass index; bpm, beats per minute; BSA, body surface area; cDBP, central 
diastolic blood pressure; cMAP, central mean arterial pressure; cSBP, central systolic blood 
pressure; DBP, diastolic blood pressure; Hb, haemoglobin; MAP, mean arterial pressure; n/a, 
not applicable; SBP, systolic blood pressure; WCC, white cell count. Data expressed as 
median (interquartile range) or as mean ± standard deviation.  
Post hoc testing:  
*p<0.01 Group 1 vs Group 2  
†p<0.01 Group 1 vs Group 3 
‡p<0.01 Group 2 vs Group 
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5.4.3 Cross sectional analysis of echocardiographic parameters at baseline 
Haemodynamics  
Whilst the median stroke volume was the same for both groups of pregnant women at 
baseline, the increase compared to non-pregnant controls reached statistical significance only 
for Group 2 (P=0.003), which persisted after adjusting for BSA (see Table 25).  Cardiac 
output and cardiac index were significantly increased in pregnant women (P<0.001), with 
similar values observed regardless of previous hypertension.  This higher cardiac output was 
observed alongside reduced resistance, with total vascular resistance index (TVRI) 
significantly lower in Group 1 (P=0.001) and Group 2 (P<0.001) compared with Group 3.   
There was no significant difference in the systolic tissue Doppler average velocity at the 
septal and lateral mitral valve annuli.   
Cardiac structure  
The size of the left atrium was unchanged across groups.  Pregnant women exhibited a 
significant increase in left ventricular volume and its index to BSA (P<0.001).  Women with 
previous gestational hypertension had a significantly higher left ventricular mass index 
compared to non-pregnant women (P=0.006), whilst the increase compared to pregnant 
women without hypertension history was not significant with the Bonferroni adjustment of 
alpha to account for multiple comparisons (P=0.03).  There was no significant difference in 
the cross-sectional comparison of left ventricular end diastolic dimension, interventricular 
septum thickness at end diastole or relative wall thickness.  The difference in posterior wall 
thickness at end diastole was not significantly different when post hoc testing was performed.
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Stroke volume (ml) 68 (59–72) 68 (58–76) ‡ 59 (51–69) 0.019 
Stroke volume index (ml/m2) 37.3 (34.0–42.8) 37.6 (33.6–43.6) ‡ 32.8 (30.0–37.3) 0.017 
Cardiac output (L/min) 5.0 (4.6–5.8)† 4.8 (4.5–5.6) ‡ 3.8 (3.1–4.5) <0.001 
Cardiac index (L/min/m2) 3.0 (2.7–3.2) † 2.8 (2.4–3.3) ‡ 2.1 (1.8–2.4) <0.001 
Total vascular resistance 
(dyne.s/cm5) 1.4 (1.2–1.5)
† 1.2 (1.1–1.5) ‡ 1.7 (1.5–2.1) <0.001 
Total vascular resistance index 
(dyne.s/cm5/m2) 0.80 (0.65–0.89)
 † 0.69 (0.58–0.89) ‡ 0.97 (0.83–1.20) <0.001 
Average s’ (cm/s) 9.6 (8.5–10.2) 9.5 (8.8–10.1) 9.5 (8.9–10.4) 0.84 
Structure 
Left atrium volume (ml) 41 (31–45) 39 (31–46) 42 (30–51) 0.71 
Left atrium volume index 
(ml/m2) 22 (18–28) 22 (17–26) 23 (18–28) 0.76 
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Left ventricle volume (ml) 98 (84–127) † 110 (91–121) ‡ 91 (80–101) <0.001 
Left ventricle volume index 
(ml/m2) 59 (52–64)
 † 60 (50–71) ‡ 51 (44–58) <0.001 
Left ventricular mass (g) 117 (95–152) 119 (97–143) 103 (81–129) 0.10 
Left ventricular mass index 
(g/m2) 70.9 (57.4–82.5)
 † 65.4 (56.8–78.7) 61.6 (49.7–69.2) 0.03 
Left ventricular end diastolic 
dimension (cm) 4.5 (4.3–5.0) 4.5 (4.2–4.8) 4.4 (4.3–4.8) 0.93 
Posterior wall thickness at end 
diastole (cm) 0.9 (0.7–1.1)
  0.9 (0.8–1.0) ‡ 0.8 (0.7–0.9) 0.047 
Interventricular septum 
thickness at end diastole (cm) 0.79 (0.69–0.91) 0.73 (0.66–0.87) 0.72 (0.57–0.82) 0.10 
Relative wall thickness  0.38 (0.32–0.49) 0.40 (0.33–0.46) 0.36 (0.29–0.41) 0.11 
Diastolic function (mitral inflow) 
Early filling (E) (cm/s) 85 (75–99) † 88 (77–96) ‡ 74 (67–85) <0.001 
Atrial filling (A) (cm/s) 62 (51–67) *† 48 (44–62) 49 (40–74) 0.005 

















E/e’ (average from septal and 
lateral) 6.6 (5.7–8.2)
 † 6.5 (5.2–7.5) ‡ 5.4 (4.6–6.4) 0.001 
Derived values including elastance 
Left ventricular ejection 
fraction 0.63 (0.59–0.67) 0.63 (0.60–0.67) 0.66 (0.62–0.69) 0.066 
Left ventricular end diastolic 
pressure (mmHg) 10.1 (9.0–12.1)
 † 9.9 (8.4–11.2) ‡ 8.6 (7.9–9.9) 0.008 
Arterial elastance (Ea) 1.6 (1.4–1.8) 1.4 (1.2–1.7) ‡ 1.7 (1.5–1.9) 0.005 
Arterial elastance index (EaI) 0.95 (0.79–1.11) 0.79 (0.72–0.95) ‡ 0.95 (0.80–1.10) 0.004 
End-systolic elastance (Ees) 2.0 (1.8–2.3)  1.9 (1.6–2.2) ‡ 2.3 (1.8–2.7) 0.015 
End-diastolic elastance (Eed) 0.9 (0.08–0.11) 0.08 (0.07–0.10) 0.08 (0.07–0.10) 0.24 
Arterial-ventricular 
interaction (Ea/Ees) 0.85 (0.78–0.88) 0.81 (0.74–0.90) 0.76 (0.71–0.85) 0.084 
Arterial-ventricular 
interaction index (EaI/Ees) 0.47 (0.42–0.59) 0.44 (0.40–0.53) 0.45 (0.41–0.48) 0.22 
Data expressed as median (interquartile range) or as mean ± standard deviation. E, mitral valve early filling on Pulsed-Wave Doppler; e’, 
velocity of early myocardial relaxation measured on tissue Doppler imaging; A, mitral valve late (atrial) filling. 
Post hoc testing:  
*p<0.01 Group 1 vs Group 2 
†p<0.01 Group 1 vs Group 3 
‡p<0.01 Group 2 vs Group 3
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Diastolic function  
Significant differences were observed for mitral inflow velocities.  The maximum early mitral 
valve inflow velocity on Pulsed-Wave Doppler (E wave) was significantly greater in the 
pregnant women irrespective of former hypertension history (P=0.003 Group 1 vs Group 3; 
P<0.001 Group 2 vs Group 3).  The maximum late diastolic mitral inflow velocity was 
significantly increased in the women with previous hypertension, compared to both 
unaffected pregnant women and non-pregnant women (P=0.001 for both comparisons).    
Similarly the calculated E/A ratio of early to late ventricular filling in diastole, was 
significantly lower when pregnancy was complicated by previous gestational hypertensive 
disease (P<0.001).  There was no difference in e’, the velocity of early myocardial relaxation 
measured on tissue Doppler imaging, between the three groups.  The E/e’ ratio of early mitral 
inflow to the average tissue Doppler early myocardial relaxation at the septal and lateral 
mitral valve annuli, was significantly increased in both groups of pregnant women compared 
to the non-pregnant controls (P=0.001 for both).  
Elastance parameters and other derived values  
Left ventricular ejection fraction (LVEF) was similar in all groups (P=0.07).  Left ventricular 
end diastolic pressures were higher in each group of pregnant women compared to non-
pregnant controls but not to each other (P=0.008).  There was a significant decrease in arterial 
elastance index (EaI, P <0.001) and left ventricular end-systolic elastance (Ees, P=0.002) in 
healthy pregnant women in Group 2 compared to non-pregnant controls.  Similar values of 
EaI were seen in Groups 1 and 3 and the reduction in Ees in Group 1 was not statistically 
significant after post hoc testing.  There was no difference in EaI/Ees, the arterial-ventricular 
interaction index, between the three groups. 
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Arterial stiffness  
Augmentation index, standardised to heart rate 75 beats per minute, was significantly 
increased in Group 1 with previous hypertension compared to Group 2 (P=0.004) and to 
Group 3 (P<0.001, Table 26). There was no significant difference in arterial stiffness in 
pregnancy without hypertension history compared to non-pregnant women. 

















15 (6–19)  5 (–2–12) 7	(2–16)	 0.06	
Augmentation 
index HR75 
16 (4–21) *	† 4 (–3–14) 2	(–6–11)	 0.003	
Augmentation 
index HR75 
adjusted for MAP 
0.16 (0.05–0.24)	*	† 0.05 (–0.03–0.17) 0.03	(–0.08–0.13)	 0.003	
Data expressed as median (interquartile range) or as mean ± standard deviation. HR75 
denotes adjustment to standardise for heart rate 75 beats per minute; MAP, mean arterial 
pressure. Post hoc testing: *p<0.01 Group 1 vs Group 2; †p<0.01 Group 1 vs Group 3; ‡p<0.01 
Group 2 vs Group 3 
 
 
5.4.4 Cross-sectional analysis of clinical and cardiovascular parameters at follow up 
Blood pressure was persistently higher in Group 1 compared to Group 2.  Systolic, diastolic 
and mean arterial pressures were significantly increased at 21±1and 32±1 weeks of gestation 
in women previously affected by gestational hypertension or preeclampsia, compared to 
healthy pregnant women (Table 27).  There was no significant difference in heart rate 
observed between the groups of pregnant women at follow up. 
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A significantly lower stroke volume was observed in Group 2 in the third trimester, compared 
to Group 1 at the same timepoint and compared to the values observed early in pregnancy 
when there had been no difference between the groups.  At the follow up appointments, 
cardiac index was significantly higher in Group 1 compared to Group 2 (P=0.025 for 2nd 
trimester and P=0.045 for 3rd trimester).  There were no other significant differences between 
the groups when the previously described echocardiographic measurements were subjected to 
cross sectional comparison at the later gestations (Table 28).  For augmentation index, the 
increase in Group 1 compared to Group 2 at baseline, was not observed later in pregnancy, 













1st visit 2nd visit 3rd visit 1st visit 2nd visit 3rd visit 
Number of women 25 24 20 50 41 34 
Gestation 
(weeks) 13±1 21±1 32±1 13±1 20±1 32±1 
SBP 
(mmHg) 115 (113–121)
 * 115 (111–127) * 119 (111–125) * 108 (100–114) 106 (97–112) 114 (102–116) 
DBP 
(mmHg) 71 (65–75)
 * 71 (65–75) * 73 (64–76) * 64 (58–69) 60 (56–66) 65 (60–69)  
MAP 
(mmHg) 87 (81–91)
 * 88 (79–91) * 87 (83–93) * 77 (72–82) 75 (69–82) 80 (75–86) 
cSBP 
(mmHg) 102 (95–106)
 * 102 (94–108) * 102 (96–106) * 91 (85–96)  90 (81–96)  94 (87–100)  
cDBP 
(mmHg) 72 (68–77)
 * 73 (66–77) * 72 (66–79) * 65 (59–70)  62 (57–67) 68 (62–72)  
cMAP 
(mmHg) 85 (80–90)




* 85±14 86±13 74±9 79±12 86±13 
Weight 
(kg) 73 (58–85)
  76 (62–94) 80 (68–87)  72 (59–81 74 (62–83)  80 (66–89)  
BSA 
(m2) 1.78±0.29 1.82±0.28  1.84±0.21 1.80±0.22 1.82±0.23 1.86±0.23 
Haemoglobin 
(g/L) 120±11 115±10 115±10 122±11 116±8 113±10 
WCC 
(x109/L) 9.4 (7.2–10.9)
 * 9.9 (7.8–11.3) 9.7 (8.2–11.4) 8.3 (7.0–9.4) 8.6 (7.5–10.0) 9.3 (8.0–10.1)  
Platelets 
(x109/L) 253 (210–291) 259 (231–287) 263 (218–277) 247 (202–292) 265 (204–291) 248 (197–298) 
Creatinine 
(µmol/L) 51 (49–54) 50 (45–53)
 * 50 (45–54) 53 (50–56) 53 (50–56) 51 (49–56)  
 
BMI, body mass index; BSA, body surface area; cDBP, central diastolic blood pressure; cSBP, central systolic blood pressure; cMAP, central 
mean arterial pressure; DBP, peripheral diastolic blood pressure; MAP, peripheral mean arterial pressure; SBP, peripheral systolic blood 
pressure; WCC, white cell count. Data expressed as median (interquartile range) or as mean ± standard deviation. * p<0.05 vs group 2.
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1st visit 2nd visit 3rd visit 1st visit 2nd visit 3rd visit 
Number of women 25 24 20 50 41 34 
Gestation 
(weeks) 13±1 21±1 32±1 13±1 20±1 32±1 
Haemodynamics	
Stroke volume 
(ml) 68 (59–72) 69 (56–75) 65 (53–75) 68 (58–76) 65 (57–72) 56 (49–64) 
Stroke volume 
index (ml/m2) 37.3 (34.0–42.8) 38.2 (32.0–45.0) 36.4 (28.5–41.5)
 * 37.6 (33.6–43.6) 35.6 (31.3–40.2) 29.0 (26.7–33.9) 
Cardiac output 
(L/min) 5.0 (4.6–5.8) 5.8 (4.9–6.6)
 * 5.7 (4.6–6.1) 4.8 (4.5–5.6) 4.9 (4.3–6.0) 5.0 (4.0–6.0) 
Cardiac index 
(L/min/m2) 3.0 (2.7–3.2) 3.2 (2.9–3.7) 








0.80 (0.65–0.89) 0.65 (0.56–0.90) 0.67 (0.54–0.88) 0.69 (0.58–0.89) 0.66 (0.56–0.79) 0.70 (0.59–0.85) 
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Average s’ (cm/s) 9.6 (8.5–10.2) 10.3 (9.1–11.1) 10.0 (8.4–11.3) 9.5 (8.8–10.1) 9.9 (9.1–10.7) 9.6 (8.8–11.1) 
Structure	
Left atrium 




22.1 (18.5–28.0) 23.1 (18.0–25.5) 17.9 (16.3–21.2) 22.2 (17.0–26.3) 20.3 (18.0–26.1) 21.2 (15.7–26.8) 
Left ventricle 




56.7 (51.6–63.9) 55.3 (50.3–67.0) 63.7 (52.9–68.4) 59.5 (49.9–70.9) 57.5 (50.7–62.3) 63.7 (59.5–66.7) 
Left ventricular 
mass (g) 117 (95–152) 114 (92–142) 132 (96–165) 119 (97–143) 108 (93–142) 130 (108–146) 
Left ventricular 




4.5 (4.3–5.0) 4.5 (4.1–4.8) 4.3 (4.0–4.6) 4.5 (4.2–4.8) 4.5 (4.2–4.8) 4.5 (4.3–4.8) 
Posterior wall 
thickness at end 
diastole (cm) 
0.9 (0.7–1.1) 0.9 (0.7–1.1) 1.0 (0.8–1.2) 0.9 (0.8–1.0) 0.8 (0.7–1.0) 0.9 (0.8–1.1) 
Interventricular 
septum thickness 
0.79 (0.69–0.91) 0.80 (0.73–0.90) 0.81 (0.68–1.15) 0.73 (0.66–0.87 0.73 (0.59–0.95) 0.85 (0.73–0.95) 
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at end diastole 
(cm) 
Relative wall 
thickness 0.38 (0.32–0.49) 0.40 (0.32–0.47) 0.46 (0.37–0.57) 0.40 (0.33–0.46) 0.35 (0.30v0.46) 0.42 (0.35–0.49) 
Diastolic	function	(mitral	inflow)	
E (cm/s) 84.9 (74.9–99.4) 90.5 (80.7–103.9) 75.7 (71.5–87.8) 87.9 (77.0–95.6) 86.6 (73.8–100.0) 75.3 (64.9–87.4) 
A (cm/s) 61.9 (51.0–67.1) * 59.2 (50.1–69.4) 62.7 (54.0–76.2) * 48.5 (44.4–61.5) 52.8 (42.7–62.7) 50.5 (41.7–64.1) 
E/A ratio 1.4 (1.1–1.6) * 1.4 (1.3–2.0) 1.3 (1.1–1.4) 1.8 (1.5–1.9) 1.6 (1.4–2.0) 1.5 (1.2–1.8) 
Average e’ (cm/s) 13.1 (11.6–13.7) 12.9 (11.6–14.4) 10.9 (9.6–12.9) 13.5 (12.1–14.9) 13.4 (11.3–14.8) 12.1 (10.4–13.6) 
Average E/e’ 6.6 (5.7–8.2) 7.0 (6.2–8.2) 7.4 (6.2–9.2) 6.5 (5.2–7.5) 6.6 (5.4–8.4) 6.3 (5.4–7.3) 
Derived	values	including	elastance	
Left ventricular 
ejection fraction 0.63 (0.59–0.67)




10.1 (9.0–12.1) 10.6 (9.6–12.1) 11.0 (9.6–13.2) 9.9 (8.4–11.2) 10.1 (8.6–12.3) 10.4 (8.8–11.9) 
Arterial elastance 
(Ea) 1.6 (1.4–1.8)
 * 1.5 (1.4–1.9) 1.6 (1.4–2.0) 1.4 (1.2–1.7) 1.5 (1.3–1.8) 1.8 (1.5–2.1) 
Arterial elastance  
index (EaI) 0.95 (0.79–1.11)
 * 0.92 (0.80–1.07) 0.97 (0.72–1.13) 0.79 (0.72–0.95) 0.86 (0.69–0.97) 0.95 (0.80–1.16) 
End-systolic 
elastance (Ees) 2.0 (1.8–2.3) 2.4 (2.0–2.6) 2.3 (1.9–2.7) 1.9 (1.6–2.2) 2.4 (2.0–2.7) 2.4 (1.9–2.9) 
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End-diastolic 









 *	 11 (3–18)	 12 (3–21)	 5 (–2–12)	 6 (–2–16)	 7 (1–16)	
Augmentation 
index HR75	 16 (4–21)




0.16 (0.05–0.24) *	 0.18 (0.05–0.31)	 0.17 (0.10–0.27)	 0.05 (–0.03–0.17)	 0.08 (0.01–0.24)	 0.11 (0.04–0.24)	
 
Data expressed as median (interquartile range) or as mean ± standard deviation. 
CO, cardiac output; CI, cardiac index; Ea, arterial elastance; EDP, end diastolic pressure; Eed, end diastolic elastance; Ees, end systolic 
elastance;  LA, left ventricle; LAD, left atrial dimension; LVEDd, left ventricular end diastolic dimension; LVEF, left ventricular ejection 
fraction; LVM, left ventricular mass; LVMI, left ventricular mass index;  MAP, mean arterial pressure; PWT, posterior wall thickness; 
RWT, relative wall thickness; SV, stroke volume; SVI, stroke volume index; TVR, total vascular resistance; TVRI, total vascular resistance 
index. HR75 denotes adjustment to standardise for heart rate 75 beats per minute. 
 * P<0.05 vs group 2. 
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5.4.5 Longitudinal analysis for Group 1 (previous hypertension in pregnancy) 
Heart rate increased as pregnancy progressed (Table 29).  There was a significant increase in 
weight throughout the pregnancy.  Haemoglobin decreased significantly from the first to 
second appointment, then plateaued in the third trimester.  No significant change in average 
blood pressure was observed throughout the study period in Group 1. 
 
Several of the echocardiographic measures of cardiac structure and function showed 
significant changes in the pregnant women with previous hypertension, when studied 
throughout pregnancy (Table 30).  Cardiac output increased from baseline to second visit 
(P=0.01) then remained unchanged into the third trimester.  The average s’ showed a similar 
trend (P=0.009).  The median left atrial volume index was lower at the third visit (P=0.008).  
Left ventricular volume and left ventricular mass increased between second and third 
appointments, but there was no significant longitudinal change.   
 
The maximum velocity of early filling across the mitral valve (E wave) was seen to increase 
from baseline to second measurement, and then decrease in the third trimester (P=0.02), 
resulting in a significant reduction in E/A ratio by the last visit (P=0.03).  Meanwhile e’, the 
velocity of early myocardial relaxation, reduced significantly during the pregnancy (P=0.01) 
but E/e’ was unchanged.  A significant increase in the end-systolic elastance from baseline to 
follow up measurements (P=0.02) led to a decrease in the arterial-ventricular interaction in 
the women with previous hypertension (P=0.02).  There was no significant longitudinal 
change in augmentation index in Group 1 during the study.
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115 (113–121) 115 (111–127) 119 (111–125) 0.52 
DBP 
(mmHg) 
71 (65–75) 71 (65–75) 73 (64–76) 0.39 
MAP 
(mmHg) 
87 (81–91) 88 (79–91) 87 (83–93) 0.61 
cSBP 
(mmHg) 
102 (95–106)  102 (94–108) 102 (96–106) 0.85 
cDBP 
(mmHg) 
72 (68–77)  73 (66–77)  72 (66–79)  0.45 
cMAP 
(mmHg) 
85 (80–90)  88 (79–91)  85 (82–93)  0.28 
Heart rate 
(bpm) 
79±10 85±14† 86±13† 0.02 
Weight 
(kg) 
73 (58–85) 76 (62-94) † 80 (68–87) †‡ <0.001 
Haemoglobin 
(g/L) 
120±11 115±10† 115±10 0.060 
WCC 
(x109/L) 
9.4 (7.2–10.9) 9.9 (7.8–11.3) 9.7 (8.2–11.4) 0.42 
Platelets 
(x109/L) 
253 (210–291) 259 (231-287) 263 (218–277) 0.54 
Creatinine 
(µmol/L) 
51 (49–54) 50 (45–53) 50 (45–54) 0.27 
BMI, body mass index; BSA, body surface area; cDBP, central diastolic blood pressure; 
cSBP, central systolic blood pressue; cMAP, central mean arterial pressure; DBP, peripheral 
diastolic blood pressure; MAP, peripheral mean arterial pressure; SBP, peripheral systolic 
blood pressure; WCC, white cell count. Data expressed as median (interquartile range) or as 
mean ± standard deviation. Post hoc testing: † P<0.05 vs baseline visit; ‡ P<0.05 vs 
midtrimester 2nd visit. 
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Table 30: Longitudinal echocardiographic and pulse wave analysis parameters for Group 1 at baseline, second and third trimester 
 Baseline 













Stroke volume (ml) 68 (59–72) 69 (56–75) 65 (53–75) 0.63 
Stroke volume index (ml/m2) 37.3 (34.0–42.8) 38.2 (32.0–45.0) 36.4 (28.5–41.5) 0.43 
Cardiac output (L/min) 5.0 (4.6–5.8) 5.8 (4.9–6.6) † 5.7 (4.6–6.1) 0.17 
Cardiac index (L/min/m2) 3.0 (2.7–3.2) 3.2 (2.9–3.7) † 3.0 (2.4–3.6) 0.35 
Total vascular resistance 
(dyne.s/cm5) 1.4 (1.2–1.5) 1.3 (0.96–1.4) 1.2 (1.0–1.6) 0.30 
Total vascular resistance index 
(dyne.s/cm5/m2) 0.80 (0.65–0.89) 0.65 (0.56–0.90) 0.67 (0.54–0.88) 0.12 
Average s’ (cm/s) 9.6 (8.5–10.2) 10.3 (9.1–11.1) † 10.0 (8.4–11.3) 0.03 
Structure 
Left atrium volume (ml) 41 (31–45) 41 (31–49) 34 (29–38) †‡ 0.05 
Left atrium volume index (ml/m2) 22.1 (18.5–28.0) 23.1 (18.0–25.5) 17.9 (16.3–21.2) †‡ 0.008 
Left ventricle volume (ml) 98 (84–127) 98 (88–113) 103 (94–112) ‡ 0.13 
Left ventricle volume index (ml/m2) 56.7 (51.6–63.9) 55.3 (50.3–67.0) 63.7 (52.9–68.4) 0.26 
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Left ventricular mass (g) 117 (95–152) 114 (92–142) 132 (96–165) ‡ 0.09 
Left ventricular mass index (g/m2) 71 (57–82) 63 (53–77) 76 (54–85) 0.16 
Left ventricular end diastolic 
dimension (cm) 4.5 (4.3–5.0) 4.5 (4.1–4.8) 4.3 (4.0–4.6) 0.22 
Posterior wall thickness at end 
diastole (cm) 0.9 (0.7–1.1) 0.9 (0.7–1.1) 1.0 (0.8–1.2) 0.13 
Interventricular septum thickness 
at end diastole (cm) 0.79 (0.69–0.91) 0.80 (0.73–0.90) 0.81 (0.68–1.15) 0.09 
Relative wall thickness  0.38 (0.32–0.49) 0.40 (0.32–0.47) 0.46 (0.37–0.57) 0.14 
Diastolic function (mitral inflow) 
E (cm/s) 84.9 (74.9–99.4) 90.5 (80.7–103.9) 75.7 (71.5–87.8) ‡ 0.02 
A (cm/s) 61.9 (51.0–67.1) 59.2 (50.1–69.4) 62.7 (54.0–76.2) ‡ 0.41 














9.7 (7.8–10.9) † ‡ 
12.0 (10.2–14.7) ‡ 





E/e’  6.6 (5.7–8.2) 7.0 (6.2–8.2) 7.4 (6.2–9.2) 0.40 
Derived values including elastance 
Left ventricular ejection fraction 0.63 (0.59–0.67) 0.61 (0.57–0.63) 0.59 (0.56–0.63) 0.16 
Left ventricular end diastolic 10.1 (9.0–12.1) 10.6 (9.6–12.1) 11.0 (9.6–13.2) 0.39 
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pressure (mmHg) 
Arterial elastance (Ea) 1.6 (1.4–1.8) 1.5 (1.4–1.9) 1.6 (1.4–2.0) 0.75 
Arterial elastance index (EaI) 0.95 (0.79–1.11) 0.92 (0.80–1.07) 0.97 (0.72–1.13) 0.71 
End-systolic elastance (Ees) 2.0 (1.8–2.3) 2.4 (2.0–2.6) † 2.3 (1.9–2.7) 0.02 
End-diastolic elastance (Eed) 0.09 (0.08–0.11) 0.09 (0.08–0.11) 0.10 (0.08–0.12) 0.45 
Arterial-ventricular interaction 
(Ea/Ees) 0.85 (0.78–0.88) 0.72 (0.66–0.81)
 † 0.76 (0.69–0.88) 0.02 
EaI/Ees 0.47 (0.42–0.59) 0.39 (0.36–0.46) † 0.42 (0.38–0.50) 0.005 
Arterial stiffness 
Augmentation index 15 (6–19) 11 (3–18) 12 (3–21) 0.58 
Augmentation index HR75 16 (4–21) 16 (5–25) 15 (8–23) 0.70 
Augmentation index HR75 
adjusted for MAP 0.16 (0.05–0.24) 0.18 (0.05–0.31) 0.17 (0.10–0.27) 0.55 
 
Data expressed as median (interquartile range) or as mean ± standard deviation. 
CO, cardiac output; CI, cardiac index; Ea, arterial elastance; EDP, end diastolic pressure; Eed, end diastolic elastance; Ees, end systolic 
elastance;  LA, left ventricle; LAD, left atrial dimension; LVEDd, left ventricular end diastolic dimension; LVEF, left ventricular ejection 
fraction; LVM, left ventricular mass; LVMI, left ventricular mass index; MAP, mean arterial pressure;  PWT, posterior wall thickness; 
RWT, relative wall thickness; SV, stroke volume; SVI, stroke volume index; TVR, total vascular resistance; TVRI, total vascular resistance 
index. HR75 denotes adjustment to standardise for heart rate 75 beats per minute. 
Post hoc testing: † P<0.05 vs baseline visit; ‡ P<0.05 vs midtrimester 2nd visit. 
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5.4.6 Longitudinal analysis for Group 2 (no prior hypertension in pregnancy) 
For the pregnant women with no prior hypertension, there was a significant increase in 
systolic, diastolic and mean arterial blood pressures throughout the pregnancy.  Heart rate 
increased (P<0.001) and haemoglobin decreased (P<0.001) during the study period.  Weight 
gain was also significant (P<0.001).   
 
A reduction in stroke volume index was observed longitudinally in the women without 
hypertension history (P<0.001).  The volume of the left ventricle increased significantly 
(P=0.01) with a corresponding increase in left ventricular mass (P=0.02), although this trend 
did not reach statistical significance once adjusted for body surface area.  An increase in 
interventricular septum thickness at end diastole was observed (P=0.04). 
 
The maximum velocity of early filling across the mitral valve (E) decreased significantly 
throughout the pregnancies of the women without prior hypertension (P=0.005), whilst the 
maximum velocity of late filling (A) was unchanged.  The ratio of E/A was significantly 
lower in these women by the third trimester (P=0.01).  A significant reduction in average e’ 
was also demonstrated in pregnant controls in longitudinal analysis (P<0.001). 
 
Arterial elastance index (EaI) increased throughout the study period (P<0.001) whilst end 
systolic elastance (Ees) also increased (P<0.001).  The ratio EaI/Ees as a measure of arterial-
ventricular interaction showed a decrease from baseline to third trimester assessment 
(P<0.001). 
 
Augmentation index, adjusted for heart rate and blood pressure, showed a successive increase 
from baseline through 20±1 and 32±1 weeks of gestation (P<0.001).  
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(mmHg) 108 (100–114) 106 (97–112) 114 (102–116) 
†‡ 0.02 
DBP 
(mmHg) 64 (58–69) 60 (56–66) 65 (60–79) 
†‡ <0.001 
MAP 
(mmHg) 77 (72–82) 75 (69–82) 80 (75–86)
 †‡ <0.001 
cSBP 
(mmHg) 91 (85–96) 90 (81–96) 94 (87–100) 
†‡ 0.008 
cDBP 
(mmHg) 65 (59–70)  62 (57–67) 68 (62–72) 
†‡   <0.001 
cMAP 




† 86±13†‡ <0.001 
Weight 
(kg) 72 (59–81) 74 (62–83)
 † 80 (66–89) †‡ <0.001 
Haemoglobin 
(g/L) 122±11 116±8
† 113±10†‡ <0.001 
WCC 
(x109/L) 8.3 (7.0–9.4) 8.6 (7.5–10.0)
 † 9.3 (8.0–10.1) †  0.02 
Platelets 
(x109/L) 247 (202–292) 265 (204–291) 248 (197–298) 0.30 
Creatinine 
(µmol/L) 53 (50–56) 53 (50–56) 51 (49–56)
 † 0.54 
BMI, body mass index; BSA, body surface area; cDBP, central diastolic blood pressure; 
cSBP, central systolic blood pressue; cMAP, central mean arterial pressure; DBP, peripheral 
diastolic blood pressure; MAP, peripheral mean arterial pressure; rANOVA, repeated 
measures ANOVA; SBP, peripheral systolic blood pressure; WCC, white cell count. Data 
expressed as median (interquartile range) or as mean ± standard deviation. Post hoc testing:  † 
P<0.05 vs baseline visit; ‡ P<0.05 vs midtrimester 2nd visit.
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Table 32: Longitudinal echocardiographic and pulse wave analyisis parameters for Group 2 at baseline, second and third trimester 
 Baseline 














Stroke volume (ml) 68 (58–76) 65 (57–72) 56 (49–64) † ‡ <0.001 
Stroke volume index (ml/m2) 37.6 (33.6–43.6) 35.6 (31.3–40.2) 29.0 (26.7–33.9) † ‡ <0.001 
Cardiac output (L/min) 4.8 (4.5–5.6) 4.9 (4.3–6.0) 5.0 (4.0–6.0) 0.54 
Cardiac index (L/min/m2) 2.8 (2.4–3.3) 2.7 (2.4–3.5) 2.5 (2.2–3.1) 0.15 
Total vascular resistance 
(dyne.s/cm5) 1.2 (1.1–1.5) 1.2 (1.0–1.4) 1.3 (1.1–1.7) 0.05 
Total vascular resistance index 
(dyne.s/cm5/m2) 0.69 (0.58–0.89) 0.66 (0.56–0.79) 0.70 (0.59–0.85) 0.10 
Average s’ (cm/s) 9.5 (8.8–10.1) 9.9 (9.1–10.7) 9.6 (8.8–11.1) 0.24 
Structure 
Left atrium volume (ml) 39 (31–46) 40 (32–44) 39 (33–47) 0.93 
Left atrium volume index (ml/m2) 22.2 (17.0–26.3) 20.3 (18.0–26.1) 21.2 (15.7–26.8) 0.84 
Left ventricle volume (ml) 110 (91–121) 102 (91–114) 112 (98–123) ‡ 0.01 
Left ventricle volume index (ml/m2) 59.5 (49.9–70.9) 57.5 (50.7–62.3) 63.7 (59.5–66.7) 0.07 
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Left ventricular mass (g) 119 (97–143) 108 (93–142) 130 (108–146) ‡ 0.02 
Left ventricular mass index (g/m2) 65 (57–79) 64 (54–73) 69 (62–78) ‡ 0.14 
Left ventricular end diastolic 
dimension (cm) 4.5 (4.2–4.8) 4.5 (4.2–4.8) 4.5 (4.3–4.8) 0.78 
Posterior wall thickness at end 
diastole (cm) 0.9 (0.8–1.0) 0.8 (0.7–1.0) 0.9 (0.8–1.1) 0.36 
Interventricular septum thickness 
at end diastole (cm) 0.73 (0.66–0.87 0.73 (0.59–0.95) 0.85 (0.73–0.95)
 † 0.04 
Relative wall thickness  0.40 (0.33–0.46) 0.35 (0.30v0.46) 0.42 (0.35–0.49) 0.48 
Diastolic function (mitral inflow) 
E (cm/s) 87.9 (77.0–95.6) 86.6 (73.8–100.0) 75.3 (64.9–87.4) † ‡ 0.005 
A (cm/s) 48.5 (44.4–61.5) 52.8 (42.7–62.7) 50.5 (41.7–64.1) 0.52 














10.2 (8.5–11.3) † ‡ 
15.2 (12.5–16.3) † 





E/e’ Average 6.5 (5.2–7.5) 6.6 (5.4–8.4) 6.3 (5.4–7.3) 0.56 
Derived values including elastance 
Left ventricular ejection fraction 0.63 (0.60–0.67) 0.62 (0.58–0.64) 0.60 (0.58–0.65) 0.35 
Left ventricular end diastolic 9.9 (8.4–11.2) 10.1 (8.6–12.3) 10.4 (8.8–11.9) 0.54 
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pressure (mmHg) 
Arterial elastance (Ea) 1.4 (1.2–1.7) 1.5 (1.3–1.8) 1.8 (1.5–2.1) † ‡  <0.001 
Arterial elastance index (EaI) 0.79 (0.72–0.95) 0.86 (0.69–0.97) 0.95 (0.80–1.16) † ‡ <0.001 
End-systolic elastance (Ees) 1.9 (1.6–2.2) 2.4 (2.0–2.7) † 2.4 (1.9–2.9) † <0.001 
End-diastolic elastance (Eed) 0.08 (0.07–0.10) 0.08 (0.07–0.11) 0.09 (0.08–0.13) † 0.11 
Arterial-ventricular interaction 
(Ea/Ees) 0.81 (0.74–0.90) 0.69 (0.65–0.73)
 † 0.76 (0.68–0.89) † <0.001 
EaI/Ees 0.44 (0.40–0.54) 0.39 (0.34–0.44) † 0.40 (0.36–0.51) † <0.001 
Arterial stiffness 
Augmentation index 5 (-2–12) 6 (-2–16) 7 (1–16) 0.14 
Augmentation index HR75 4 (-3–14) 8 (2–19) 13 (5–19) <0.001 
Augmentation index HR75 
adjusted for MAP 0.05 (-0.03–0.17) 0.08 (0.01–0.24)
 † 0.11 (0.04–0.24)† ‡ <0.001 
 
Data expressed as median (interquartile range) or as mean ± standard deviation. 
CO, cardiac output; CI, cardiac index; Ea, arterial elastance; EDP, end diastolic pressure; Eed, end diastolic elastance; Ees, end systolic 
elastance;  LA, left ventricle; LAD, left atrial dimension; LVEDd, left ventricular end diastolic dimension; LVEF, left ventricular ejection 
fraction; LVM, left ventricular mass; LVMI, left ventricular mass index; MAP, mean arterial pressure;  PWT, posterior wall thickness; 
RWT, relative wall thickness; SV, stroke volume; SVI, stroke volume index; TVR, total vascular resistance; TVRI, total vascular resistance 
index. HR75 denotes adjustment to standardise for heart rate 75 beats per minute. 
Post hoc testing: † P<0.05 vs baseline visit; ‡ P<0.05 vs midtrimester 2nd visit. 
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5.5 Discussion 
The peripheral systolic blood pressure in Group 1 at 13±1 weeks of gestation was 
significantly higher than both other groups after correcting for multiple comparisons 
(P<0.001 vs Group 2; P=0.007 vs Group 3).  Systolic, diastolic and mean arterial pressures 
remained significantly higher at 21±1 weeks and 32±1 of gestation in those women whose 
previous pregnancy was affected by hypertension.  These findings are similar to those of a 
two year follow up study of women after preeclamptic pregnancy.50  My study showed that 
these changes persist into the subsequent pregnancy.   The concept of prehypertension was 
formally introduced into American guidelines over a decade ago.254  Patients with a systolic 
blood pressure of 120–139mmHg or a diastolic blood pressure of 80–90mmHg are classified 
as prehypertensive.  The current European guidelines255, 256  designate this group ‘high 
normal’.  At baseline 5/50 women in Group 2 and 10/25 women in Group 1 would have been 
classed as prehypertensive according to the Joint National Committee Guideline.254  The 
proportion of women with prehypertension in Group 1 is significantly higher (P=0.002).  
 
People with prehypertension have double the odds of developing hypertension compared to 
those with lower blood pressure.254  When observed at postpartum follow up over 4–10 years 
after preeclampsia, prehypertension is associated with asymptomatic heart failure.257  Over 
time, prehypertension causes left ventricular hypertrophy and diastolic dysfunction.258  
Previous preeclampsia, especially in association with prehypertension, is independently 
associated with an increased risk of subclinical cardiac failure.257  The relationship between 
blood pressure and risk of cardiovascular disease events is continuous and independent of 
other risk factors.  If prehypertension is identified (rather than simply stating that blood 
pressure is in the “normal” range), primary prevention strategies, starting with lifestyle 
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modification, can be implemented. 
 
The increase in stroke volume index was only significant in the group of pregnant women 
unaffected by previous hypertension.  The reduced stroke volume in the healthy pregnant 
women at 32±1 weeks is a surprise finding, as it was only at the final cross-sectional 
comparison that this difference was observed.  Previous studies have reported a wide range of 
values for stroke volume in pregnancy, with considerable disagreement regarding the 
expected physiological, longitudinal changes.19  Stroke volume is not dependent only on the 
heart itself as extracardiac factors (preload and afterload) have an important effect.  Arterial 
blood pressure and vascular tone create the afterload against which the ventricles must eject 
blood.  If afterload is increased then the stroke volume will decrease.  The interplay between 
the pressure and volume components means that the reduction in stroke volume with an 
increased afterload depends on the end diastolic volume, and whether a secondary increase in 
preload can result in a greater contractile force according to the Frank-Starling principle. 
 
The physiological increase in left ventricular volume and left ventricular mass corresponded 
with the increase in body surface area and hence did not reach statistical significance after 
indexation.  A large component of the increased body weight throughout pregnancy is the 
increasing size of the feto-placental unit.  Therefore, if the left ventricle increases in size 
relative to placenta and its demands for blood supply, it makes mathematical sense that 
indexation would ‘cancel out’ any significance in the longitudinal comparison of LV 
structure. 
 
Both groups of pregnant women demonstrated a higher cardiac output, lower peripheral 
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resistance state at baseline compared to the non-pregnant controls.  This hyperdynamic state 
was reflected by an increase in left ventricular volume index.  The reduced peripheral 
vascular resistance, likely due to the effects of oestrogen, progesterone and relaxin, leads to 
increased plasma volume in normal pregnancy.  This is mediated by the renin-angiotensin-
aldosterone system which controls sodium homeostasis.259  There is a dilution effect leading 
to a reduction in the haemoglobin level.  In pregnancies where there is not a physiological 
reduction in vascular resistance and where the plasma volume is low, there will be relatively 
higher haemoglobin concentration unless there is interplay with another factor such as iron 
deficiency. 
 
The increase in left ventricular mass compared to non-pregnant women was only significant 
for the women previously affected by hypertension.  This increase in left ventricular mass in 
Group 1 occurred in conjunction with increased cardiac output at the midtrimester visit, which 
remained elevated from baseline at the next assessment.  In my systematic review (see section 
2.1) and in a review of cardiac function in normal pregnancy by Melchiorre et al19, cardiac 
output was a parameter with considerable variation in reported measures and trends.  This is 
likely to be due to different patient characteristics, timing of assessment and methodological 
variation in relation to measurement of stroke volume.  It is also possible that the legacy of a 
hypertensive disorder in pregnancy is different according to its association with fetal growth 
restriction.  A recent study demonstrated that preeclampsia is associated with increased 
cardiac output, but when fetal growth restriction coexists, cardiac output is reduced and 
peripheral vascular resistance is increased.260  In studies such as this and my own, it remains 
to be shown whether the cardiovascular profile is altered due to maladaptation in the index 
pregnancy, or whether there was pre-existing pathology in the cardiovascular system 
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unmasked by pregnancy.  The women with prior hypertension had an increased cardiac index 
in later pregnancy compared to women without previous gestational hypertensive disease, 
demonstrating that irrespective of blood pressure these women have an exaggerated increase 
in their cardiac output in pregnancy.  Left ventricular ejection fraction was unchanged, neither 
by pregnancy nor by prior hypertension, in line with expectations of this asymptomatic 
cohort.  
 
A recent meta-analysis showed that LVM and RWT both increase in normal pregnancies, 
which demonstrates concentric rather than eccentric hypertrophy.261  Eccentric hypertrophy is 
seen in healthy athletes in response to training.  Physiological remodelling is seen in healthy 
pregnancy, as a woman develops a heart akin to a sportswoman.  This type of hypertrophy 
was previously thought to be a sign of pathology in hypertensive pregnancies.262  When there 
is increased volume load, the end diastolic pressure increases.  The cardiac myocytes increase 
so the wall thickness increases.  This compensates for the increase in pressure.   
A greater increase in LVM and RWT was demonstrated in hypertensive pregnancies.  This 
shows that in some cases the pregnant heart reaches its limit of physiological adaptation 
(where the remodeling would be expected to be eccentric) and the hypertrophy becomes the 
kind more associated with pathology.  This maladaptation to chronic volume overload even in 
healthy pregnancy has recently been reported in an echocardiographic study.263  It has been 
shown that some 40% of women with preeclampsia have persistently abnormal cardiac 
structure and function up to one year postpartum, with diastolic dysfunction amounting to 
subclinical heart failure.50  
 
The increased early diastolic mitral inflow (E wave) in pregnancy is typical of healthy, fit 
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individuals.  As the ventricular wall recoils there is negative pressure in the ventricle so blood 
is sucked down the pressure gradient from the atrium across the mitral valve.  This results in a 
higher E wave.  There is relatively little atrial filling as most of the volume has already flowed 
out of the atrium, leaving a smaller atrial contribution.  This is the pattern seen in healthy 
pregnancy and in the non-pregnant controls.  Since there is an increased volume load in 
pregnancy, the already stretched heart is less compliant.  This explains the reduction in E/A 
seen in normal pregnancy.  In the women affected by previous hypertension, late diastolic 
filling caused by atrial contraction was greater, leading to a significantly lower E/A ratio in 
this group.  The larger A wave usually reflects compensation for reduced early filling, after its 
being impaired by a stiffer ventricle.  In the case of Group 1 at baseline, the results suggest a 
trend towards a ‘pseudonormal’ filling pattern which is a marker of diastolic dysfunction.  As 
the left atrial pressure rises as a marker of progressive diastolic dysfunction, an increase in the 
E wave is caused not by reduced pressure in the ventricle, but rather by increased pressure 
from the atrium driving blood through the mitral valve in early diastole and in this pattern 
both E and A are increased as seen in my study group.  Women with prior hypertension had a 
lower E/A at the final follow up compared to baseline.  The maximum early mitral inflow 
velocity peaked in the midtrimester follow up for women in Group 1, whilst for women in 
Group 2 there was a stepwise decrease observed during the pregnancy.  Both groups had 
similar values at the final follow up.  The longitudinal trend in normal pregnancy is consistent 
with existing literature.19  The E and A waves are affected by the loading conditions of 
pregnancy.132, 264. Pregnancy affects volume haemostasis with an approximately 1600ml 
increase in the intravascular compartment (1300ml extra plasma volume and 30ml extra red 
blood cell volume).265  I did not assess volume status, which would have provided further 




The fact that there is no significant difference in e’ between groups shows that myocardial 
relaxation/recoil is unchanged.  The velocity of early myocardial relaxation measured with 
Tissue Doppler Imaging (e’) reduced during the pregnancy in both groups and this change 
was significant.  This reflects a degree of diastolic dysfunction in both groups, and if this were 
to persist after pregnancy this would confer increased cardiovascular risk.266  Although E/e’ 
was increased in pregnancy, the average for each group was in the normal range and this 
difference largely reflects the difference in E already described.   
 
In the healthy pregnant women arterial elastance index was decreased significantly at 
baseline, but this adaptation was not seen in women with prior hypertension.  Arterial 
elastance relates to the ability of the aorta to receive blood.  In healthy pregnancy there is 
increased compliance in the arterial system.  In my study the women with prior hypertension 
did not demonstrate this physiological adaptation.  Both peripheral and aortic arterial stiffness 
has been demonstrated in preeclampsia.267  Increased arterial stiffness has been shown to be 
present postpartum.111, 268  To my knowledge this is the first demonstration of arterial stiffness 
in a normotensive pregnancy following gestational hypertensive disease.  Increased arterial 
stiffness was demonstrated in the women with prior hypertension at baseline, compared to 
their pregnant counterparts without hypertension history and with non-pregnant controls.  
This is consistent with other studies showing increased arterial stiffness after pregnancy 
hypertension.143, 148  This adverse effect leads to increased risk of future hypertension, 
coronary artery disease and heart failure.269  Although the difference was statistically 
significant only at baseline, the augmentation index remained increased in women with 
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previous hypertension throughout pregnancy. 
 
Ventriculo-arterial coupling (VAC) is a marker of cardiovascular performance and has not 
been widely reported in studies of maternal cardiac function during and after pregnancy 
hypertension to date.  Increased arterial stiffness and impaired systolic function reduces the 
efficiency of the myocardium which is reflected in decreased VAC.  This may be discovered 
prior to LV dysfunction being detectable.  The cross talk between the vascular and ventricular 
behaviour is important because if normal it means that blood can be ejected from the heart to 
the periphery without an abnormal pressure change.  Normal Ea/Ees signifies mechanical and 
energetic efficiency.  Both study groups demonstrated increased end-systolic elastance during 
follow up, with evidence of reduced arterial-ventricular interaction when assessed 
longitudinally.  One would expect the left atrial volume to increase in healthy pregnancy due 
to an increase in preload,19 however in women with prior hypertension there was a reduction 
in left atrial volume in the third trimester alongside a plateau in cardiac output.  This may 
reflect a reduced plasma volume in these women, or be a feature of the increased elastance 
preventing a physiological expansion within this chamber. 
 
I observed an increase in s’ in Group 1 during follow up.  This measure of LV contraction is a 
surrogate marker of systolic function.270  In their echocardiographic studies Buddeberg and 
colleagues demonstrated a reduction in s’ in preeclamptic women at term, and no difference 
in obese women.164, 271  This may demonstrate that women affected by previous hypertension 
in pregnancy are able to optimise their systolic function and that subendocardial fibre function 
is preserved.  Increased posterior wall thickness in Group 1 is an adaptation thought to 




5.6 Strengths and limitations 
My systematic review demonstrated that most studies of maternal cardiac function have a 
cross sectional design, with investigations performed on a single occasion in pregnancy.  
Longitudinal designs, of which my study is an example, are less common.  Where serial 
investigations are performed on the same subjects throughout pregnancy, it is said that the 
women act as their own control and changes over the time course of pregnancy can be 
observed.17  This study has the advantage of using a non-pregnant control group with which to 
compare in the cross sectional analysis at baseline.  Longitudinal studies in pregnancy present 
challenges to the researcher.  Study appointments must be arranged in tight timescales, since 
the advancing gestation does not slow down to facilitate research.  There are many factors 
which might prevent a pregnant woman from attending an appointment (work commitments, 
childcare, fatigue), and non-attendance is more likely when there is an expectation for her to 
attend more than once.  Although every effort was made to maximise the convenience for the 
patient, for example by scheduling research appointments to coincide other commitments in 
the hospital, we did not have funding to offer other incentives.  Therefore, in common with 
other longitudinal studies, complete data sets were not obtained for every patient. 
 
A full dataset was collected for 19/25 patients in Group 1 and 33/50 patients in Group 2.  In 
common with other longitudinal studies in pregnancy, some women did not return for follow 
up.  The distribution of attendance across all three appointments is shown in Table 36.  There 
were no women who did not attend due to finding the echocardiogram uncomfortable or 
unacceptable to them.  No woman withdrew consent for her data to be used in the analysis.  
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Reasons for non-attendance included inability to travel to the hospital, not answering phone or 
responding to message in time, or transfer of care to another geographical area.  Patients who 
did not have a complete dataset are unlikely to demonstrate different (patho)physiology to 
those who completed all follow up appointments. 








Baseline only 0 8 
1st and 2nd appointments (missed 3rd) 5 8 
1st and 3rd appointments (missed 2nd) 1 1 
Complete dataset (3 appointments) 19 33 
 
In a small minority of cases the echo images were of insufficient quality to evaluate all of the 
parameters specified.  There were no missing data from the parasternal long axis view.  
Indicative numbers of missing data points at the baseline visit are 2 ejection fractions (it was 
not possible even to approximate the “eyeball” ejection fraction) and from the third trimester 
appointment 3 of the ejection fractions were approximated as the measurements were not 
possible, despite adjusting the machine settings to reduce noise and to delineate the 
endocardium as clearly as possible. 
 
It is common for gestational hypertensive disease to coincide with other maternal medical 
conditions, such as diabetes or obesity.  These conditions could be viewed as confounders 
which contaminate the cohort.  It can also be argued that the presence of comorbidities 
reflects the overall clinical condition and the challenges faced in antenatal practice.  To 
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remove women from the study on the basis of pre-existing or gestational diabetes, would have 
resulted in a smaller sample size.  Similarly, during the development of the study protocol, it 
was decided not to exclude extremes of body weight.  Obesity is prevalent in the obstetric 
population.  To have excluded obese women would have been detrimental to the sample size 
and reduced the generalisability of the results.  Indexation of key echocardiographic 
measurements controlled for variation in body habitus.   
 
There is some controversy in the literature regarding use of cardiac index in pregnancy. 
Indexing in pregnant women may be misleading because the change in the body contour is 
not consistent with the standard way in which body surface area is calculated.272  Furthermore 
it is debatable whether pre-pregnancy or baseline body weight should be used in the 
calculations or whether the actual weight at the time of assessment should be incorporated.272  
Scaling according to maternal size is a crude correction, since it is not possible to correct for 
the metabolic demands of pregnancy.  It is clear from Table 9 in the systematic review in 
Chapter 2, that researchers show variation in practice in terms of adjusting for maternal 
height and weight.  Some correct for maternal stature using height only273, whilst others 
advocate indexing according to body surface area.158  Some investigators index all the cardiac 
dimensions to body surface area154 whilst others make no quantitative adjustment for maternal 
anthropometry.153  I have used indexing for specific pre-specified derived measurements, and 
in each case have displayed the raw data alongside the adjusted data.  It would be useful to 
have a consensus amongst the international research community as the current variation in 
reporting limits comparisons between studies and precludes meta-analysis of the data without 
recourse to individual participant data.  
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Some researchers in the field of maternal cardiac function have adjusted tissue Doppler 
velocity indices to left ventricular long or short axis lengths.132, 149  In common with the 
majority of studies of pregnant women, I did not incorporate this adjustment into my analysis.  
The principle of accounting for the size of the heart is routine practice in paediatrics, and its 
importance in adult cardiology has been recognised.274, 275  Dewey and colleagues reviewed 
the evidence for ratiometric and allometric scaling276, demonstrating how crucial it is to 
consider these principles in experimental planning.  The confounding effect of body size in 
cardiovascular medicine and in particular in pregnancy is important, and it would be useful to 
establish a consensus statement on how indices should be reported.  For research purposes, 
such a consensus would facilitate comparisons between studies and quantitative synthesis of 
data would be less complex.  Arguably this concept is even more important in clinical practice 
where diagnostic criteria and treatment decisions rely on accurate numerical thresholds, which 
may be altered depending on scaling.   
 
Adjustment of augmentation index to heart rate of 75 beats per minute is not universally 
accepted.  This method is recommended by the manufacturers of SphygmoCor®, and has 
been used in previous studies in pregnancy.103, 112, 277  The correction assumes that the 
relationship between heart rate and arterial stiffness is uniform across populations.  It has 
been suggested that in longitudinal studies it may be more appropriate to use the unadjusted 
AIx and use heart rate as a covariate, as it may help to explain the change in arterial 
stiffness.278  It has also been suggested that AIx be corrected not only for heart rate but also 
for blood pressure, therefore I also present a MAP-adjusted Aix75.98  There has been recent 
criticism for the use of negative AIx values in analyses of wave reflection as they may distort 
the results.  Negative values are associated with a waveform where peak pressure coincides 
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with peak flow and a forward travelling decompression wave causes a late systolic shoulder 
after this peak.  The corresponding fall in pressure and flow causes a reduction in peak 
pressure which is detected by the tonometer and results in a negative AIx.279  If the backwards 
wave superimposes on the forward moving wave after the systolic peak, then the systolic 
blood pressure is unaffected by the backwards waves so the augmentation index will be zero 
or negative 
 
Researchers affiliated with the Fetal Medicine Foundation have published many studies 
relating to prediction of adverse pregnancy outcomes.  This institution advocates the use of 
multiples of the (normal) median (MoMs), adjusted for maternal characteristics.  The MoM 
values are established from extensive population studies.  This approach has recently been 
applied to maternal cardiovascular parameters near term in order to investigate whether 
haemodynamic data improve the sensitivity of a Bayes’ theorem-based screening model for 
late PET.280  The rationale for use of MoMs is to recognise that a parameter may be altered by 
a maternal factor, such as age, and therefore adjustment is required to avoid overestimation of 
an association with the outcome of interest.281  These values are not transferable to 
echocardiographic studies since it has been shown that the NICOM device used in the 
screening study obtains significantly different values to echocardiographic measures, 
therefore might be considered device-specific.280, 282  MoMs for echocardiographic 
measurements in pregnancy have not been established, and since echocardiography is said to 
represent the Gold Standard in non-invasive assessment of maternal haemodynamics97, these 
will be important to ascertain in future large studies.   
 
Aortic root diameter (AoD) does not change as much as the left ventricular outflow tract 
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diameter in pregnancy, which alters the geometric assumptions involved in calculations 
involving the latter.  When calculating stroke volume some investigators use the AoD 
multiplied by the AoD VTI in the apical 3 Chamber view.  Others use LVOT and its 
corresponding VTI.  I chose the latter as it is the most commonly reported in similar research 
and forms part of the standard echocardiography protocol. 
 
The pregnant heart is more spherical compared to the more ellipsoid non-pregnant heart.  
There is no geometrical assumption in the Simpson method of discs to calculate the left 
ventricular volume.  This method was employed to calculate left ventricular ejection fraction, 
which is the proportion of blood ejected relative to the intraventricular volume.  Simpson’s 
method represents the longitudinal contractile function only and does not account for the 
radial contractile function.  Unfortunately, although ventricular volumes were measured in 
two planes, the software was unable to calculate the biplane Simpson method and therefore a 
single plane was used. 
 
A strength of this research is that both interobserver and intraobserver reliability is recorded 
in the methodology.  I have demonstrated that as the primary observer, my measurements are 
consistent with a second observer for a random sample of patients.  Ideally, all measurements 
would be performed by two observers, but demonstrating good interobserver reliability is the 
next best, pragmatic, option as the human resource to perform all measurements in duplicate 
was not available.  I was able to show that my measurements are reliable by reporting 
intraobserver coefficients of variation.  Lack of reporting of such validation was a weakness 
of many of the studies in my systematic review. 
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The echocardiographic image acquisition by experienced cardiologists is another strength of 
the study.  Whilst writing the protocol, consideration was given to my training in 
echocardiography.  It was decided that the echocardiograms should be performed by expert 
cardiac sonographers, certified by the British Society of Echocardiography.  The rationale was 
twofold, firstly to maximise the quality of the images and therefore the quality of the data, and 
secondly to ensure that as the investigator I would be truly blinded to all demographic and 
clinical details relating to the patient during offline analysis.  Whilst this is a strength of the 
study in terms of its generating high quality data, it might also be considered a limitation as 
scheduling the appointments at times convenient for two researchers and the patient was, on 
occasion, challenging and a more complete dataset might have been possible if I had 
performed the scans myself.  The experience gained during this fellowship, combined with 
my training in obstetric ultrasound, should enable me to develop echocardiography skills for 
future research. 
 
Speckle tracking technology is more independent of the loading conditions of pregnancy and 
cardiac motion, therefore it is useful to study alterations in cardiac function.  It can also be 
used to assess complex torsional heart movement in order to detect preclinical impairment of 
LV function.283  Speckle tracking imaging technology has become more prominent in the 
lifetime of this study and its not being employed in my methodology results in a less 
comprehensive evaluation of systolic function, lacking information relating to strain and 
rotation/torsion data. 
 
Arterial elastance as a measure of arterial load is important as it recognises the pulsatile 
nature of the pressure and flow in the arterial system.  In hypertension, vascular resistance 
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alone is an inadequate measure as it does not take the oscillatory nature of the pulse pressure 
into account.  The ventricular-arterial interaction should be part of the expected dataset in 
studies of maternal haemodynamics, and its inclusion in this study should be considered a 
strength. 
 
Non-invasive devices like the Sphygmacor® have been criticised since the brachial blood 
pressures to which they are calibrated may underestimate the true (were it to be measured 
invasively) blood pressures.284  Central systolic and diastolic pressures may therefore be 
falsely low.  My methodology used the radial arterial pulse for pulse wave analysis, assuming 
radial systolic and diastolic blood pressures to be equal to the brachial recordings.  Unknown, 
and therefore unaccounted for, amplification or diminution of the wave form between the 
brachial and radial arteries would make the estimation of central pressure inaccurate.  This 
potential flaw should be considered a limitation.  
 
The Sphygmacor® software reports an ‘Operator Index’ which is a measure of waveform 
reproducibility and signal strength.  The operator index is a composite quality control 
parameter.  If the average pulse height is unacceptably low or there is too much variation in 
the pulse height the system will report a low operator index.  Prior to commencement of the 
study I honed my technique to ensure that my operator index was consistently high.  High 
operator indices are achieved when both the operator and the patient have stable and steady 
forearm position and the tonometer is held close to the base to allow application of constant 
pressure to the waveform location.  Since the operator index is reported in real time, the 
measurement should be repeated until an Operator Index of at least 75 was achieved, but 
ideally operator index should be above 80 for best results.  There were 26 cases out of 231 
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pulse wave experiments with operator index of 74 and below.  The operator index was above 
75 in 89% of cases.  Since operator index was not considered in the original methodology all 
values were included in my analysis.  There were 3 studies where a waveform could not be 
detected and therefore these data points are missing. 
 
According to recommendations of Kaplan and Bennett the ethnicity of subjects in this study is 
that reported by the women themselves285, but self-reporting may not be reliable.69  I have 
described the study group as ethnically diverse, but it must be borne in mind that all 
participants were booked for antenatal care at a single institution in a densely populated part 
of Birmingham.  The geographical area from which the patients come is relatively small.  I do 
not have data on the diversity within the different ethnic groups, for example socio-economic 
factors and diet.  The British Journal of Obstetrics and Gynaecology published a commentary 
by Steer69, who described the development of accepted practice in reporting on race and 
ethnic origin, drawing attention to the differences between ethnicity (which has a cultural 
basis) and racial groups (more related to geography and genetics).  The relationship between 
ethnicity and health outcomes is complex.  The ECCHO Study was not powered to make 
comparisons between different ethnic groups for any of the parameters under investigation.  I 
was not able to study any candidate genes to assess any genetic associations.  
 
The non-pregnant control group included women on the contraceptive pill and I did not obtain 
information regarding menstrual cycle which can affect vascular function.286  This should be 
considered as a limitation and borne in mind when developing future research protocols. 
 
Women with persistently abnormal ventricular structure and function after preeclampsia are 
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more likely to develop essential hypertension.50  When women with early onset preeclampsia 
were studied up to 2 years postpartum, the majority had asymptomatic cardiac failure and 
40% developed hypertension.50  Since women with hypertension at booking were excluded 
from my study, it is unlikely to capture the full burden of cardiac impairment after 
hypertensive pregnancy.  If there were larger numbers, women with former preeclampsia, 
former gestational hypertension and women with chronic hypertension could be studied in 
subgroups to evaluate the differences between these conditions. 
 
5.7 Conclusions 
I have described cardiovascular system differences in pregnancy, depending on history of 
gestational hypertension or preeclampsia.  I have shown increased prevalence of 
prehypertension, and increased arterial stiffness in pregnant women previously affected by 
gestational hypertensive disease.  An increased atrial component to ventricular filling reflects 
altered diastolic function after hypertensive pregnancy.   
 161 
CHAPTER 6: 
MONOCYTE SUBSETS IN WOMEN 




6.1 Introduction to chapter 
Monocyte biology, with particular reference to women’s cardiovascular health and pregnancy, 
was discussed in Chapter 2.  In this chapter I assess monocyte heterogeneity in women in the 
ECCHO Study and suggest an association between these leucocytes and cardiovascular risk in 
pregnancy. 
 
6.2 Aims and hypothesis 
This part of the study was designed to provide mechanistic insight into the echocardiographic 
changes described in Chapter 5.  My objective was to assess changes in monocyte subsets in 
pregnancy, including those pregnancies with the additional risk factor of prior gestational 
hypertension or preeclampsia.  Functionally distinct monocyte subsets play distinct roles in 
the pathogenesis of cardiovascular disease, but their implications in hypertension in 
pregnancy are unclear.  I hypothesised that there would be significant differences between 
pregnant women and controls, and differences in pregnant women according to history of 
hypertension in pregnancy.  
 
6.3 Methods and materials 
6.3.1 Pregnant women 
59 pregnant women, comprising 17 with hypertension in a previous pregnancy and 42 with no 
history of hypertension, were recruited in the ante natal clinic at City Hospital, Birmingham, 
as described in section 4.2 according to strict, predefined inclusion and exclusion criteria.  
For this substudy an additional exclusion criterion was the presence of inflammatory bowel 
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disease, which affected one woman in each group of pregnant women. 
 
6.3.2 Control group 
27 healthy non-pregnant controls were recruited as described in section 4.2.2.  
 
6.3.3 Experimental measurements 
The experimental design is described in detail in section 4.2.  Blood sampled from a 
peripheral vein was promptly processed and analysed by flow cytometry.  The BD 
FACSCalibur flow cytometer (Becton Dickinson, Oxford, UK) would yield the absolute 
monocyte count, as well as counts of the three monocyte subsets.  According to the most 
recent international consensus statement, the monocyte subsets were defined as 
CD14++CD16-CCR2+ (Mon1), CD14++CD16+CCR2+ (Mon2) and CD14+CD16++CCR2- 
(Mon3).171  Data were also recorded for monocytes’ interaction with platelets (monocyte-
platelet aggregates, MPAs) and their expression of cell surface markers.   
 
6.3.4 Statistical analysis 
The statistical analysis plan is described in section 4.9.  Where demographic and clinical 
characteristics were normally distributed, ANOVA was used to assess differences between the 
three study groups.  For the monocyte data, the Mann-Whitney test was applied to 
comparisons between the two groups of pregnant women.  The Kruskal-Wallis test was used 
to analyse differences between all three groups.  Post hoc testing (Dunn-Bonferroni 




6.4.1 Patient characteristics 
There were 17 pregnant women in Group 1 (previous hypertension), 42 pregnant women in 
Group 2 (no previous hypertension) and 27 non-pregnant women in Group 3 (no 
hypertension).  Although the monocyte substudy involved fewer women, the groups remained 
matched for age, ethnicity and smoking status (P>0.05 for all, Table 36).  All women in 
Group 1 were parous, since previous hypertensive pregnancy was an inclusion criterion.  
Differences in aspirin consumption (higher in Group 1, P<0.001) and hormonal contraception 
(only in the non-pregnant controls, P<0.001) were present, as discussed in section 1.4.1.  The 
pregnant women were studied at 13±1 weeks of gestation (P=0.65).  There was a trend 
towards higher BMI for women in Group 1 (P=0.07).  As discussed previously, blood 
pressures at baseline were higher in Group 1.  Heart rate was higher and haemoglobin lower 
in the pregnant women (P<0.001).  White cell count was significantly higher in pregnancy, 
and higher still in pregnant women with prior hypertension (P<0.001). 
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Age, years 30 (27–33) 30 (25–33) 27 (25–34) 0.68 


































































































BMI (kg/m2) 27.9 (26.0–30.5) 26.4 (22.3–29.5) 23.7 (20.6–28.6) 0.07 








72 (66–75) * 64 (58–67) 66 (59–71) 0.007 
Peripheral mean 
arterial pressure 87 (82–92)
 * 77 (72–81) 81 (73–86) 0.001 
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(mmHg) 
Central systolic blood 
pressure (mmHg) 101 (99–105)




72 (68–77) * 65 (59–69) 67 (59–72) 0.004 
Central mean arterial 
pressure (mmHg) 86 (80–92)
 * 77 (72–81)  81 (73–86) 0.01 
Heart rate (beats per 
minute) 
82±10 *† 74±9† 65±11 <0.001 
Haemoglobin (g/L) 118±12† 120±9† 132±11 <0.001 
White cell count 
(x109/L) 
10.6 (9.3–11.6) *† 8.3 (7.1–9.2) † 6.3 (5.3–7.1) <0.001 
Platelets (x109/L) 259 (226–306) 241 (199–289) 270 (249–303) 0.15 
Creatinine (µmol/L) 51 (49–54) † 53 (50–55) † 66 (64–71) <0.001 
Continuous data are expressed as median (interquartile range). Categorical data are expressed 
as n (%). BMI, body mass index; BSA, body surface area; n/a, not applicable. Post hoc 
testing: *p<0.01 vs group without previous gestational hypertension; †p<0.01 vs non-
pregnant controls; ‡p=0.01 vs non-pregnant controls. Cross sectional analysis of 
echocardiographic parameters at baseline 
 
 
6.4.2 Cross sectional analysis of monocytes at baseline 
Mon1 count was significantly higher in women with previous hypertension in pregnancy 
compared to non-pregnant controls (P<0.001, Figure 14 and Table 37).  The Mon1 count in 
pregnant women without previous hypertension was not significantly higher than in non-
pregnant controls (P=0.06) and was lower than Mon1 count in the group with prior 
hypertension, but this comparison did not reach significance after post hoc testing (P=0.02).  
Mon3 was increased in both groups of pregnant women (P=0.002 Group 1 vs Group3; 
P=0.007 Group 2 vs Group 3).  The increase in total monocytes in Group 1 was highly 
significant compared to Group 3 (P<0.001) and trended towards significance compared to 
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Group 2 (P=0.053).  Mon1-platelet aggregates (MPA1) were significantly increased in the 
previous hypertension group (P=0.006) compared to the non-pregnant control group. Mon3-
platelet aggregates (MPA3) were increased in both groups of pregnant women (P≤0.005 for 
both).  For total monocyte platelet aggregate count, the only significant difference observed 
on cross sectional comparison at baseline was a higher count in Group 1 compared to Group 3 
(P=0.004).  
 
Figure 15:  Mon1 count for each study group 
 
 
The expression of cell surface markers on the monocyte subsets and their aggregates with 
platelets was also analysed (Table 38), with the relative expression demonstrated by median 
fluorescence intensity (MFI) according to convention.  This comparison showed that the C-C 
chemokine receptor type 2 (CCR2) was expressed less on Mon1 (P=0.002), Mon 2 (P=0.037) 
and MPA1 (P<0.001) of the pregnant women compared to the non-pregnant women.  The 
relative expression of CD14, CD16 and CD42a was unchanged in cross sectional comparison 
at baseline.



























Total monocytes, per µl 
Mon1, per µl 
Mon2, per µl 
Mon3, per µl 
 
545 (455–592) † 
441 (376–512) † 
15 (9–49) 

















MPA, per µl 
MPA1, per µl 
MPA2, per µl 
MPA3, per µl 
 
51 (43–69) † 
40 (33–62) † 
2 (1–6) 
















MPA, monocyte-platelet aggregates; Data expressed as median (interquartile range).  
Post hoc testing:  
*p<0.01 Group 1 vs Group 2 
†p<0.01 Group 1 vs Group 3 
‡p<0.01 Group 2 vs Group 3 
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CCR2 (Mon1), MFI 
CCR2 (Mon2), MFI 
CCR2 (Mon3), MFI 
CD14 (Mon1), MFI 
CD14 (Mon2), MFI 
CD14 (Mon3), MFI 
CD16 (Mon2), MFI 
CD16 (Mon3), MFI 
CCR2 (MPA1), MFI 
CCR2 (MPA2), MFI 
CCR2 (MPA3), MFI 
CD42a (MPA1), MFI 
CD42a (MPA2), MFI 
CD42a (MPA3), MFI 














126 (98–147) ‡ 









































MFI, mean fluorescent intensity. Data expressed as median (interquartile range).  
Post hoc testing:  
*p<0.01 Group 1 vs Group 2 
†p<0.01 Group 1 vs Group 3 
‡p<0.01 Group 2 vs Group 3
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Table 39:  Longitudinal flow cytometry data for Group 1 at baseline, second and third trimester 
 
Baseline 






























































Data expressed as median (interquartile range). MPA, monocyte-platelet aggregates; MFI, mean fluorescent intensity. 
Post hoc testing: 
† P<0.05 vs baseline visit; ‡ P<0.05 vs midtrimester 2nd visit. 
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Table 40:  Longitudinal flow cytometry data for Group 2 at baseline, second and third trimester 
 
Baseline 























491 (407–581) † 




554 (473–673) † 
465 (423–555) † 
































Data expressed as median (interquartile range). MPA, monocyte-platelet aggregates; MFI, mean fluorescent intensity. 
Post hoc testing: 
† P<0.05 vs baseline visit; ‡ P<0.05 vs midtrimester 2nd visit. 
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6.5 Discussion 
The associations I have found may be involved in the aetiology of hypertension in pregnancy 
and its conferring increased cardiovascular risk after affected pregnancy.  Whilst it is 
scientifically plausible that the associations could imply causation, they could also represent 
coincidental changes, or changes associated with compensatory mechanisms for other 
disease-related changes.  The overall increase in monocyte count in pregnancy is consistent 
with previous studies222 demonstrating an immunological response to the gravid state.   
 
The increase in Mon1 counts that I have shown in pregnant women with previous 
hypertension could be interpreted in several ways.  The increased number of these circulating 
monocytes which release cytokines could be involved in the pathogenesis of prehypertension 
and hypertension in pregnancy.  Endothelial damage/dysfunction and resulting inflammatory 
response may be responsible for the increased monocyte counts.  The increase in monocyte 
platelet aggregates, especially those associated with Mon1, in women with prior hypertension 
reflects monocyte activation in these women.  Previous work has shown Mon 2 to be 
increased, and make up a greater proportion of the monocyte count in women with 
preeclampsia, with counts correlating with disease severity.222  My results show Mon2 to be 
unchanged at baseline or during pregnancy in women with prior gestational hypertensive 
disease.  The increase in Mon3 in both groups of pregnant women could point to a pattern of 
increased immune surveillance.  
 
Monocyte migration can be controlled by the modulation of their cell surface receptors. 
Monocyte chemo attractant protein-1 (MCP1) binds to CCR2 on Mon1 to promote its active 
recruitment to sites of inflammation.183  Bosco et al propose that downregulation of CCR2 
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leads to trapping of monocytes to retain them at pathological sites.  A reduction in CCR2 
expression has been shown in hypoxic states.287  Increased expression of CCR2 reflects 
increased activation of monocytes.  CCR2 being less expressed on both subsets on which it is 
present (Mon1 and Mon2) in pregnant women compared to non-pregnant controls may mean 
it is attenuated in pregnancy as part of the immunological adaptation to the pregnant state. 
Reduced CCR2 expression may be detrimental if it results in less clearance of cellular debris 
and reduced beneficial phagocytosis and cytokine release.  In contrast, CCR2 expression has 
been shown to be increased on monocytes of obese women, with enhanced migration towards 
inflammatory stimuli.209   
 
Monocytes interact with lipopolysaccharide via CD14, which is the molecule on the surface 
of monocytes involved in their activation.216  This interaction stimulates the production of 
cytokines.  It has been suggested that altered CD14 expression on monocyte subsets may play 
a role in the altered immunological state in heart failure.288  No difference in CD14 expression 
was shown between the groups in this study so further evidence for the role of this cell 
surface marker in cardiovascular pathophysiology cannot be provided. 
 
Monocyte count is perhaps less important than monocyte function.  The functional role of 
monocytes was beyond the scope of my study.  The phagocytic function of monocytes has 
been previously demonstrated in pregnancy and in hypertension.236  Reduced elimination of 
factors causing cardiovascular dysfunction may be a mechanism contributing to the evolution 
of pregnancy complications. 
 
It was interesting to observe the monocyte count in women with prior hypertension being 
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higher than in unaffected women at baseline, but reduce during the pregnancy, whilst for 
women without prior hypertension the opposite was true with the count starting lower and 
rising to reach a level similar to that of the baseline of Group 1.  It is possible that women in 
Group 1 mount an increased inflammatory response during pregnancy, and this accounts for 
their previous pregnancy complication.  It could also be true that having had a pregnancy 
complication last time, the innate immune system shows increased activity in the subsequent 
pregnancy.  These data cannot explain why the counts are increased or delineate cause and 
effect. 
 
6.6 Strengths and limitations 
Because of the paucity of existing literature on the roles of the monocyte subsets in 
pregnancy, the potential for confounding is greater.  I acknowledge the potential for 
confounding due to as yet unrecognised cofactors, the identification of which requires further 
work.   
 
Appointments were routinely made in the mornings to standardize the sample collection time.  
On rare occasions if a patient could only attend in the afternoon then in order to maximise the 
completeness of follow up a minority of appointments were made later but conditions were 
standardised in accordance with the protocol.  Since the number of afternoon appointments 
was few, the influence of diurnal variation is likely to be small, but may represent a limitation 
of the study.252 
 
Studies with a small sample size are more susceptible to random errors.  The care taken 
during data acquisition, checking and analysis should minimise this risk.  The small number 
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of participants in the study increases the chance of a false negative findings, the so-called 
Type 2 error.  The repeated measures of the same participants in the longitudinal study 
introduces the possibility of Type 1 error.  In order to reduce the risk of false positive 
findings, post hoc testing was employed in order to raise the threshold for significance levels 
as previously described. 
 
I measured monocytes in peripheral blood, and these levels might not reflect the counts of 
their counterparts in the tissues, such as macrophages in the placenta or myocardium.  These 
observational, in vivo, data can be used to generate hypotheses but more experimental data is 
required to test them.   
 
Differences between the groups (and indeed aspects in which they are similar) could be 
attributable to variables which are not controlled for.  An example is aspirin use in the study 
group.  It was not possible to exclude women taking aspirin as aspirin is recommended for all 
women with previous hypertension in pregnancy.  There is emerging evidence that the so-
called “low dose” aspirin (75mg) is insufficient and a higher dose is more effective in 
reducing pregnancy complications.89, 289  Antiplatelet therapy has been previously shown to 
reduce MPAs.241, 242  Recent evidence  from a study which assured compliance with aspirin 
therapy showed no significant difference in MPA count with low dose aspirin.290    In my 
study MPAs were higher in Group 1 in which aspirin consumption was higher.  There was no 
difference in platelet count between the groups.  Sensitivity to aspirin and treatment response 
varies.291  Patients whose platelet reactivity remains high despite antiplatelet treatment are at 
increased risk of major adverse cardiac events and this might be related to the pro-
inflammatory effects of MPA formation.292  It is likely that other factors in Group 1 cause 
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platelet activation and their complex formation with monocytes despite being on treatment.  I 
did not assess compliance with aspirin treatment and additionally there are numerous 
mechanisms of aspirin resistance including poor absorption, accelerated platelet turnover 
producing new unaffected platelets and platelet interactions with other cells such as 
monocytes.293 
 
The fact that all women with previous pregnancy hypertension were by definition parous 
introduced another difference between the groups.  Matching for parity would have 
necessitated the exclusion of primigravidae from the study.  Restricting recruitment to 
multiparous women would have reduced rate of recruitment and the ability to compare 
findings with other published work. 
 
I did not perform any work on the levels of pro- or anti-inflammatory cytokines which would 
have been useful data support hypotheses about the function roles of the monocyte subsets.  
Since these are observational data, the biological importance of the differences seen between 
groups is debatable, and one can only speculate at this stage.  This substudy was not powered 
to evaluate the effect of individual monocyte subsets on clinical outcomes.   
 
6.7 Conclusions 
I have described for the first time the differences in monocyte subsets between women with 
previous gestational hypertensive disease and healthy pregnant women.  These data are 
enhanced by comparison with a group of healthy non-pregnant women, and by use of the 
most up-to-date nomenclature to define the monocyte subsets.  These preliminary data 




STRUCTURE AND FUNCTION, 
MONOCYTE SUBSETS AND 
PREGNANCY OUTCOMES 
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7.1 Introduction to chapter 
In Chapter 5 I presented data from the cardiovascular studies and in Chapter 6, results from 
the monocyte substudy were shared.  The aim of this chapter is to integrate these data in order 
to assess the relationship between echocardiographic structure and function and monocyte 
heterogeneity in pregnancies with and without current and past hypertension. Maternal and 
fetal outcomes will also be discussed. 
 
7.2 Aims and hypothesis 
My aims and hypotheses are stated in Chapter 3.  To briefly recap, the hypotheses are that: 
1) abnormal ventricular-arterial interaction will be found in women with a history of 
hypertension in pregnancy; 
2) changes in cardiac structure and function may be predictive of recurrent gestational 
hypertensive disease; 
3) levels of circulating monocytes would be related to the ventricular-arterial interaction. 
 
7.3 Methods and materials 
7.3.1 Postnatal data collection 
Data pertaining to delivery, obstetric complications and blood pressure was obtained from the 
electronic patient record, information from General Practitioners and verification with 
patients by telephone follow up.   
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7.3.2 Statistical analysis 
The statistical analysis plan is described in section 4.9.  Normally distributed data are 
expressed as mean±SD and non-normally distributed data as median±IQR.  The Chi squared 
test was used to compare outcomes between groups when they were categorical.  The 
Student’s t test was used when the data was continuous and normally distributed, whilst the 
non-parametric Mann Whitney test was used for continuous data which were not normally 
distributed.  A P value of <0.05 is considered statistically significant.  
 
For correlation and regression analyses, data were checked carefully to ensure that 
assumptions are met and that the tests are valid.  Bivariate Pearson correlation was performed 
to assess the association between monocyte subsets and cardiovascular parameters.  Variables 
which are significant in univariate analysis, and clinically important factors, are then used in 
multivariable analysis.  Binomial logistic regression was used to analyse variables associated 
with the development of hypertension in pregnancy.  Multivariable linear regression was used 
to identify independent associations in the dataset. 
 
Where statistical analysis is not appropriate due to small numbers, maternal and fetal 
outcomes are described without quantitative analysis. 
 
7.4 Results 
7.4.1  Obstetric outcomes 
Some 9 women (12%) delivered at another hospital, having transferred their care during the 
pregnancy for various reasons relating to maternal choice/convenience.  There were no 
 180 
transfers of care for obstetric or fetal indications.  All the women who delivered elsewhere 
gave permission for their data to be used in the study and for the collection of outcome data.  
A complete set of outcome data was collected.   
 
The mean gestation at delivery was 39+0 weeks (273±10 days) for Group 1 and 39+5 weeks 
(278±11 days) for Group 2 (P=0.08).  In Group 1 there were 14 vaginal deliveries, of which 1 
was assisted.  In Group 2 there were 41 vaginal deliveries of which 6 were assisted.  There 
were 3 emergency and 8 elective Caesarean sections in Group 1, and 9 Caesarean sections in 
Group 2, of which 4 were emergencies and 5 planned.  The increased Caesarean section rate 
in Group 1 is most likely due the number of these parous women with a previous Caesarean 
section, who had a repeat Caesarean section in this pregnancy.   
 
There was no significant difference in birthweight between groups with a mean birthweight of 
3198±568g in Group 1 and 3330±586g in Group 2 (P=0.36).  Birthweight was under the 10th 
customised centile for gestation for 7 babies overall, 3/25 in Group 1 and 4/50 in Group 2 
(P=0.58).   At the other end of the spectrum for growth, there were 10 babies with birthweight 
above the 90th customised centile, 2/25 in Group 1 and 8/50 in Group 2 (P=0.34).  
 
The only known case of fetal abnormality was a baby with Down syndrome that was not 
diagnosed antenatally.  The mother was the 40-year-old multipara who developed gestational 
hypertension.  She had declined screening for trisomies 13, 18 and 21 and there had been no 
anomalies detected on antenatal scans.  Other obstetric complications included one case of 
spontaneous preterm labour and delivery in each group, both after 35 completed weeks.  
Some 5 women developed gestational diabetes during the study.  There were 3 cases of 
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postpartum haemorrhage.  There were no cases of placenta praevia or abnormally invasive 
placenta in the study participants.  There was one case of term stillbirth in a woman from 
Group 2 with normal blood pressure.  She attended for elective repeat Caesarean section and 
reported reduced fetal movements and scan diagnosed late intrauterine fetal death.  The 
birthweight was normal and consistent with antenatal scans.  Placental histology and post 
mortem was declined by the parents, and routine investigations failed to reveal any cause, 
therefore the stillbirth is unexplained.  None of these adverse obstetric outcomes were related 
to the conduct of the study or the patient’s participation in my research.  There were no 
complications with any of the study procedures. 
 
7.4.2 Hypertension in pregnancy 
Overall 9 women (12%) developed hypertension in pregnancy, of which 6 were in Group 1 
(prior hypertension) and 3 from Group 2.  The incidence of hypertension in pregnancy was 
significantly different between groups (6/25 vs 3/50, P=0.024).  Of those in Group 1 who 
developed hypertension in pregnancy, there were 4 cases of gestational hypertension, of 
which all were late onset at term.  Two women developed recurrent preeclampsia.  One case 
was in a patient who had early onset preeclampsia in her first pregnancy, who developed 
hypertension and proteinuria with a PCR of 96 from 37 weeks of gestation.  She was induced 
then had a vaginal delivery of a 4920g baby complicated by shoulder dystocia.  The other 
case of recurrent preeclampsia was a woman who had late onset PET last time and presented 
with a booking blood pressure of 137/75mmHg.  At her research appointment at 19 weeks of 
gestation her blood pressure was 140–145/69–72mmHg with no proteinuria.  She developed 
proteinuria from 23 weeks of gestation, with PCR of 63 and normal renal function throughout 
the pregnancy.  This is most likely to be a case of essential hypertension with superimposed 
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preeclampsia.  The preeclampsia remained a mild case controlled with labetalol monotherapy 
and delivery was at 38 weeks with normal birthweight.  Blood pressure settled into the 
prehypertension range after the cessation of antihypertensives in the postnatal period.  
 
In Group 2 there were 3 women who developed hypertension for the first time.  One was 40 
years old, now Para 3.  She had a BMI of 40 and Type 2 diabetes requiring insulin in 
pregnancy.  She developed hypertension postnatally which then resolved with no requirement 
for antihypertensives 6 weeks after delivery.  The other two cases were in primiparae, one of 
whom developed gestational hypertension at 36 weeks, the other mild preeclampsia with a 
PCR of 129 at 38 weeks.   
 
The women who developed hypertension had a significantly higher booking weight compared 
to those women who remained normotensive (P=0.04).  The ratio E/e’ was significantly 
higher at 20±1 weeks of gestation in women who developed gestational hypertensive disease 
(P=0.005) and affected women also had a reduced ejection fraction at the midtrimester time 
point (P=0.01).  No other significant differences were observed, accounting for the small 
number of cases. 
 
7.4.3 Correlation and regression analyses of experimental data 
Correlation 
There was a significant, positive correlation between Mon1 and total vascular resistance 
index, end-systolic elastance and arterial elastance index (Table 41).  For total monocyte 
count, there was also a significant positive correlation with ventricular (Ees) and arterial (EaI) 
elastance parameters.  For augmentation index adjusted to heart rate 75 beats per minute, 
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Mon1, Mon3 and total monocytes were all positively correlated (P<0.05 for all).  Mon1 was 
significantly and negatively correlated with left ventricular volume index, as was total 
monocyte count.   
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Table 41:  Correlation analysis between monocyte subsets and cardiovascular parameters at 13±1 weeks of gestation 
 
Mon1 Mon2 Mon3 Total monocytes 
r P r P r P r P 
Haemodynamics 
Stroke volume index (ml/m2) –0.17 0.21 –0.02 0.90 –0.01 0.97 –0.15 0.27 
Cardiac index (L/min/m2) –0.03 0.80 –0.08 0.55 0.13 0.34 –0.01 0.92 
Total vascular resistance index 
(dyne.s/cm5/m2) 0.27 0.04 0 1.0 –0.02 0.86 0.19 0.15 
Ventricular parameters 
Left ventricle volume index 
(ml/m2) –0.33 0.02 –0.24 0.08 –0.14 0.31 –0.34 0.01 
Left ventricular mass index (g/m2) –0.05 0.72 0.11 0.38 –0.05 0.69 –0.03 0.84 
End-systolic elastance 0.34 0.008 0.04 0.74 0.14 0.29 0.32 0.01 
End-diastolic elastance 0.25 0.06 0.06 0.64 –0.07 0.58 0.21 0.11 
Diastolic function 
E/A ratio –0.16 0.22 –0.01 0.95 –0.11 0.42 –0.17 0.19 
E/e’ –0.02 0.88 0.04 0.76 –0.09 0.49 –0.01 0.92 
Arterial parameters 
Arterial elastance index 0.43 <0.001 –0.10 0.46 0.06 0.67 0.35 0.007 
AIx75 0.29 0.03 –0.02 0.90 0.27 0.04 0.31 0.02 
Aix75MAP 0.10 0.50 –0.02 0.91 0.11 0.48 0.14 0.36 
Ventricular-arterial coupling 
Arterial-ventricular interaction  –0.03 0.83 –0.08 0.52 –0.15 0.27 –0.05 0.69 
AIx75, augmentation index adjusted to standardise for heart rate 75 beats per minute; Aix75MAP, Aix75 adjusted for mean arterial 




In this final section I present some exploratory analyses of my experimental data, to assess the 
association between the cardiovascular parameters (presented in Chapter 5) and the 
monocyte subsets (presented in Chapter 6).  
Table 42:  Multivariable logistic regression of predictors of hypertension – blood 
pressure at 13±1 weeks of gestation 
Variable OR 95% CI P 
Age 1.04 0.90–1.21 0.58 
Parity 0.81 0.13–4.97 0.82 
SBP (mmHg) 1.11 1.02–1.20 0.02 
CI, confidence interval; OR, odds ratio; SBP, peripheral systolic blood pressure. 
 
These variables statistically significantly predict development of hypertension in the current 
pregnancy P=0.03, R2=0.16.  Systolic blood pressure was the only variable adding 
significantly to the prediction. 
Table 43:  Multivariable logistic regression of predictors of hypertension – blood 
pressure at 13±1 weeks of gestation 
Variable OR 95% CI P 
Age 1.04 0.89–1.23 0.59 
Parity 0.82 0.13–5.10 0.84 
SBP (mmHg) 1.11 1.02–1.21 0.02 
White ethnicity 1.12 0.21–6.04 0.90 
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Aspirin 0.74 0.11–5.04 0.76 
CI, confidence interval; OR, odds ratio; SBP, peripheral systolic blood pressure. 
This model is not statistically significant for the prediction of hypertension in the current 
pregnancy but demonstrates that systolic blood pressure remains a significant predictor for 
hypertension later in pregnancy after adjustment for age, parity, ethnicity and aspirin 
consumption.  
Table 44:  Multivariable logistic regression for association with left ventricular mass 
index at 13±1 weeks of gestation 
Variable Coefficient Standard error P 
Age –0.003 0.007 0.03 
Parity 0.037 0.073 0.61 
White ethnicity 0.045 0.071 0.53 
Systolic blood 
pressure 0.011 0.003 0.001 
Mon1 –0.15 0.11 0.19 
 
Systolic blood pressure is statistically significantly associated with left ventricular mass 
index, after adjustment for age, parity, ethnicity and Mon1 count.  This model has F(4,70)= 
2.7, P=0.03, R2=0.13 with systolic blood pressure the only significant association. 
Table 45:  Multivariable logistic regression for association with total vascular resistance 
index at 13±1 weeks of gestation 
Variable Coefficient Standard error P 
Age 0.008 0.006 0.22 
Parity –0.14 0.064 0.03 
White ethnicity –0.69 0.063 0.27 
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Systolic blood pressure –0.0006 0.0027 0.84 
Mon1 0.21 0.10 0.04 
 
These variables have a statistically significant association with total vascular resistance index, 
F(5,53)=2.42, P=0.047, R2=0.11.  Mon1 count and parity were the only variables adding 
significantly to the model. 
Table 46:  Multivariable logistic regression for association with left ventricular volume 
index at 13±1 weeks of gestation 
Variable Coefficient Standard error P 
Age –0.003 0.006 0.62 
Parity 0.041 0.061 0.50 
White ethnicity –0.034 0.059 0.57 
Systolic blood pressure 0.003 0.003 0.18 
Mon1 –0.26 0.092 0.007 
 
This model does not statistically significantly predict left ventricular volume, F(5,49)=1.77, 
P=0.14, R2=0.07.  The association between left ventricular volume index and Mon1 count 
remains statistically significant after adjustment for age, parity, ethnicity and systolic blood 
pressure. 
Table 47:  Multivariable logistic regression for association with end systolic elastance at 
13±1 weeks of gestation 
Variable Coefficient Standard error P 
Age 0.0004 0.011 0.97 
Parity –0.17 0.12 0.17 
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White ethnicity –0.18 0.12 0.14 
Systolic blood pressure 0.003 0.005 0.54 
Mon1 0.45 0.19 0.02 
 
Mon1 is significantly associated with end systolic elastance, after correcting for age, parity, 
ethnicity and systolic blood pressure.  This model statistically significantly predicts end 
systolic elastance, F(5,53)=2.49, P=0.04 , R2=0.11.  
Table 48:  Multivariable logistic regression for association with arterial elastance index 
at 13±1 weeks of gestation 
Variable Coefficient Standard error P 
Age 0.001 0.005 0.80 
Parity 0.0001 0.051 0.99 
White ethnicity –0.08 0.05 0.10 
Systolic blood pressure 0.0008 0.002 0.73 
Mon1 0.23 0.077 0.004 
 
Mon1 remains significantly associated with arterial elastance index after correction for age, 
parity, ethnicity and systolic blood pressure.  For this model F(5,53)=3.23, P=0.01 , R2=0.16. 
 
7.5 Discussion 
I have shown an association between monocyte counts, especially Mon1, and measures of 
arterial and ventricular elastance in pregnant women.  Mon1 monocytes are large, highly 
phagocytic cells involved in resolving inflammation and repairing tissue injury, but their 
adherence and infiltration into vascular walls at the sites of endothelial injury can also be 
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detrimental.  These data suggest that monocytes may have a role in the pathogenesis of 
hypertension in pregnancy.  Mon1 may be involved in the development of hypertension, or 
may be part of the (mal)adaptation to raised blood pressure.  I described in my systematic 
review (Chapter 2) that cardiac structural and functional changes are present before 
hypertensive disorders of pregnancy manifest clinically.  More work is required to discover if 
differences in monocyte subsets are associated with these findings in women destined to 
develop hypertension in pregnancy. 
 
Of the 9 women who developed hypertension in pregnancy, all but one had a BMI greater 
than 25 at booking.  Some 4 were overweight (BMI 25-29.9), 1 was obese (BMI 30-30.9), and 
3 were severely obese (BMI>40).  It is proposed that the presence of metabolic syndrome, 
low-grade inflammation and endothelial dysfunction lead to the increased incidence of 
preeclampsia in obese women.294  In a recent review, Arena et al describe an obesity-
hypertension phenotype in the midst of the “non-communicable disease crisis” posed by the 
obesity epidemic.295  Accumulation of adipose tissue leads to increased sympathetic nervous 
system activity, changes in endocrine function (particularly blood glucose regulation and 
sodium homeostasis via hyperinsulinaemia and insulin resistance) and altered renal and 
endothelial function.295  There are proponents of the placental origin hypothesis, as well as 
those who advocate for the cardiovascular origins of preeclampsia.  It is possible that PET 
represents a common phenotypic expression of two distinct processes, the first being a 
predisposition to cardiovascular disease and the second being impaired trophoblastic 
invasion.296 
 
There are several reasons why incidence of hypertension in pregnancy is a risk factor for 
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future cardiovascular disease.  PET and cardiovascular disease share the same risk factors.  
Pregnancy can be regarded as a ‘stress test’ whereby a problem is unmasked by the demands 
of pregnancy.  It is also possible that hypertension itself, and PET in particular, causes 
endothelial damage and dysfunction of which the legacy is future cardiovascular disease.  It 
would be interesting to compare the long-term outcomes of women with an increased latency 
from PET diagnosis to delivery, with those whose pregnancy shortened by early planned 
delivery, to determine whether duration of exposure makes a difference to outcome. 
 
7.6 Strengths and limitations 
In sections 5.6 and 6.6 of the preceding chapters I have discussed the limitations of my 
methodology.  This previous critical appraisal of the study is relevant also to this chapter.  
The number of patients in this study is relatively small and this must be borne in mind when 
interpreting the results, as there is a chance of bias.  In striving for a thorough analysis of the 
data in order to explore any plausible relationship between measurements, multiple 
comparisons have been made.  This increases the risk of false positive findings.  If 20 null 
hypotheses were rejected during a thesis where the threshold for significance is P<0.05, it is 
likely that one difference quoted as significant would be a chance finding.  With this in mind, 
I have described throughout when post hoc tests have been employed, and when the P value 
to achieve statistical significance has been adjusted to reduce the risk of Type 1 error.  
 
Changes in cardiac function happen in early gestation.  The first trimester should not be 
ignored and recently innovative studies have been able to follow women from before 
conception to early gestation and throughout pregnancy.  Pre-conceptual can determine a 
woman’s baseline cardiac function, rather than using non-pregnant or postpartum indices as a 
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control.  More studies starting before pregnancy will help to answer whether women affected 
by hypertension in pregnancy have alterations even before the pregnancy begins.  
Preconceptual studies are methodologically challenging.  Women accessing obstetric and 
gynaecological services prior to pregnancy tend to have medical problems requiring 
preconceptual counselling or subfertility issues.  In my study over 10% of women who 
booked their antenatal care at City Hospital delivered their baby elsewhere.  Studies 
beginning in the preconceptual period are likely to require either a more stable population (for 
example in more remote, rural areas) or a commitment from or incentive for women to attend 
follow up appointments. 
 
7.7 Conclusions 
I have demonstrated an association between monocytes and arterial and ventricular stiffness.  
The importance of recognising ‘high normal’ blood pressure as ‘not normal’ has been 
reiterated, since increasing blood pressure in early pregnancy is related to development 
hypertension later.  More prospective studies involving large numbers of women, ideally 




SUMMARY, CONCLUSIONS AND 
FUTURE DIRECTIONS 
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8.1 Summary of findings 
My systematic review identified that echocardiography is a valuable tool to stratify risk and 
can guide management in the preclinical and clinical phases of gestational hypertension and 
preeclampsia.  Increased vascular resistance and LV mass were the most consistent findings 
in hypertensive disorders of pregnancy.  Differentiating features from normal pregnancy were 
LV wall thickness ≥1.0cm, exaggerated reduction in E/A and lateral e’ <14cm/s. There was 
disagreement between studies with regard to cardiac output due to the timing of 
echocardiography, although reduced stroke volume was an indicator of adverse prognosis. 
Diastolic dysfunction and left ventricular remodelling are most marked in severe and early-
onset PET, but are also markers of PET before clinical manifestation, and are associated with 
adverse outcomes. 
Women with prior hypertension are more likely to have blood pressure in the 120–139/80–
99mmHg (prehypertension) range, and their blood pressures were higher than other pregnant 
women throughout.  There is an association between blood pressure level at the beginning and 
end of second trimester and later development of hypertension.   
 
I recognised the physiological adaptation of the heart to pregnancy in many of the parameters 
studied at baseline (13 weeks of gestation).  When comparing pregnant women to non-
pregnant controls, the former had increased cardiac output, reduced total vascular resistance 
and increased left ventricular volumes.  Increased left ventricular filling pressures were 
observed in pregnancy.   
 
In the study group of pregnant women with previous hypertension in pregnancy some 
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differences were observed.  There was a trend towards increased left ventricular mass index.  
Late diastolic transmitral flow velocities (A wave) were increased compared to other pregnant 
and non-pregnant women and the E/A ratio was lower.  Augmentation index (adjusted for 
heart rate and blood pressure) was increased compared to both other groups.  Women without 
prior hypertension demonstrated more compliance (reduced EaI and Ees) compared to the 
non-pregnant controls, but this adaptation was not seen in pregnancy after hypertension where 
increased arterial stiffness was observed. 
 
In the longitudinal analysis of cardiovascular parameters, some changes were seen 
irrespective of history of hypertension.  There was a reduction in E/A and e’ in the third 
trimester.  An increase in Ees resulted in a reduced EaI/Ees (ventriculo-arterial coupling) as a 
measure of cardiovascular performance by the third trimester.   
 
CD14++CD16–CCR2+ (Mon1) and CD14+CD16++CCR2– (Mon3) subsets and their 
aggregates with platelets were increased in pregnant women with previous hypertension at 
baseline.  Total monocyte counts, and Mon1 in particular, were significantly and positively 
correlated with ventricular (Ees) and arterial (EaI) elastances.  Mon1 was also positively 
correlated with augmentation index and total vascular resistance index.  
 
The women who developed hypertension during the study had a significantly higher booking 
weight compared to those women who remained normotensive.  Worse myocardial 
compliance in association with higher left ventricular early filling pressures (significantly 
higher E/e’) were observed at 20±1 weeks of gestation in women who developed 
hypertension later in pregnancy. 
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8.2 Conclusions 
Elevated arterial elastance occurs in pregnant women with a past history of gestational 
hypertension or preeclampsia, despite similar ventricular elastance to women without prior 
hypertension.  Mon1 monocytes are large, highly phagocytic cells involved in resolving 
inflammation and repairing tissue injury, but their adherence and infiltration into vascular 
walls at the sites of endothelial injury can also be detrimental, and may be responsible 
increased arterial stiffness in women with a history of hypertension in pregnancy.  Changes in 
cardiovascular performance and their relationship to monocyte heterogeneity may potentially 
be mechanisms leading to increased long term cardiovascular risk following pregnancy 
hypertension.  Echocardiography is a valuable tool to stratify risk and can guide management 
and counselling for women with current or past history of hypertension in pregnancy.  
 
8.3 Implications for clinical practice 
The Rapid Obstetric Screening Echocardiogram (ROSE) has been developed by Alicia 
Dennis and colleagues in Melbourne.297  They advocate its use for acutely unwell pregnant 
women and its clinical utility will be tested in prospective studies.  In a recent systematic 
review and validation study, transthoracic echocardiographic assessment of cardiac output 
was found to have excellent agreement with pulmonary artery catheterization in pregnant 
women in the critical care setting.  The authors therefore suggest that echocardiography be 
considered the new gold reference standard.97  As the use of echocardiography in obstetric 
care increases, there will be more potential for large scale collaborative studies.  More data is 
required regarding added clinical value in terms of improving outcomes, in order to make 
recommendations for the use of echocardiography in routine clinical practice.  
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Since the publication of my systematic review in which I suggested that haemodynamic 
assessment could be used to guide choice of antihypertensive medication, Stott et al have 
published exciting results from a study in which they demonstrated that the implementation of 
haemodynamic monitoring reduced the rate of severe hypertension in women starting 
antihypertensive therapy.298  The haemodynamic insight enabled informed decisions to 
provide labetalol monotherapy to women with low vascular resistance and dual therapy with a 
vasodilator for those with high vascular resistance.299  Prospective clinical studies have been 
made more possible by the advent of non-invasive monitors. 
 
Several non-invasive monitors for haemodynamic assessment have emerged on the market 
during the lifetime of this research.  The Ultrasound Cardiac Output Monitor (USCOM®, 
USCOM Ltd, Sydney, Australia) uses continuous wave Doppler to analyse transthoracic 
blood flow.  The Non-Invasive Cardiac Output Monitor (NICOM®, Cheetah Medical, 
Boston, USA) uses probes applied to the chest wall to measure thoracic bioreactance and as 
such is operator-independent.  In a recent study the USCOM and NICOM devices were 
compared with transthoracic echocardiography and there was good agreement for 
measurement of cardiac output in the third trimester, although due to differences in precise 
values the authors recommend the development of device-specific reference ranges.282  I will 
consider such devices when developing future research protocols since the learning curve for 
their use is shorter than that for echocardiography, facilitating more widespread training 




8.4 Future directions and suggestions for future study 
It is important to delineate which factors are responsible for irreversible changes in cardiac 
structure and function.  If modifiable risk factors for pathological remodeling can be 
identified then interventions can be targeted towards preventing maladaptation with its 
adverse long-term consequences. 
 
Cardiac magnetic resonance imaging (MRI) is superior to echocardiography in terms of the 
amount and quality of data it provides about cardiac structure and function.  It is an accurate 
and precise imaging modality but is less available and acceptable to pregnant women.  
Expertise is required to perform and interpret the MRI findings.  Cardiac MRI in maternal 
medicine is an exciting prospect. 
 
Whilst research investigating cardiac output is important, it is crucial that increased attention 
is given to diastole in future research.  Pregnant women are different to the older population 
who comprise majority of cardiologists’ patients.  In younger patients, diastolic dysfunction 
will precede systolic heart failure for considerable time, in contrast to the elderly where there 
is increased myocardial fibrosis.  Diastolic dysfunction should be at the forefront of future 
research. 
 
Obstetricians and their patients require a better screening test for the hypertensive disorders of 
pregnancy and their complications in order to improve maternal and fetal outcomes.  If 
women could be triaged more accurately into high and low risk groups then resources (more 
regular monitoring, growth surveillance, planned delivery) could be targeted where they are 
most needed.  Maternal haemodynamics, besides mean arterial pressure and uterine artery 
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Doppler, do not yet have a defined role in prediction of pregnancy hypertension.  These 
parameters are likely to be used in screening models for PET, including that superimposed on 
chronic hypertension or developing from GH, and its complications.  To justify screening, 
whether it be in the first trimester or later in pregnancy, further research into effective 
interventions is also required in order to improve outcomes for ‘screen positive’ women and 
their babies. 
 
The results of a recent randomised controlled trial show that aspirin prevents preeclampsia.89  
The Pre-eclampsia in Hospital: Early Induction or Expectant Management (Phoenix) Study is 
a randomised trial, due to report later in 2019, which investigated whether a decision for 
delivery or expectant management, when PET is diagnosed between 34+0 and 36+6 weeks, 
leads to the better maternal and fetal outcomes.300  Objective measures are required for 
decision tools in clinical practice since randomisation is only justified in the research setting.  
Availability of haemodynamic assessment after PET diagnosis may help to stratify women 
into a high risk group requiring early delivery and a low risk group suitable for standard 
management.  The extent to which the heart is affected by preeclampsia, or by non-proteinuric 
hypertension, might depend on the latency between diagnosis, delivery and resolution of the 
condition.  It is possible that expectant management may be detrimental to the woman, due to 
prolonged and excessive exposure of a heart that has failed to adapt to pregnancy to further 
stress.  In this sense, obstetric management may contribute to the excess of cardiovascular 
morbidity in later life following preeclampsia.  Data relating to length of exposure of the 
cardiovascular system to raised blood pressure, or to the multisystem syndrome of 
preeclampsia, would be useful in future studies.  This would be methodologically difficult in 
terms of definition of start and end points and acquisition of the data. 
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This thesis has studied cardiac structure and function in relation to hypertensive disorders in 
pregnancy.  Cardiac dysfunction is linked to placental dysfunction, since the placenta is an 
organ requiring adequate perfusion.  Placental pathology secondary to cardiovascular 
pathology results in disordered fetal growth.  Screening, diagnosis and management of fetal 
growth restriction focusses on reducing stillbirth and developmental handicap.  Further work 
is required to determine if the failure of the maternal heart to meet the demands of pregnancy 
is related to disorders of fetal growth and their sequelae, and which techniques will enable 
such cases to be identified.  If cardiac dysfunction can be identified near term, this may help 
to identify the fetuses at risk.  The key problem with growth restriction at term is detection as 
most are not small.  Many of the babies at risk have an estimated fetal weight in the normal 
range, but they are growth restricted because they had the potential to be bigger.  Cardiac 
dysfunction could be a new indication for a third trimester fetal growth scan for women who 
would otherwise not qualify for this examination, which is more sensitive than the routine 
measurement of symphysis-fundal height.  
 
How to follow up women with a history of hypertension in pregnancy has not been defined 
and as such practice varies.  It is important to identify what sort of surveillance these women 
require and which healthcare professional should oversee this.  Strategies to reduce the risk of 
long term cardiovascular morbidity might include lifestyle modification, structured exercise 
programmes or medications such as aspirin or angiotensin-converting-enzyme inhibitors even 
in asymptomatic patients. 
 
Prehypertension has not yet received much recognition from obstetricians and warrants 
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further study.   Future work must clarify the effect of prehypertension preconceptually and 
during pregnancy.  It is important to ascertain whether reducing the length of time the heart is 
exposed to blood pressure in the prehypertensive range will improve long term outcomes.  In 
the maternal medicine sphere the effect of lowering blood pressure on maternal and fetal 
outcomes is also of great interest.  Although contraindicated during pregnancy, the use of 
angiotensin-converting enzyme (ACE) inhibition for cardioprotection may prevent 
pathological remodelling in prehypertensive women of childbearing age, and their use might 
be considered before conception and after delivery. 
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3. Standard operating procedures (SOPs) used in this thesis 
SOP: General Operation of the Flow Cytometer 




This is the general purpose SOP on 
• start up 
• calibration, and  
• clean up of the flow cytometer.  
 
Blood sample analysis for specific population will be dealt with by other SOPs 
Health and Safety / COSHH issues 
Beware of…. 
• Lasers  
• Danger of electric shocks 
• assume bloods may be biohazardous 
• Bleach is toxic – do not eat/drink. 
Contact details: 
 
2.1   BD “FACS Flow” Running solution [Becton Dickinson Catalogue No. 342003]10L 
containers. Source: Becton Dickinson (UK) Between Towns Road Cowley Oxford , 
Oxfordshire,OX4 3LY Fax: 01865 781578 
 
2.2   BD “FACS Clean” Cleaning Solution [Becton Dickinson Catalogue No. 340345]  
 
2.3   Three ml BD Falcon tubes [Becton Dickinson, Catalogue No. 352054] 
 
2.4   Clear pipette tips [Alpha Laboratories Limited Catalogue No FR1250 1250ul Fastrak Refill 




2.5   Yellow pipette tips [[Alpha Laboratories Limited Catalogue No FR1200 200ul Fastrak Refill 
NS] 40 Parham Drive Eastleigh, Hampshire SO50 4NU UK Tel – 02380483000 Fax – 
02380643701 
 




3. Start up procedure 
 
Part 1 – restoring reagents and preparation 
 
1. Switch on Flow Cytometer by pressing the green switch on the right hand side.  The 
Apple Macintosh computer must also be switched on, but only 15 secs after the Flow 
Cytometer, or the link will not be recognised. Open the reagent panel on the left hand 
side (LHS) by pulling the lid towards you. On the left is the sheath fluid reservoir, in 
the middle are switches and tubes, on the right is the waste reservoir. 
 
2. Carefully unscrew the top of the sheath fluid reservoir and fill with sheath fluid (in 
large box on shelf at head height – use plastic tube) to the level indicated on the top 
right hand corner of the reservoir (little plastic bar). 
 
3. Carefully disconnect/unscrew the waste container and empty contents down sink with 
plenty of water.  Add approximately 40ml concentrated household bleach along with 
360 ml of distilled water and reconnect container (plastic tubes available). 
 
4. Pressurise the unit (takes about 20-30 sec) by moving the black toggle switch “Vent 
Valve” switch to the down/front position. It is located at the rear of the middle section 
between the sheath fluid tank and the waste container. 
 
5. Air must be excluded from the tubing system by flushing it out. Any excess air 
trapped in the sheath filter can, if necessary, be cleared by venting through the bleed 
tube (the dead-ended rubber tube with a cap). 
 
6. Close the drawer 
 
Part 2 - cleaning the machine 
 
7. Ensure that a 3 ml Falcon tube (labelled 1) approximately 1/3 full of distilled water is 
positioned over the sample injection port (SIP) – a needle sheath - and that the swing 
arm is positioned under this tube.  Press the prime button on the panel.  When the 
system enters “standby” with in 30 seconds then press the “prime” button again. When 
the standby and low buttons comes on again then remove tube 1. We will re-use tube 1 
in the shut down procedure. 
 
8. Prepare a second falcon tube (labelled 2) with FACS-clean (should contain about 2750 
microliters so that when inserted on to the sip it doesn’t touch the O ring). This is a 
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smaller box on a shelf at above head height and above the bigger box of sheath flow 
fluid 
 
9. Present tube 2 to the SIP and place support arm underneath it. Press the buttons “run” 
and “high” on the panel at the same time, and run the FACS-clean in falcon tube 2 
with supporting arm to left or right open for one minute. Then return the supporting 
arm to underneath the tube and “run-high” five minutes.  This process ensures the 
machine is clean prior to running samples and helps minimise blockages.  
 
10. Return to falcon tube 1 with distilled water. Repeat the above step 9 with this distilled 
water tube. 
 
11. Press the ‘STANDBY’ and ‘LOW’ button on the system. 
 






Whoever calibrates the machine at the beginning of the day, carries the 
responsibility for ensuring correct function. 
 
He/she will sign in the log book that the machine is calibrated. 
 
The calibration sheet itself must be signed by the operator and placed in 
the folder on top of the printer.  
 
Mr Balakrishnan is responsible for keeping these sheets in order and 
responding to any problems. He will periodically remove ‘old’ 




This procedure must be done right after the start up procedure so that the system is calibrated. 
The regents (beads with known characteristics) can be found in the fridge behind the door. 
Check the expiry dates and prepare the reagents as advised. 
1. Take two 3 ml falcon tubes and mark one of them as A and the other one as B. 
 
2. Aliquot 1 ml (clear tip micropipette) of sheath flow (big box head height on shelf) in 
tube A and 2 ml in tube B. 
 
3. Take the box of Calibrite bead from the top rack of the fridge door. 
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4. Gently mix the five tubes by inverting upside down ten times so that the beads are 
suspended uniformly before using them 
 
5. Prepare the tube A by very gently squeezing out a single drop of unlabelled beads (i.e. 
no flurochrome) (white top) and the labelled APC beads (blue). Be sure to mix the 
contents of tubes before inserting it onto the needle of the SIP. 
 
6. Prepare the tube B by pouring a single drop of each of five beads; Unlabelled (white) 
APC beads (blue), Per-CP Beads (red), PE Beads (pink) and FITC Beads (green). 
 
7. On the computer, click on the FACS-comp icon (with a picture of a test tube) in the 
icon menu bar and the FACS-comp window will appear on the computer screen 
displaying the user ID and other details. Click ‘accept’, which proceeds on to the 
product code/lot number. Ensure that the bead lot numbers are accurate and then carry 
on with the procedure. 
 
8. Replace the beads back into their box and then into the fridge 
 
9. Click the “run” button on the screen which indicates to insert the tube labelled A on to 
the SIP. Mix gently before inserting and press the buttons “high” and “run” on the 
control panel of the FAScalibur. Then press start. 
 
10. The system then sets the photo-multiplier tube voltage settings (takes about 2 minutes) 
based on the tube A beads, and then tells you to insert the Tube B. Insert the tube B 
after mixing it gently, then press start. 
 
11. The system again analyses the compensations and, if satisfied, gives the result that it is 
Ok to proceed.  
 
12. Once this result is satisfactory, the results of this set up will be printed out. Write your 
name on the print out and place it in the FACS comp results folder. If the machine is 
not satisfied, it will tell you and you will seek assistance from Scientific Staff. 
 
13. The machine is now ready to run blood samples according to the specific SOP 
 
 




Each operator must decide if he/she is the last operator of the day. This may be achieved 








2. Install FACS Clean tube 2 over the SIP needle. Press button ‘High’ and ‘Run’ on the 
panel. Leave the support arm out at 90 degrees for approximately 1 minute.  This 
cleans the outer portion of the aspiration sheath.  The fluid will be rapidly aspirated, so 
ensure that the tube doesn’t empty completely. 
 
3. Now replace the side arm under the Falcon tube and allow to run for approximately 5 
minutes.  This cleans the inner portion of the aspiration sheath and the FACS machine 
itself. 
 
4. Repeat steps 2 and 3 with the distilled water tube 1.  Once step 3 is complete, Leave 
the sheath in falcon tube 1 containing distilled water and press ‘STANDBY’. 
 
5. Open the reservoir draw and depressurise the machine by moving the “Vent Valve” 
toggle switch to the up/rear position.  The machine will hiss as it depressurises. 
 
6. Leave the machine on for a further 5 minutes to allow the laser lamp to cool.  Turning 
the machine off prematurely will result in the lamp cracking. 
 
7. Finally power down the FACScalibur (green button) and Apple Mac, by clicking on 
the apple icon and clicking on the shut down option in the drop down menu. 
 
8. Clean up ! 
 
9. Note: * IF THE SYSTEM IS TO BE USED AGAIN ON THE SAME DAY… 
 
LEAVE THE SYSTEM ON STANDBY and then 
 
DEPRESSURISE THE SYSTEM. 
SOP: Absolute count of monocyte subsets and assessment of surface marker expression 
on them by Flow Cytometry 
N.B. Use of the flow cytometry is forbidden without having been officially trained 
Required pre-training 
1. SOPs on venepuncture, good clinical practice 
 
2. SOP 195 – general operation of the flow cytometer 
 
1. Introduction 
Monocytes are circulating blood cell participating in innate immunity, inflammatory response 
as well as other processes such as angiogenesis, formation of tissue macrophages and 
dendritic cells, etc. Monocyte include several subsets that can be discriminated on the basis of 
surface expression of CD14 (lipopolisacharide receptor) and CD16 (Fc gamma receptor III. 
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This method describes enumeration and characterisation of: 
- CD14+CD16- monocytes (about 85%),  
- CD14+CD16+ monocytes (also CCR2+, about 5%) and  
- CD14lowCD16+ monocytes (also CCR2-, about 10%), 
 
2. Materials and Supplier contact details: 
 
1) BD “FACS Flow” Running solution [Becton Dickinson, Catalogue No. 342003] 
10L containers.  
2) BD “FACS Clean” Cleaning Solution [Becton Dickinson, Catalogue No. 340345]  
3) 3 ml BD Falcon tubes [Becton Dickinson, Catalogue No. 352054] 
 
4) BD Lysing solution [Becton Dickinson Catalogue No. 349202] 
 
5) Sterile Phosphate Buffered Saline solution, 0.5L bottles [Invitrogen Ltd, Catalogue No 
20012-068] 
 
6) BD TruCount™ tubes [Becton Dickinson Catalogue No. 340334] 
 
7) CD16-Alexa Fluor 488-conjugated monoclonal antibody [AbD Serotec, Oxford, UK, 
Cat No. MCA2537A488] 
 
8) CD14 -PE conjugated monoclonal antibody [R&D Systems Europe Ltd, Cat No. 
FAB3832P] 
 
9) CD14-PerCP-Cy5.5 conjugated monoclonal antibody [Becton Dickinson Catalogue 
No. 550787] 
 
10) CCR2-APC conjugated monoclonal antibody [R&D Systems Europe Ltd, Cat No. 
FAB151A] 
 
11) CD42a- conjugated monoclonal antibody [Becton Dickinson, Catalogue No. 340537] 
 
12) VEGF R2 (KDR)-APC conjugated monoclonal antibody [R&D Systems Europe Ltd 
Catalogue No. FAB321A] 
 
13) CD34-PE conjugated monoclonal antibody (Becton Dickinson, Catalogue No. 
555822) 
 




15) TLR4 (CD284)-PE conjugated monoclonal antibody [R&D Systems Europe Ltd 
Catalogue No. FAB14781P] 
 
 
16) IL-6 receptor α-APC conjugated monoclonal antibody [R&D Systems Europe Ltd 
Catalogue No. FAB227A] 
 
17) Mac-1-PE conjugated monoclonal antibody (CD11/CD18, receptor for ICAM-1) 
[R&D Systems Europe Ltd Catalogue No. FAB1730P] 
 
18) Integrin α4/CD49 complex-APC conjugated monoclonal antibody [R&D Systems 
Europe Ltd Catalogue No. FAB1354A] 
 
19) CD163-APC conjugated monoclonal antibody [R&D Systems Europe Ltd Catalogue 
No. FAB1607A] 
 
20) CXCR4-PE conjugated monoclonal antibody (CD184) [R&D Systems Europe Ltd 
Catalogue No. FAB170P] 
 
21) VEGFR1-APC conjugated monoclonal antibody (R&D Systems Europe Ltd 
Catalogue No. FAB321A) 
 
22) Clear pipette tips [Alpha Laboratories Limited Catalogue No FR1250 1250ul Fastrak 
Refill NS]  
 
23) Yellow pipette tips [[Alpha Laboratories Limited Catalogue No FR1200 200ul Fastrak 
Refill NS]  
 
24) Pipettes required –  2-20ul (gray), 5-40ul (red), 40-200 ul (yellow), 200-1000ul 
(purple), 10-100ul and 100-1000ul digital  
 
3. Detailed method 
3.1 General Preparation 
3.1.1 Lysing solution.   
Make from 50ml concentrate 10x FACS Lysing Solution (kept at room temperature). Dilute 
with 450ml distilled water in ½ litre bottle. This solution should not be used if it is older than 
a month (kept at room temperature). 
 
3.1.2. Mastermixes 
Mastermixes are made by responsible person in clearly labelled tubes from dark glass. 
Estimated number of samples to be done from one mastermix should not exceed monthly 
number of samples done. 
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3.1.3. Time from blood sample collection to beginning of sample preparation should be less 
30 min, and must not be more than 60 min. 
 
3.2 Blood sample preparation 
 
3.2.1. Place EDTA blood sample on rotator. 
3.2.2. Label tubes 1-5 and additional tube for absolute count (AC) 
3.2.3. Place Antibodies from ‘mastermixes’: 
Tube 1 - 22.5ul (red) 
Tube 2 - 22.5ul (red) 
Tube 3 - 22.5ul (red) 
Tube 4 - 27.5ul (red) 
Tube 5 - 22.5ul (red) 
AC tube - 12.5ul (gray) - place on opposite side to count beads. Do not touch the!!!! 
If this happened – change the tube. 
3.2.4. Add blood to tubes  
a) Absolute count tube: 
- Take 10-100ul digital pipette 
- Set to 2 x 50ul 
- Withdraw blood then expel by pressing ‘RESET’, take up blood once again 
- Wipe pipette tip to remove excess blood 
- Eject 50ul into AC tube – keep the tip well above the metal greed. Do not touch count 
beads!!! 
- Replace tube top 
b) Tubes 1-5 
- Take 100-1000ul digital pipette 
- Set to 10 x 100ul 
- Withdraw blood then expel by pressing reset, take up blood once again 
- Wipe pipette tip to remove excess blood 
- Eject 100ul into tubes 1-5 (1 press)  
- Replace rest of blood into EDTA blood tube (keep it in case you need to repeat the 
procedure) 
3.2.5. Vortex all samples (level 3) 
3.2.6. Place samples in dark for 15 minutes (taken from when last sample prepared) 
 
3.3 Start up procedure [See SOP 195 on General Operation] 
 
- Turn on FC and after few seconds computer. 
- Empty waste (right container) and refill with 360ml distilled water and 40ml bleach (ensure 
no bleach on gloves) 
- Fill machine with left container by FacsFlow to appropriate level (level of indentation) 
- Pressurise 
- Press LOW/PRIME with the arm closed (distilled water in place)- once PRIME light goes 
off press once more 
- Remove distilled water and place ‘top right’ on rack 
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- Insert FacsClean tube (2ml of FacsClean) – opened arm 1 minute, closed 5 minutes - then 
remove and place ‘top left’ on rack- set FC on ‘high/run’ 
- Insert a tube with sterile PBS - 1 minute open arm, 5 minutes closed arm 
 
3.4. Further sample preparation 
 
3.4.1. Red blood cell lysing  
- Use purple pipette(200-1000ul) 
- Put 2mls of FacsLyse in Tubes 1-5 
- Put 450ul in AC tube 
- Place tops on tubes and vortex 
- Place AC tube in dark for 15 minutes- after which add 1.5 mls of PBS, vortex - sample 
ready to run 
- Place tubes 1-5 in centrifuge- leave for 10 minutes before spinning for 5 minutes (300RPM) 
- Remove tubes 1-5 from centrifuge , decant, add 3 mls of PBS, replace tops, vortex, spin 
again - 300RPM for 5 minutes 
- Decant supernatant, resuspend in 100 ul of PBS – sample ready to run 
 
3.5. Sample acquisition 
3.5.1. Absolute count 
- Run FacsComp if you are first user of the flow cytometer during the day 
- Press CellQuest icon 
- ‘FILE’ – ‘Open document’ – ‘Data 1’ – ‘Mon protocols’ – ‘Mon no wash’ 
- ACQUIRE – ‘Connect to cytometer’ 
- CYTOMETER – ‘Choose instrument settings’ – ‘Mon no wash’ – ‘Set’ – ‘Done’ 
- Change appropriate directory to save flow data 
- Change file name 
- Place AC into cytometer and press ‘Acquire’ (press ‘Acquire’ on top bar, press ‘Counters’) - 
once finished, print 
3.5.2. Expression of surface markers 
- ‘FILE’ – ‘Open document’ - choose – ‘Mon wash Luke/Ben’ 
- CYTOMETER – ‘Instrument settings’ – ‘Open’ - choose ‘Mon wash Luke/Ben’ – ‘Set’ – 
‘Done’ 
- ‘WINDOWS’ – ‘Show browser’ 
- Change directory and file name as before 
- Vortex and run tubes 1-5, changing file on each sample (1, 2, 3 etc)- print after each 
 
 
3.4 Shut-down procedure [See SOP 195 on General Operation] 
 
1. In this section we re-use tubes 1 and 2 with distilled water and FACS clean 
respectively. 
 
2. Install FACS Clean tube 2 over the SIP needle. Press button ‘High’ and ‘Run’ on the 
panel. Leave the support arm out at 90 degrees for approximately 1 minute.  This 
cleans the outer portion of the aspiration sheath.  The fluid will be rapidly aspirated, so 
ensure that the tube doesn’t empty completely. 
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3. Now replace the side arm under the Falcon tube and allow to run for approximately 5 
minutes.  This cleans the inner portion of the aspiration sheath and the FACS machine 
itself. 
 
4. Repeat steps 2 and 3 with the distilled water tube 1.  Once step 3 is complete, Leave 
the sheath in falcon tube 1 containing distilled water and press ‘STANDBY’. 
 
5. Open the reservoir draw and depressurise the machine by moving the “Vent Valve” 
toggle switch to the up/rear position.  The machine will hiss as it depressurises. 
 
6. Leave the machine on for a further 5 minutes to allow the laser lamp to cool.  Turning 
the machine off prematurely will result in the lamp cracking. 
 
7. Finally power down the FAC-Scalibur (green button) and Apple Mac. 
 
8. Clean up! 
 
9. Note: * IF THE SYSTEM IS TO BE USED AGAIN ON THE SAME DAY… 
 
LEAVE THE SYSTEM ON STANDBY and then 
 
DEPRESSURISE THE SYSTEM. 
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SOP: Monocyte subsets and monocyte platelet aggregates by flow cytometry 
SOP written by Eduard Shantsila and Andrew Blann 
N.B. Use of the flow cytometry is forbidden without having been officially trained 
Required pre-training 
1. SOPs on venepuncture and on  good clinical practice 
 




Monocytes are large mononuclear cells (MNCs) derived from the bone marrow but on transit 
to the tissues where they seem likely to become semi-resident macrophages. Traditionally, 
they have been defined by glass-slide morphology, size, and scatter, but we now have the 
ability to define monocytes by cell surface molecules, using the FACS. For example, CD14 is 
a receptor for LPS present on monocytes, macrophages and neutrophils. CD16 is an antigen 
found on the Fc receptors and is present on natural killer cells, neutrophil polymorphonuclear 
leukocytes, monocytes and macrophages. So leukocytes populations can be further classified 
by the density of the expression of these markers, for example…. 
 
• M1 = CD14 strong CD16  negative 
• M2 = CD14 strong  CD16 strong 
• M3 = CD14 weak CD16 strong 
 
A further characteristic of monocytes in chemotaxis, such as to the chemokine monocyte 
chemoattractant protein-1 (MCP-1), a cytokine involved in monocyte infiltration in 
inflammatory diseases such as rheumatoid arthritis as well as in the inflammatory response 
against tumors. CCR2, short for chemokine (C-C motif) receptor 2, is a chemokine receptor 
for MCP-1 CCR2 has also recently been designated CD192.   
 
Platelets are anucleate fragments of the cytoplasm of the megakaryocyte. They form thrombi 
when self-aggregating but more so in the presence of fibrin. However, platelets may also bind 
to monocytes. Cell surface markers of platelets include CD42a, also known as GpIX. It 
follows that dual labelling of blood with a monocyte marker (CD14/CD16/CCR2) and a 
platelet marker (CD42a) will identify monocyte-platelet aggregates (MPAs).  
 
This SOP describes enumeration of monocyte subsets (dependent on expression of CD14, 
CD16 and CCR2) and their participation in the formation of MPAs. And of course you will 




2. Materials and Supplier contact details: 
 
Micro-reagents are kept in the fridge behind the door or on nearby shelves. Bulk fluids in 
boxes on other shelves and beneath the benches. 
 
1) BD “FACS Flow” Running solution [Becton Dickinson, Catalogue No. 342003] 
10L containers. 
2) 3 ml BD Falcon tubes [BD Catalogue No. 352054] 
 
3) BD“FACS Clean” Cleaning Solution [BD Catalogue No. 340345]  
 
4) BD Lysing solution [BD Catalogue No. 349202] 
 
 
5) Sterile Phosphate Buffered Saline solution, 0.5L bottles [Invitrogen Ltd, Catalogue No 
20012-068] 
 
6) CD14 -PE conjugated monoclonal antibody - 100 tests [BD Catalogue No. 555398] 
 
7) CD16 – Alex-flour 488 conjugated monoclonal antibody - 100 tests [ABD Serotec, 
Cambridge] 
 
8) CD42a-PerCP conjugated monoclonal antibody [BD Catalogue No. 340537]  
 
9) CCR2-APC conjugated monoclonal antibody [R&D Systems Europe Ltd, Cat No. 
FAB151A] 
[n.b. this combination of  antibodies constitute a Mastermix: See ADB, ES] 
10) Clear pipette tips [Alpha Laboratories Limited Catalogue No FR1250 1250ul Fastrak 
Refill NS]  
 
11) Yellow pipette tips [[Alpha Laboratories Limited Catalogue No FR1200 200ul Fastrak 
Refill NS]  
 
12) Count beads [BD (Trucount™ tubes)]. This is a crucial aspect as it will give us the 
number of monocytes/ml of venous blood. The product tube has a statement of the 
number of beads in each tube and so from this you can work out beads/mL. 
 
Remember to dispose of all material thoughtfully.  
 
3. Detailed method 
3.1 General Preparation 
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3.1.1 Lysing solution.   
Make from 50ml concentrate 10x FACS Lysing Solution (kept at room temperature). Dilute 
with 450ml distilled water in ½ litre bottle. This solution should not be used if it is older than 
a month (kept at room temperature) 
3.2 Blood sample preparation 
 
1. Add 12.5µL of Mastermix Absolute Monocyte Count (which includes CD14 2.5 μL, 
CD16 2.5μL, CD42a 5μL and CCR2 2.5 μL fluorochrome labelled antibodies) with an 
electronic micropipette.  Just place into the tube below a metal grid without touching 
the pellet. 
 
2. Gently vortex the EDTA blood sample.  Take 0.05 mL (=50 μL) of whole blood with 
electronic pipette and add to a Trucount™ tube.  
 
3. Do not touch the pellet (this is critical!). Mix the tube gently with the vortex (3 sec). 
Incubate for 15 minutes in the dark, room temperature, shaking with horizontal shaker 
(set at 500 units). Add 0.45 ml (=450 μL) pre-diluted BD FACS Lyse solution (see 
3.1.1) with a clear tip using the 1ml pipette. Incubate for 15 minutes on shaker as 
above. 
 
4. Add 1.5 ml of PBS solution without touching the sample, followed by gentle vortex to 
ensure thoroughly mixed 
 
3.3 Start up procedure [See SOP 195 on General Operation] 
 
Part 1 – restoring reagents and preparation 
 
13. Switch on Flow Cytometer by pressing the green switch on the right hand side.  The 
Apple Macintosh computer must also be switched on, but only 15 secs after the Flow 
Cytometer, or the link will not be recognised. Open the reagent panel on the left hand 
side (LHS) by pulling the lid towards you. On the left is the sheath fluid reservoir, in 
the middle are switches and tubes, and on the right is the waste reservoir. 
 
14. Carefully unscrew the top of the sheath fluid reservoir and fill with sheath fluid (in 
large box on shelf at head height – use plastic tube) to the level indicated on the top 
right hand corner of the reservoir (little plastic bar). 
 
15. Carefully disconnect/unscrew the waste container and empty contents down sink with 
plenty of water.  Add approximately 40ml concentrated household bleach along with 
360 ml of distilled water and reconnect container (plastic tubes available). 
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16. Pressurise the unit (takes about 20-30 sec) by moving the black toggle switch “Vent 
Valve” switch to the down/front position. It is located at the rear of the middle section 
between the sheath fluid tank and the waste container. 
 
17. Air must be excluded from the tubing system by flushing it out. Any excess air 
trapped in the sheath filter can, if necessary, be cleared by venting through the bleed 
tube (the dead-ended rubber tube with a cap). 
 
18. Close the drawer 
 
Part 2 - Cleaning the machine 
 
19. Ensure that a 3 ml Falcon tube (labelled 1) approximately 1/3 full of distilled water is 
positioned over the sample injection port (SIP) – a needle sheath - and that the swing 
arm is positioned under this tube.  Press the prime button on the panel.  When the 
system enters “standby” with in 30 seconds then press the “prime” button again. When 
the standby and low buttons comes on again then remove tube 1. We will re-use tube 1 
in the shut down procedure. 
 
20. Prepare a second falcon tube (labelled 2) with FACS-clean (should contain about 2750 
microlitres so that when inserted on to the sip it doesn’t touch the O ring). This is a 
smaller box on a shelf at above head height and above the bigger box of sheath flow 
fluid 
 
21. Present tube 2 to the SIP and place support arm underneath it. Press the buttons “run” 
and “high” on the panel at the same time, and run the FACS-clean in falcon tube 2 
with supporting arm to left or right open for one minute. Then return the supporting 
arm to underneath the tube and “run-high” five minutes.  This process ensures the 
machine is clean prior to running samples and helps minimise blockages.  
 
22. Return to falcon tube 1 with distilled water. Repeat the above step 9 with this distilled 
water tube. 
 
23. Press the ‘STANDBY’ and ‘LOW’ button on the system. 
 




 3.4 Running blood samples. 
 
Note. This must be learned from an experienced operator and you must seek scientific staff 
support to clear queries as the intricacies of the Cell Quest software are complex. 
 
1. Open CellQuest Pro software  
2. Click ‘File’ – ‘Open’  
3. Click on the ‘Monocyte Protocols’ folder within ‘Data 1’ folder.  
4. Click on the ‘Monocyte Absolute Count’. This will open study protocol. 
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5. Click ‘Connect to Cytometer’, located under the ‘Acquire’ menu. 
 
6. Under the ‘Cytometer’ menu, click ‘Instrument Settings’.  The window appears 
displaying the compensations and threshold. Change settings by clicking on the open 
icon on the window which displays the folders select ‘Monocyte Protocols’ folder 
with in the ‘Data 1’ folder and click on the ‘Monocyte Absolute Count’ instrument 
settings in this folder. This will update the system settings to the preferred settings for 
the acquisition. Click ‘Set’ on the window and by clicking ‘Done’ the windows 
disappears.  Make sure to click ‘Set’ prior to clicking ‘Done’. 
 
7. Click the ‘Acquire’ menu once more and click ‘Show browser’.   
 
8. Click directory-‘Change’ in order to specify the location folder. 
 
9. Initial user must create new folder by clicking on ‘New folder’ and by entering the 
title of the folder and choose that folder. 
 
10. Change the custom suffix to the preferred title and number for data and click ‘OK’. 
 
11. Untick the setup box (by clicking on it) in the browser Acquisition window. Now 
insert your sample and press “RUN” and “HIGH”.  
 
12. Open swing arm at bottom right of the cytometer and replace the Falcon tube with the 
sample to be run.  Replace the swing arm under the Falcon tube. 
 
13. Press the buttons ‘Run’ and ‘High’ on the control panel of the cytometer.  
 
14. Click ‘Acquire’ on the browser menu.  The sample will now run for ~ 12 mins.  Cell 
events will be displayed on the screen throughout the process (n.b. the higher the cell 
density, the more rapidly the cells will be acquired). 
 
15. Click on ‘Counters’ under the ‘Acquire’ and observe the events per second which 
varies from 1000 to 8000 depending on various factors. The objective is to acquire 
10,000 count beads for analysis. 
 
16. Observe the acquisition closely since the system may get blocked (which happens very 
rarely) and the plots may not show any progress and the counters may not show any 
events per second. 
 
17. Click pause on the acquisition window and replace the sample from the SIP with 
sterile PBS and run for 20/30 seconds minutes (clicking acquire wouldn’t change the 
results) and then continue acquisition with your sample on the SIP. If the problem still 
persists please inform the senior scientific staff and seek assistance. 
 
18. After attaining the target events the analysis stops and the file number changes 
automatically. Click on ‘print’ under the ‘files’. Confirmation window appears again 
click on print. 
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19. Vortex your next sample gently. Re-programme the software with a new sample 
number, and repeat the step 11. 
 
20. If the cytometer is not ready message appears open the drawer and check the fluids 
level which may need refilling or emptying. The system may run out of Sheath fluid if 
there are more samples. 
 
21. Be absolutely sure you have downloaded your results on to paper. Keep this paper 
safe. Do not assume the computer will keep the results safe, even if you have directed 
it to do so. Obtain all the raw data (cell numbers) and apply them into the specific 
spreadsheet you have designed for your project. The same spreadsheet should have the 
WBC and platelet count results from the Advia 
 
 
3.5 Shut-down procedure  [See SOP 195 on General Operation] 
 
3. In this section we re-use tubes 1 and 2 with distilled water and FACS clean 
respectively. Install FACS Clean tube 2 over the SIP needle. Press button ‘High’ and 
‘Run’ on the panel. Leave the support arm out at 90 degrees for approximately 1 
minute.  This cleans the outer portion of the aspiration sheath.  The fluid will be 
rapidly aspirated, so ensure that the tube doesn’t empty completely. 
 
4. Now replace the side arm under the Falcon tube and allow it to run for approximately 
5 minutes.  This cleans the inner portion of the aspiration sheath and the FACS 
machine itself. 
 
5. Repeat steps 2 and 3 with the distilled water tube 1.  Once step 3 is complete, Leave 
the sheath in falcon tube 1 containing distilled water and press ‘STANDBY’. 
 
6. Open the reservoir draw and depressurise the machine by moving the “Vent Valve” 
toggle switch to the up/rear position.  The machine will hiss as it depressurises. 
 
7. Leave the machine on for a further 5 minutes to allow the laser lamp to cool.  Turning 
the machine off prematurely will result in the lamp cracking. 
 
8. Finally power down the FACScalibur (green button) and Apple Mac, and then clean 
up! 
 
9. Note: * IF THE SYSTEM IS TO BE USED AGAIN ON THE SAME DAY… 
 
LEAVE THE SYSTEM ON STANDBY and then DEPRESSURISE THE SYSTEM. 
 
4. Interpretation of plots 
 
For the first couple of analyses you will need to have all this explained to you by Dr Blann or 




TOP THREE PLOTS 
 
1. The top left initial plots show the FSC/SSC plot (forward and side scatter, all in 
green). This is needed to gate the presumed monocytes. Be generous at this stage, 
include all monocytes. Contamination by granulocytes and lymphocytes will be 
removed during the next stage.  
 
2. Immediately to the right (i.e. centre) is a plot of the cells stained with CD14 (light 
blue) which further gates the monocytes to separate them from granulocytes. Note a 
large residual proportion of granulocytes at the top of the SSC index. 
 
3. Top right is plot of CD14/CD16 events (red/brown). Four gates have been drawn to 
define different populations of monocytes. M1 defines CD14strong/CD16-ve, whilst 
M4 defines cells expressing a lot of CD16. The latter will be sub-typed shortly. 
 
CENTRE THREE PLOTS 
 
4. Centre left is a plot of the Count beads (green), which are sampled at a concentration 
of, for example, 50,000 beads/tube. From this you will get monocytes/mL and thus 
MPAs/mL. The CD14-PE horizontal axis is irrelevant. 
 
5. Centre middle is (green) plot of CD16 versus CD14, which allows you to gate and 
exclude lymphocytes from analysis. Note that pattern is a bit like the upper right box, 
but with CD14-ve/CD16-ve events present. 
 
6. Centre right is a plot derived from Gate 4. It shows events (cells) that express high and 
low levels of CCR2 according to side scatter. There is a gating line down the middle 
of this plot to give cells staining high and low staining for CCR2. Gate 5 is cells 




LOWER THREE PLOTS (all CD42a versus CCR2) 
 
7. Lower left is a plot of CD42a versus CCR2 on population M1. MPAs are to the right 
of the line  
 
8. Lower middle is a plot of CD42a versus CCR2 in M2. MPAs are to the right of the 
line  
 
9. Lower right is a plot of CD42a versus CCR2 in M3. MPAs are to the right of the line  
 
 
Other numbers on the sheet (1- 12) refer to mathematical analyses, not to plots, as, follows…. 
 
5. Interpretation of results (numbers) 
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This is complicated, so pay attention. There are 12 analyses – the first 4 are raw data: 
 
1. The total number of events counted and the acquisition date are given top left of the 
numbers section (i.e. 60,964 on 08-Apr-10). 
 
2. On the far right is number of count beads (9127) used to quantify events to cells/μL  
 
3. On the left is some maths from the opening plots showing number of total events 
collected in this particular analysis and the proportion that are monocytes. 
 
4. Below this is the maths from Gates 5 and 6 (SSC and CCR2, middle right plot). So 
there are 667 M2 events and 871 M3 events, giving you relative proportions.  This 
data is used to calculate the absolute count of subsets M2 and M3.  
 
From these analyses numbers 1 – 4 the machine works out for you (given the count bead 
number in analysis 2 i.e. 9127) the percentage and numbers of monocytes and monocyte 
subsets, and these are given as numbers 5 – 12 as follows….  
 
5. Mon is the total number of monocytes per μl, i.e. 582.95 cells/μL. 
6. Mon 1 is the number of M1 monocytes per μl, i.e. 409.5 cells/μL.  
7. Mon 2 is the number of M2 monocytes per μl, i.e. 98.23 cells/μL 
8. Mon 3 is the number of M3 monocytes per μl, i.e. 75.22 cells/μL 
 
The machine has also worked out the % of each subset immediately below. 
 
Next – for MPAs… 
 
9. MPA is the total number of MPAs per μL, i.e. 102.86 cells/μL 
10. MPA1 is the total number of MPAs in the M1 population, i.e. 71.29 cells/μL 
11. MPA2 is the total number of MPAs in the M2 population, i.e. 19.28 cells/μL 
12. MPA3 is the total number of MPAs in the M3 population, i.e. 12.29 cells/μL 
 
From this you can work out the proportions given a calculator. It follows that since you have 
the platelet count from the Advia, you can also work out how many of the total platelet pool 





Using this dataset as a template, the numbers that need to go into your spreadsheet are as 
follows… 
 
Total monocyte count = 582.95 cells/μL 
 
Subsets:  M1 count = 409.50 cells/μL (70.25%) 
M2 count = 98.23 cells/μL (16.85%) 
M3 count = 75.22 cells/μL (12.9%) 
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Total MPA count = 102.86 cells/μL 
 
Subsets: MPA1 count = 71.29 cells/μL 
  MPA2 count = 19.28 cells/μL 
  MPA3 count = 12.29 cells/μL 
 
Once in the spreadsheet, you can easily do the arithmetic for conversion to % 
 
 
6. Validation and quality control (all work done by a single operator) 
 
The intra-assay reproducibility of the methods was assessed on six samples of blood; one set 
of three from a healthy male and second set of three from a woman with a history of renal and 
ovarian cancer. The inter-assay reproducibility was derived from 6 weekly samples from a 
healthy middle aged man. Intra-assay coefficients of variation (CV)(%) were as follows: 
 
   Subject A  Subject B   Mean 
Mon1   0.9   1.4   1.15 
Mon2   10.6   9.9   10.25 
Mon3   3.9   4.7   4.3 
Total Mon  0.6   0.4   0.5 
 
MPA1   3.4   5.2   4.3 
MPA2   14.1   9.7   11.9 
MPA3   8.2   6.8   7.5 
Total MPA  3.2   4.5   3.85 
 
     Median intra assay CV 4.6%  
 
Inter-assay coefficients of variation (CV)(%) were as follows: 
 
Monocytes 10.5%, then on a different occasion, 9.6%  
Monos 1 18.7%, ditto 17.2% 
Monos 2 39.3%, ditto 35.6% 
Monos 3  29.9%, ditto 27.5% 
 
Total MPAs 21.2%, then on a different occasion, 19.5% 
MPA1  31.8%, ditto 29.2% 
MPA2  28.4%, ditto 22.3% 
MPA3  31.8%, ditto 29.7%   Mean inter-assay CV 26.4%, then 23.8%  
 
SOP: Arterial stiffness 
Sern Lim November 2008 
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Left ventricular (LV) contraction generates a forward travelling pressure wave. Some of this 
pressure wave will be reflected at certain sites (e,g. bifurcations and sites of constriction). 
Increased arterial stiffness results in earlier return of the reflected pressure wave in systole 
rather than diastole, and is generally believed to be a surrogate of poor blood vessel 
compliance. We can assess these aspects of vascular function with two methods: 
 
(a) pulse wave analysis (PWA), which reports the reflected pressure wave as pressure 
augmentation and may be expressed as the augmentation index (AI), and  
 
(b) pulse wave velocity (PWV, reporting in units of metres per second). 
 
Increased arterial tone, such as that associated with endothelial dysfunction, also increases the 
reflected wave and the AI. PWA may therefore provide information on the functional 
properties of the arterial system. The end point index of PWA is the speed at which the pulse 
is transmitted along arteries, hence PWV, and is reported in metres per second. Both PWV 
and PWA can be done at the same time on the same subject. 
 
The method may also be used to further analyse vascular function. The administration of 
salbutamol and GTN also allows assessment of endothelial-dependent and independent 
function as NO-mediated vasodilatation reduces arterial wave reflection. The relative change 
in augmentation index to salbutamol and GTN provides a measure of systemic endothelial 
function.  
 
n.b. The SOP refers to radial and carotid artery assessment but can be adapted for the femoral. 
 





The patient, SphygmoCor with pressure transducer (Millar), Laptop computer with 
SphygmoCor software (for around 45 minutes), Power cables and USB connection cables, 
ECG monitoring dots, Omron BP recorder. If doing additional vascular function - 




a. Allow the subject to rest in the room for about 10 minutes before scanning. 
The test must be done in a supine position. 
b. While the patient is resting, you should connect the power cables to the 
SphygmoCor machine (at the back) and the laptop computer. The computer 
should then be connected to the SphygmoCor machine (use the USB 
connection at the back). The ECG cables should be connected to the 
SphygmoCor machine (in front where it says ‘ECG’).  
c. Switch on the SphygmoCor machine first. The lights in front will blink. When 
the lights stop blinking and green light stays on ‘ready’, turn on the computer. 
This sequence will allow the software in the computer to recognise the 
SphygmoCor.  
d. The SphymoCor icon should be on the computer desktop. Double-click to 
activate the software. A warning will come on the screen, just click ‘allow’. 
e. You will see PWA and PWV on the top left of the screen. Click on PWA for 
pulse wave analysis. 
f. Click ‘create new’ on the top right of the screen. You will need to enter the 
patient details in the relevant boxes (eg: date of birth) and click ‘update’. 
g. Click on PWA on the top left for pulse wave analysis and then ‘study’ on the 
top left of the screen. Choose radial or carotid by ticking the box. Measure the 
patient’s brachial blood pressure (Omron). Take 3 measurements and use the 
average of the last two readings.  
h. Enter BP measurements. Height and weight if you have the data.  
i. Place the ECG leads on the patient and click ‘Capture data’ on the top right of 
the screen. You are now ready to go! (NOTE: To ensure a stable, artifact free 
ECG, the skin should be properly prepared (hair removed at electrode site and 
skin cleaned with an alcohol wipe), and the electrodes positioned correctly. 
The leads can be placed either on the limbs or on the chest area if required for 
stronger QRS levels). 
 
3. In the drawer of the tonometer machine, you will find the Millar tonometer with a 
plastic cap to protect the high fidelity tip (this cap is important, DO NOT lose it!). The 
tonometry should be connected already. DO NOT disconnect the tonometer. Remove 
the plastic cap and it is ready for use. 
 
4. Feel for the radial or carotid pulse (depending on which you want to measure) and 
place the tonometer over the pulsation. You will see a pressure trace on screen. The 
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screen will automatically adjust the scale to accommodate the pressure trace. You 
need to make sure the trace is consistent for at least 12 seconds. To obtain the 
measurement, press the spacebar on the laptop. The machine will not take the last 2 
seconds of recording to give you time to let go and press the spacebar.   
 
5. The computer screen will then change to the data screen with the ensemble-averaged 
pressure trace (radial or carotid depending on the one you have chosen) shown and the 
derived central arterial pressure trace. First thing to do: check the quality control box 
on the top left of the screen. If this number is red, then the data is of insufficient 
quality and the measurement will need to be repeated.  
 
6. The data will be available at the bottom of the screen. At the top right of the screen, 
click ‘Export’ to save the data in your folder. You can store the data as a text file or 
jpeg (the screen shot). I would suggest you store both. If you are not doing endothelial 
function assessment with the SphygmoCor, then your study is done! 
 
 
3. Sub-method for endothelial function 
 
1. If you want to assess endothelial function, you will need to assess endothelium-
dependent and independent vasodilatation. Endothelium-dependent vasodilation is 
assessed by giving 2 puffs of salbutamol (inhaler). Blood pressure (the other arm) and 
PWA measurement should be repeated at 5, 10 and 15 and 20 minutes to look for 
maximal decrease in augmentation index. 
 
2. This is then followed by 2 puffs of sublingual GTN (warn the patient they may get a 
mild headache / feel dizzy) to assess endothelium-independent vasodilatation. 
Similarly, BP and PWA measurement should be repeated at 5, 10, 15 and 20 minutes.  
 
3. Make sure you label the files (eg: salbutamol and GTN) when you are storing the data. 
Figure 1 shows typical responses to these pharmaceuticals 
 
Figure 1 shows differences in plots according to the use of these drugs 
 
4. PVW measurement. 
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a. Return to the ‘Patient Screen’, select ‘PWV’ mode by either clicking on the arrow 
on the selection box (located next to the ‘Analysis’ button), or by pressing F6 on your 
keyboard to scroll through the mode options. 
 
b. Open the Study Screen by clicking on the “Study” button or pressing F3 on your 
function keys on your keyboard. This screen will allow you enter the study details and to 
proceed to ‘Capture data’. Mandatory fields to be selected or entered: 
 
• Sites from where the measurement is to be taken. This is to be done for both 
Site A and Site B. Site A is the site at which the first measurement is to be 
taken and Site B refers to the site at which the second measurement will be 
taken. 
• When carotid is selected as the first site, enter the systolic and diastolic blood 
pressure values that have been obtained from the cuff sphygmomanometer or 
automatic blood pressure device.  
• The Capture Time is set to a default of 10 seconds for both the Site A and Site 
B measurement. Alternative times can be selected for either or both Sites if 
required. 
• The Distance should be measured and entered as follows: for carotid – femoral 
(if being done) and carotid – radial, the distance directly between the each 
artery location and the supra-sternal notch are entered in the distal and 
proximal boxes (NOTE: At present, there is no definitive way to measure the 
distance between the aorta and the femoral artery non-invasively. As a result 
there a number of methods that is used to measure the distance. If there is no 
existing methodology already in place, it is recommended that the 
measurement be taken in a direct line between the supra-sternal notch and the 
femoral artery 
• The Medication, Notes, Operator and Anthropometric fields are optional. 
 
c. To proceed to the capture data screen, click on the ‘Capture Data’ button or press 
‘enter’ on your keyboard. Once the ECG trace is shown along the screen and is steady, 
proceed as follows: 
• The tonometer should be placed at Site A location and adjustments to the 
position of the tonometer made until a strong, accurate and reproducible 
waveform is displayed in the ‘Signal Detail’ window. This signal will be 
automatically re-scaled and zoomed to fit the waveform within the signal detail 
window every 5 seconds. When you are satisfied that you have a good reading, 
press the ‘Space Bar’ on your keyboard or click the ‘OK’ button at the top of 
the screen (NOTE: You must have a minimum of 12 seconds of signal for the 
data to be captured (minimum of 22 seconds or 32 seconds if you have selected 
a capture time of 20 or 30 sec in the Study Screen). The last 2 seconds of 
waveforms will be deleted, allowing sufficient time to remove the tonometer 
from the wrist to activate the capture of data. A prompt window will appear 
confirming that the signals have been captured successfully.  
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• When you are ready to proceed to take the reading at Site B, click the OK 
button or press ‘enter’ on your keyboard. If you wish to take the reading again, 
click No and repeat the reading at Site A. 
• Repeat the process by placing the tonometer at Site B and proceed with the 
capture when you have obtained a signal of satisfactory quality. A prompt box 
will appear to confirm that the signal was captured successfully. If you are 
satisfied with the reading at Site B and wish to proceed to the report, click OK. 
If you wish to repeat the reading at Site B, click No and repeat the reading at 
Site B (NOTE: remember that the signal representing the tonometer waveform 
for Site A should be the artery selected in the ‘Study Screen’). 
 
d. Additional comments on performing carotid measurements. The patient should be 
lying on a bed. The patient’s head should be tilted slightly to the back and to one side (either 
left or right). This is best achieved in the absence of a pillow. The operator should feel for the 
position for the strongest pulse and place the tonometer directly on the top of the skin at this 
point. The operator can be standing either behind the patient’s head or to one side. A pillow 
may be placed across the shoulder of the patient to allow the operator to rest their forearm to 
ensure that the tonometer and wrist remain steady during the measurement. 
 
e. Examine the report for quality control. 
 
After you have completed the data capture, the ‘Report Screen’ will automatically be 
displayed. This can also be recalled at any time by selecting the patient in the ‘Patient Screen’ 
and pressing the ‘Report button’. Before proceeding with the interpretation of results it 
important to check the quality control to ensure that your measurement has been recorded 
with sufficient quality. The SD (ms) in the statistical table should be below 6% of the mean 
time. If this is above 6% the number will appear in red. It is recommended that PWV should 
have a SD 10% or less. Between 10% and 15%, is borderline and careful examination of the 
waveforms should be done before making a decision as to whether to repeat the reading. For 
SD above 20% a repeat reading is recommended. The SD of the PWV and mean time provide 
an indication of how consistent the data is, and this may include some biological variation that 
is inherent in the reading. If you have performed more than one reading on a patient, the 
studies are listed chronologically in the ‘Study Time’ window and the most recent report will 
be at the bottom of the list. Each of the reports may be viewed by clicking on the study you 
wish to view. The report being displayed will correspond to the highlighted study in the 
‘Study Time’ window. 
 
5. Potential problems 
1. The high fidelity tonometer is very sensitive to pressure (that is what it is meant to do!). 
You will need practise to achieve a consistent level of pressure in order to obtain 




2. To avoid any problems with the computer, it should NOT be used for any other reasons 
(eg: surfing the internet). The computer and the tonometer (plus ALL the cables and ECG 
leads) should ALWAYS be kept together. 
 
3. Every operator should create a folder for him/herself and store ALL the data in that folder. 
This should avoid confusion and the relevant data may be easily retrieved. 
 
Intra-assay reproducibility 
This was assessed on an apparently healthy 56 year old male at approximately 9.30 in the 
morning.  
 
• PWV was 5.9, 7.1 and 6.6 m/s on three occasions in the same short session (15 
minutes). This gives a mean PWV of 6.6 m/s with a standard deviation (SD) of 0.51. 
Hence intra-assay coefficient of variation (CV) =   7.7%.  
 
• For PWA, the Augmentation index (AI) was 21, 24 and 25, giving mean (SD) of 23.3 
(1.7) so that intra assay CV = 7.3%. 
 
• Shortly afterwards, for comparison, blood pressure was measured six times using an 
Omcron machine, with the cuff being removed between each measurement. This data 
gave a mean/SD SBP of 117.3 (2.7) mm Hg. Hence intra assay CV is 2.3%. Similarly, 
the DBP was 71.2 (1.6) = 2.2%, and pulse rate was 52.8 beats/minute (1.34) = 2.5%.  
 
Thus the SphygmoCor has a variance approximately three times that of the Omcron BP 
machine. 
 
Inter-assay reproducibility (on different days) 
25/8/2010:  PVW = 8.4, AI = 27 
26/8/2010:  PVW = 6.6, AI = 23 
1/9/2010: PVW = 7.5, AI = 21 
2/9/2010: PVW = 7.4, AI = 21....on n=4, CV for PWV = 8.5%, for AI = 10.6% 
3/9/2010: PVW = 5.1, AI = 22....on n=5, CV for PWV = 15.8%, for AI = 9.8% 
4/11/2010: PVW = 6.9, AI = 21....on n=6, CV for PWV = 14.5%, for AI =  9.5%  
Diurnal variation (DV, all done on 26th August 2010) 
At 9.30 a.m.,  PVW = 6.6,  AI = 23,  SBP = 117, DBP = 71, pulse rate = 53 
At 1.30 p.m.,  PWV = 7.3,  AI = 20,  SBP = 123, DBP = 61, pulse rate = 61 
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At 5.30 p.m.,  PWV = 7.0,  AI = 24,  SBP = 121, DBP = 74, pulse rate = 48 
DV for PWV = 4.1%, AI = 7.6%, SBP = 2.1%, DBP = 8.1%,  PR = 9.9%  
SOP: Venepuncture  
1.0 Introduction  
Venepuncture is one of the most commonly performed invasive procedures (Peters et al, 
1984) and is becoming more routinely performed by nursing staff (Jackson, 1996). The 
procedure requires knowledge of anatomy and physiology and the knowledge of health and 
safety issues and infection control pertinent to the patient and practitioner.  
Venepuncture is necessary to obtain blood samples for diagnostic purposes and to monitor 
levels of blood components.  
This policy should be read in conjunction with the Trust’s Intravenous Therapy Training 
Programme Part B (Peripheral Cannulation and Venepuncture) and the following Infection 
Control Policies and Guidelines:  
a. Hand Hygiene: http://swbhweb/upload/pdf/Hand_Hygiene.pdf  
b. Personal Protective Equipment  
c. Waste and sharps management  
d. Equipment cleaning and decontamination  
e. Control of blood and body fluid spillages  
f. Specimen collection and transportation  
2.0 Aim
To ensure all healthcare professionals involved in venepuncture carry out the procedure safely 
at all times.  
3.0 Objectives  
3.1 To ensure safe and effective collection of blood samples at all times.
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3.2 To prevent infection due to microbial contamination.
3.3 To maintain the safety and comfort of the patient and staff member at all times.  
3.4 To maintain safety of the staff member carrying out the procedure.  
5.0 Venepuncture Procedure 
 5.1 Selection of site  
• The superficial veins of the upper arms are most commonly chosen for venepuncture. These 
veins are numerous and accessible and the procedure can be performed with the 
minimal of discomfort (Marieb, 1998).  
• Occasionally, the veins of the lower limb can be used but this should be avoided, as blood 
flow is less in this region and the risk of complications increase.  
5.2 Selection of Vein  
• The choice of vein must be individualised for each patient. The most prominent vein is not 
necessarily the best (Weinstein, 1997).  
• Inspect the limb for infection, bruising and phlebitis. These areas should not be considered 
due to the risk of causing more damage. Areas of previous venepuncture should also 
be avoided as this can result in pain to the patient due to repeated trauma of the vein 
(Ahrens et al, 1991).  
• Veins should feel soft, bouncy and refill when depressed. Veins which cross over joints and 
bony prominence should be avoided and those areas with little skin (inner aspect of 
the wrist), as this will cause added discomfort to the patient.  
• The main veins of choice are (listed in order of priority)  
a. Antecubital Veins- These veins are chosen for venepuncture because they are 
capable of providing copious and repeated blood specimens without 
damaging the vein providing a good technique is used (Mallet and Balley, 
1996) a.1 Cephalic Veina.2 Basilic Veina.3 Median Cubital Vein  
b. Median vein in the wrist  
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c. Dorsal metacarpal veins  
• The femoral veins can only be accessed by medical staff for venepuncture.  
• The metacarpal veins should only be used when the others are not accessible. 5.3 
Improving venous access  
a. Application of a tourniquet promotes venous distension. It should be tight enough to 
impede venous return but not restrict arterial flow.  
b. Opening and closing of the fist ensures muscles force blood into the veins.  
c. Lowering the arm below heart level.  
d. Light tapping of the vein may be useful but can be painful and may result in the 
formation of haematoma specially in elderly patients and those with fragile 
viens (Dougherty and Lamb, 1999).  
e. The use of heat, in the form of warm water or packs, encourages vasodilation and 
venous filling.  
5.4 Preparation of equipment  
Two devices commonly used for venepuncture are the straight steel needle (vacuum/closed 
system or syringe) and the winged steel infusion device (butterfly). The choice of device is 
dependent on the condition and accessibility of the patient’s veins. The use of syringe is not 
recommended as it has many inherent problems (Dougherty and Lamb, 1999). The vacuum 
system is a safer system and has increased the efficiency of blood sampling (Dougherty and 
Lamb, 1999). This Trust recommends that practitioners undertaking this procedure use the 
vacuum (otherwise known as the closed-system) in venepuncture.  
The package must be checked for integrity before use and the expiry dates checked on all 
devices and blood collection bottles.  
5.5 Prepare patient/parents  
Explain the procedure to the patient and provide opportunities for questions and discussion of 
the procedure, in order to reduce fears and anxiety and to encourage compliance in the 
patient.  
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5.6 Venepuncture technique  
. 5.6.a  Ensure lighting and privacy is adequate for the task being undertaken.  
. 5.6.b  Wash hands using an antibacterial soap or alcohol hand rub and ensure hands are 
thoroughly dry.  
. 5.6.c  Apply gloves.  
. 5.6.d  Apply a clean tourniquet to the chosen limb and select the most appropriate vein.  
. 5.6.e  Prior to venepuncture, the intended site should be cleansed with antimicrobial 
solution(s) using aseptic technique for 30 seconds (Elliot et all 1994; ICNA 2000; 
DOH 2001; CDC 2002). The antimicrobial preparation solution(s) should be allowed 
to air-dry completely before proceeding with the venepuncture (Dolan and Dougherty 
2000; DOH 2001). A 70% alcoholic swab impregnated with 0.5% chlorhexidine 
gluconate solution should be used for skin disinfection (CDC Recommendation 
Category IA) unless the patient has known allergy to chlorhexidine.  
. 5.6.f  Do not re-palpate the vein or touch the skin after skin disinfection.  
. 5.6.g  Support limb with pillow or soft cushion.  
. 5.6.h  Inspect the device to be used and ensure its integr ity.  
. 5.6.i  Anchor the vein by applying manual traction a few centimetres below the proposed 
insertion point.  
. 5.6.j  Insert the needle smoothly at an angle of approximately 30 degrees.  
. 5.6.k  Reduce the angle when puncture of the vein is felt or there is a flashback of blood in 
the tubing of the winged infusion device (i.e butterfly safety blood collection set).  
. 5.6.l  Slightly advance the needle into the vein and withdraw the required amount of blood 
using a vacuumed blood collection system.  
. 5.6.m  Only attempt this procedure twice. If unsuccessful, contact a more experienced 
practitioner.  
. 5.6.n  Tourniquet should never be left on the arm for more than 1 minute due to the 
possibility of haemoconcentration. It should therefore be released after the first blood 
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bottle has been filled.  
. 5.6.o  Mix the blood bottle by inverting it 3-5 times. Do not shake the blood bottles.  
. 5.6.p  Place a low - linting sterile dressing over the puncture site but DO NOT apply 
pressure.  
. 5.6.q  Remove the needle fully, then apply pressure to the puncture site. Digital pressure 
should be applied on straight arm -not bent (Dyson and Bogod, 1987) by the 
practitioner and not the patient (Godwin et al, 1992), until bleeding has ceased.  
. 5.6.r  Discard the needle directly into the sharps container.  
. 5.6.s  The vacuum system must also be discarded as they are single use only.  
. 5.6.t  Mix well and ensure all bottles are labelled correctly at the patient’s bedside .  
. 5.6.u  Inspect the puncture site before applying a sterile dressing.  
. 5.6.v  Ensure patient is comfortable.  
. 5.6.w  Send specimens to laboratory in specimen bags. (Policy SHC/COI/002- The 
Microbiology Laboratory)  
. 5.6.x  Discard all waste as per Trust policy (SHC/COI/013 – Waste Disposal)  
6.0 Training  
6.1 All practitioners undertaking venepuncture must be adequately trained and deemed 
competent on this skill.  
6.2 Training for venepuncture may be completed during pre-registration period (i.e. medical 
staff) or post-registration (i.e. nurses, midwives, ODAs, ODPs, etc.).  
6.3 For post-registration training (i.e. nurses, midwives etc.), practitioners must follow the 
approved training provided by the Trust and undertake assessment by an experienced 
practitioner following the Trust’s Venepuncture Assessment package (See IV Therapy Part B: 
Peripheral Cannulation and Venepuncture Training Programme ). This training can also be 
accessed and is covered in the Unit E8 of the Operating Department Practice Standard for 
theatre staff. THE TRAINING MUST ALWAYS PRECEED THE ASSESSMENT.  
6.4  Practitioners trained in other Trusts (applies to qualified non- medical practitioners only) 
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should first undergo an Assessment of Prior Learning and Experience (APLE) prior to 
undertaking venepuncture in this Trust. Practitioners who wish to undertake this assessment 
must obtain an approved APLE form from one of the Clinical Skills Educators (Learning and 
Development Department: extension 5238-City Site). The assessment must be carried out by 
an experienced senior practitioner who is competent in venepuncture and is practicing the 
skill regularly.  
6.5  All practitioners have a professional obligation to maintain their knowledge and skills 
(NMC 2002). It is therefore essential that practitioners keep abreast of clinical advances and 
changes in practice, and it is therefore recommended that training updates be attended (DHSS 
Regulations, 1976) at least every 3 years or earlier if the practitioner deem it necessary (RCN, 
1999). This should be followed by and monitored by the ward/department manager/medical 
director as part of the personal development review process.  
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